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Two major mechanisms of genomic instability, microsatellite instability (MIN), also
referred to as a replication error positive phenotype (RER+) and chromosomal
instability (CIN), have been identified to date in sporadic colorectal cancer. Each
leads to the development of a distinct phenotype of colorectal cancer.
This thesis has analysed genetic intratumoral heterogeneity in 22 sporadic colorectal
cancers and its association with two known types of underlying genomic instability. It
has also established the relevance of colorectal cancer xenografts as models for
investigating the genetics of colorectal cancer.
This study has identified the presence of genetic intratumoral heterogeneity in
sporadic colorectal cancer. It has shown that the RER+ phenotype is characteristic of
a proportion of sporadic colorectal cancer and confirmed that a single sample analysis
is sufficient for determining RER+ phenotype in these tumours. The analysis of
chromosome copy number changes in the RER- and RER+ groups of sporadic
colorectal cancers confirmed previously reported higher incidence of chromosomal
abnormalities occurring in RER- cancers. Different patterns of chromosomal changes
were found to occur in RER- and RER+ tumours. In this study the most frequently
detected chromosomal abnormalities in RER- and RER+ cancers were 20q+, 18q-,
13q+, 8p-, lp-, 8q+and lp-, 19del respectively.
The most important finding of this study is the identification of a novel group of
sporadic colorectal cancers which do not display instability of either chromosomes or
microsatellites (called non-MIN, non-CIN cancers). These tumours do not show any
striking differences in clinical and pathological features compared with RER- tumours
exhibiting high levels of chromosomal instability, but may harbour fewer
abnormalities of p53. It is likely that non-MIN, non-CIN colorectal cancers represent
a distinct entity in sporadic colorectal cancer and, based on this data, their prevalence
might be as high as 35% of RER- colorectal cancers or 25% of sporadic colorectal
cancers in total.
The analysis of colorectal cancer xenografts established from samples collected from
multiple sites from primary tumours showed that a xenograft established from a
vii
single sample is in general representative of its tumour of origin, despite the presence
of genetic heterogeneity within primary tumours. This applies firstly to the
preservation of the RER+ and RER- phenotype and secondly to specific
chromosomal abnormalities being retained in RER- colorectal cancer xenografts. The
study also showed that p53 status of the primary tumour is unchanged in a
corresponding xenograft and that the DNA ploidy closely resembles that of the
sample of origin. Preservation of all these important genetic features in colorectal
cancer xenografts makes them a valuable model for investigating the genetics of the
disease.
The results of this study provided new valuable information on genetic intratumoral
heterogeneity in sporadic colorectal cancer and its association with different
mechanisms of underlying genetic instability. Although this work has not addressed
directly the issue of response to therapy, the data provided will be important in
establishing whether classification of genetic instability in this way has a bearing on
response to different therapeutic agents.
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1.1. Epidemiology and clinical aspects ofcolorectal cancer.
1.1.1. Incidence, mortality and survival rates.
Large bowel cancer is the second most common cancer in Britain. Each year 31,200
new cases are diagnosed in the UK. It constitutes 12% of all malignant neoplasms,
excluding non-melanoma skin cancer (NMSK) in females where it is preceded only by
breast cancer. In males it closely follows lung and prostate cancer accounting for 13%
of all malignancies, excluding NMSK.
Peak incidence for colorectal carcinoma occurs in the age group 60 to 79 years, and
fewer than 20% of cases occur before the age of 50 years.
Cancer is the cause of a quarter of all deaths in the UK, 11% of which are due to large
bowel cancer. Five-year age standardised relative survival rates in adults diagnosed
with colorectal cancer during 1986-90 in England and Wales are 39% for females and
38% for males (Cancer Research Campaign Scientific Yearbook, 1999).
1.1.2. Distribution.
Colorectal carcinoma death rates vary considerably world-wide with the highest rates
in the United States and Eastern Europe and up to tenfold lower rates in Mexico,
South America and Africa. Environmental factors, particularly diet, are implicated as
major factors contributing to these striking geographic differences (Crawford, 1999).
Within Britain colorectal cancer is more common in Scotland than it is in England or
Wales (Cancer Research Campaign Scientific Yearbook, 1999).
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1.1.3. Etiologic factors.
1.1.3.1. Diet and colorectal cancer.
The evidence supporting the role of diet as an important etiologic factor in the genesis
of colorectal cancer comes from observations of different incidence rates in different
populations. Comparisons of migrant groups show lower rates of colon cancer in
Chinese native to Asia compared with Chinese born in America; studies of
populations with defined dietary patterns, i.e. vegetarians, show rates lower than
those in the general population (Motwani et al., 1997).
Although the data gathered from a large number of case-control and cohort studies
over the past decade are not entirely consistent, several important risk factors have
emerged. The dietary factors most frequently implicated as predisposing to a higher
incidence of colorectal cancer are excess energy intake relative to requirements, a low
content of unabsorbable vegetable fibre, a high content of highly refined
carbohydrates in the diet, intake of red meat and decreased intake of protective
micronutrients (see Giovannucci and Willett, 1994 for review).
Dietary components affect the biochemical composition of faecal content but direct
mechanisms by which they exert their effect on the large bowel mucosa are poorly
understood. Some substances present in the diet are highly mutagenic. These include
fecapentaenes, that can also be derived from the action of Bacteroides species on
faecal content, and heterocyclic amine, 2-amino-l-methyl-6-phenylimidazo[4,5-
bjpyridine (PhIP), present in fried or heavily browned meats. Increased dietary fat
may cause increased secretion of bile acids which have the potential to act as tumour
promoters and co-carcinogens. The direct effect of fibre is to reduce colon transit
time, thus both the effective contact time between putative carcinogens in the faecal
content and the colonic mucosa and the time for gut microflora to act on faecal
content to generate additional possible carcinogens such as fecapentaenes is reduced.
Fibre also reduces faecal bile acid levels and colonic pH, a higher level of which is
postulated to contribute to carcinogenic activity (Motwani et al., 1997).
Dietary factors also appear to have a different impact in different parts of the large
bowel. Cancers of proximal colon (caecum, ascending and transverse colon up to the
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splenic flexure) are associated with intrinsic factors such as bile acids and sex
hormones. Cancers located in the distal part of the large bowel (descending and
sigmoid colon and rectum) are more closely related to diet and cigarette smoking
(reviewed by Breivik and Gaudernack, 1999). Alcohol intake may enhance risk of
cancer in the distal colorectum and its influence is particularly strong when combined
with a diet low in methionine and folate (see Giovannucci and Willett, 1994 for
review).
1.1.3.2. Precancerous lesions and conditions preceding colorectal carcinoma.
The precancerous nature of colorectal epithelial polyps has been debated for years and
still remains controversial. Although circumstantial, there is evidence that most
colorectal carcinomas arise from pre-existing adenomatous polyps. Here some well-
documented relevant facts are presented (reviewed by Rosai, 1996).
1. Solitary hyperplastic polyps, retention polyps and the polyps of Peutz-Jeghers do
not become malignant or, if they do, the rate is negligible.
2. Patients with any type of polyposis syndrome are at increased risk for the
development of large bowel carcinoma.
3. Villous adenomas become malignant in a high proportion of cases (29% to 70%).
4. Adenomatous polyps can undergo malignant transformation as documented by
adenomatous polyps with focal carcinoma.
5. Not all adenomatous polyps become malignant within the normal life span of an
individual.
6. There is an overwhelming parallelism between adenomatous polyps and colonic
carcinoma. Populations that have a high incidence of polyps also have a high
incidence of carcinomas and vice versa. Large bowels with carcinomas have a
higher incidence of polyps elsewhere in the specimen than those without
carcinoma. Adenomatous polyps are a good epidemiologic indicator of colon
carcinoma risk. The morphologic, histochemical (mucin stains), immunochemical
(CEA, blood group substances), flow cytometric, nuclear morphometric, and
ultrastructural features of adenocarcinomas, and the most atypical areas of
adenomatous polyps are extremely similar.
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7. The malignant transformation of adenomatous polyps (so-called adenoma-
carcinoma sequence) have been documented with chemically induced colorectal
tumours in animals and has become a paradigm of the process of malignant
transformation of epithelial tissue. It has been demonstrated that the morphologic
progression from adenomatous polyp with mild to moderate to severe atypia and
to invasive and metastatic carcinoma is accompanied (and presumably caused) by
a series of molecular alterations.
8. Colonoscopic polypectomy results in a lower-than-expected incidence of
colorectal carcinoma in the population subjected to this procedure.
9. There is evidence suggesting that some colorectal carcinomas arise de novo rather
than on the basis of pre-existing polyps.
Apart from adenomatous lesions there are a number of pathological conditions
associated with elevated risk of developing colorectal carcinoma. Although sporadic
colorectal carcinoma accounts for the vast majority of all colorectal cancer cases
diagnosed, in a proportion of cases familial syndromes substantially increase the risk
of encountering the disease. Familial adenomatous polyposis coli (FAP) almost
inevitably leads to development of colorectal cancer. FAP and hereditary non-
polyposis colorectal cancer (HNPCC) represent two highly penetrant autosomal
dominant predisposition syndromes responsible for 2-10% of colorectal cancer cases.
The risk in patients with juvenile polyposis is at least as high as 10%. Peutz-Jeghers
syndrome presents only a slight risk and although occasionally malignant change has
been described in metaplastic ployps, the risk of colorectal cancer occurrence has not
been shown to be higher than for normal colorectal mucosa. Both types of
inflammatory bowel disease, ulcerative colitis and Crohn's disease, predispose to
colorectal cancer. Surgical procedures altering the colonic microenvironment
(urethrosigmoidostomy, cholecystectomy and gastrectomy) as well as anastomoses
are associated with an increased incidence of colorectal cancer.
The majority of precancerous lesions and conditions show various degrees of the
common histological change - dysplasia, and the risk magnitude of malignant
transformation appears to be closely related to the grade of dysplasia.
4
1.1.4. Clinical aspects ofcolorectal carcinoma.
1.1.4.1. Clinical features.
Two-thirds of the large bowel cancers are located in the rectum, rectosigmoid or
sigmoid colon with the one-third distributed in the remainder of the colon.
Symptoms develop late and usually accompany the advanced stages of the disease.
Ceacal and right colonic cancers often grow as bulky readily bleeding lesions and are
called to clinical attention by the appearance of fatigue, weakness and iron deficiency
anaemia. Left-sided tumours produce occult bleeding, changes in bowel habits or left-
lower-quadrant discomfort. Cancers of rectum and sigmoid colon, despite causing
prominent disturbances in bowel function, tend to be more infiltrative at the time of
diagnosis than proximal lesions and have somewhat poorer prognosis. Patients who
present with iron deficiency anaemia of unknown origin should be always carefully
examined, preferably by colonoscopy, to exclude colorectal carcinoma as a cause
(Crawford, 1999).
1.1.4.2. Staging.
Various colorectal cancer classification systems are in use, but all take into
the depth of invasion into the bowel wall, spread into the adjacent
involvement of regional lymph nodes and the presence of distant metastases
purpose of this study the widely used Dukes' system was employed.
Dukes' classification:
Dukes A : Tumour confined to the bowel wall, may involve the muscularis propria
but not beyond.
Dukes B : Tumour spreads to extramural tissue, involves the serosa or mesenteric fat
tissue, but there is no lymph node involvement.
Dukes C : Any degree of bowel wall involvement with regional lymph node
metastasis or tumour extends beyond contiguous tissue or immediately adjacent





Dukes D : Any invasion of bowel wall with or without regional lymph node
metastasis with evidence of distant metastasis.
1.1.4.3. Morphology.
Most cancers in the large bowel are adenocarcinomas. The microscopic characteristics
of right- and left-sided colorectal carcinomas are similar. Differentiation may range
from well differentiated tumours closely resembling the adenomatous lesions but now
invading the submucosa to undifferentiated, anaplastic tumours. Approximately 20%
of colorectal adenocarcinomas are well differentiated, 60% moderately differentiated
and 20% poorly differentiated. Between 10-15% of colorectal cancers are mucinous.
They show two main growth patterns: (1) glands filled with mucin together with
interstitial mucin and (2) chains or clumps of cells surrounded by mucin. Although
many colorectal tumours produce mucin only those carcinomas in which extracellular
mucin constitutes more than 60% of the cancer volume in adequate numbers of
sections are formally classified as mucinous. Mucinous cancers have in general worse
prognosis. Secretion of mucin is thought to facilitate the extension of the malignancy
by dissecting the bowel wall (Crawford, 1999). However, recent studies suggest that
mucinous histotype is not an independent prognostic factor and that the shorter
survival rate observed in mucinous colorectal cancers is attributable to a more
advanced stage of presentation (Messerini et al1999). In fact, mucinous carcinomas
more frequently show microsatellite instability (MIN) than non-mucinous cancers
(Messerini et al., 1997) and MIN tumours show a tendency towards increased patient
survival (Thibodeau et ah, 1993; Lothe et al., 1993; Bubb eta/., 1996).
Colorectal tumours spread by direct extension through the submucosa, muscularis
propria and serosa into adjacent structures. The metastases occur through lymphatic
channels and blood vessels in the regional lymph nodes, liver, lungs and bones
followed by many other sites. In general the disease has spread beyond the range of
curative surgery at the time of diagnosis in 25-30% of patients (Crawford, 1999).
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1.1.4.4. Treatment andprognosis.
Early stages of the disease are treated primarily by surgery. If at the time of diagnosis
regional or distant metastases are discovered, a combination of surgical and other
therapeutic modalities is indicated. Adjuvant therapies include pre- and postoperative
radiotherapy, chemotherapy and immunotherapy. At present, most patients with
Dukes A colorectal cancer do not have sufficiently high statistical risk of recurrence
to justify postsurgical adjuvant treatment to the entire group. A significant proportion
of these patients however will ultimately develop regional recurrence or metastatic
disease. It would be highly beneficial to identify additional prognostic markers, such
as specific genetic defects facilitating invasion or metastases, to enable the application
of adjuvant intervention in a selective fashion.
The estimated survival at 5 years is in excess of 85% among patients with large bowel
cancer diagnosed in localised state (Dukes' A). Survival ranges from 20-80% in the
group of patients diagnosed with regional involvement (Dukes' B and C) and is
directly proportional to the number of involved lymph nodes, serosal involvement,
tumour grade and patient's age. The 5-year survival is 10% or less among patients
diagnosed with distant disease (Dukes' D) (Motwani et al., 1997).
7
1.2. The genetic basis ofcolorectal cancer.
1.2.1. Introduction.
Despite variations in the gross and microscopic appearances of colorectal cancers they
share certain characteristics. They have several phenotypic attributes of a malignant
neoplasm such as excessive growth, local invasiveness, and the ability to form distant
metastases. These phenotypic characteristics are acquired in a stepwise fashion - a
phenomenon called tumour progression, and result from accumulation of specific
genetic lesions.
Neoplastic transformation is increasingly being interpreted in terms of evolutionary
mechanisms and it is generally agreed that cancer development is a multistep process
involving natural selection of mutations occurring at the somatic level. A number of
reports reveal distinct patterns of genetic alterations in tumours of different
histogenesis (Mertens et ah, 1997, Shackney and Shankey, 1997) indicating that
specific genetic alterations are not random but may be closely related to different
types of tissue of origin and exposure to specific carcinogens.
Here, the most common genetic changes encountered in colorectal cancers as well as
mechanisms implicated in colorectal carcinogenesis are reviewed.
1.2.2. Genetic changes acquired during the adenoma-carcinoma sequence.
Colorectal carcinomas represent human tumours probably most intensely investigated
at the genetic level. The fact that most of them arise from pre-existing, benign lesions
- adenomas, and gradually progress through increase in size and acquisition of
dysplastic features to malignant lesions, permits the investigation of genetic changes at
different stages of tumour development and progression. The adenoma-carcinoma
sequence provides an excellent system in which the nature and order of acquisition of
specific genetic alterations can be studied.
Although tumourigenesis has long been thought to be a multistep process, the first
genetic model of colorectal carcinogenesis was presented by Fearon and Vogelstein in
1990 (Fearon and Vogelstein, 1990). It was proposed that:
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1. Colorectal carcinomas arise as a result of mutational activation of oncogenes
coupled with mutational inactivation of tumour suppressor genes.
2. Most colorectal carcinomas probably arise from a minimum of five or more
genetic alterations, while adenomas appear to require correspondingly fewer
alterations.
3. Total accumulation of changes rather then their order is responsible for
determining tumour's biologic properties.
4. Some mutant tumour suppressor genes appear to exert a phenotypic effect in a
heterozygous state indicating their dominant properties at the cellular level.
The following genetic model for colorectal carcinogenesis was proposed (Figure 1).





















DCC? p53 Other alterations
This model was subsequently modified, as new tumour suppressor genes, oncogenes
and genes involved in controlling apoptosis were showed to play an important role in
colorectal carcinogenesis. The major breakthrough in understanding the mechanisms
responsible for acquisition of numerous genetic alterations required for the
development of a malignant neoplasm came with a discovery that defects in
"caretaker" genes responsible for maintenance of genome integrity, substantially
facilitate carcinogenesis. The notion that the spontaneous mutation rate in somatic
cells is not sufficient for multiple mutations observed in many human malignancies and
that a mutator phenotype might be required for multistep tumorigenesis has been
argued for years (Nowell, 1976, Loeb, 1991; Flartwell, 1992). However, only the
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studies of the involvement of mismatch repair (MMR) genes in HNPCC and a subset
of sporadic colorectal cancers provided evidence that mutation rates in tumour cells
with MMR deficiency are substantially higher then in normal cells (Bhattacharyya et
al., 1994; Shibata et al., 1994; Eshleman et al., 1995). Two distinct phenotypes were
subsequently described in sporadic colorectal cancer. The first, affecting a small
fraction of tumours, known as microsatellite instability (MIN) or replication error
positive phenotype (RER+). This manifests itself as a high rate of alteration in the
length of short tandemly repeated nucleotide sequences (Aaltonen et al., 1993; lonov
et al., 1993; Thibodeau et al., 1993; Eshleman et al., 1995) and is consequent upon
defects in DNA mismatch repair system. The second, believed to affect the majority of
tumours, replication error negative phenotype (RER-), shows major abnormalities in
chromosome structure and number and has been suggested to arise through
chromosomal instability (CIN) (Langauer et al., 1997b). These two distinct colorectal
cancer phenotypes are suggested to arise through two distinct pathways and have
been subsequently shown to target different subsets of oncogenes and tumour
suppressor genes (Olschwang et al., 1997; Salahshor et al., 1999).
1.2.3. Tumour suppressor genes in colorectal carcinogenesis.
1.2.3.1. The role ofAPC gene in familial and sporadic colorectal cancer.
Familial adenomatous polyposis coli is an autosomal dominantly inherited disease that
affects 1 in 7000 individuals. Patients with FAP develop hundreds to thousands of
large bowel adenomas during their second and third decade of life. Their large number
virtually guarantees that some will progress to invasive carcinomas. FAP patients
often also develop extracolonic manifestations such as retinal lesions (congenital
hypertrophy of the retinal pigment epithelium - C1TRPE), osteomas, desmoids of the
skin, and brain tumours.
The search for the gene responsible for FAP was directed toward the chromosomal
region on the short arm of chromosome 5, where cytogenetically evident deletion was
observed (Herrera et al., 1986). Further molecular studies demonstrated tight linkage
of the disease to markers on 5q21 (Bodmer et al., 1987; Leppert et al., 1987). The
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adenomatous polyposis coli (APC) gene was finally identified in 1991 using positional
cloning (Groden et al., 1991; Kinzler et al., 1991; Nishisho et al., 1991). Patients with
FAP carry a germline mutation in one copy ofAPC. Inactivation of the second copy is
required for initiation of tumour development. Complete APC inactivation has been
found in the earliest neoplastic lesions called dysplastic aberrant crypt foci (ACF),
which are believed to be precursors of adenomas (Smith et al., 1994), but the exact
mechanism of tumour initiation by APC mutation is as yet unclear.
APC is speculated to act as a "gatekeeper" of colonic epithelial proliferation (Kinzler
and Vogelstein, 1997) inactivation of which is required for net cellular proliferation.
This hypothesis is supported by the fact that the APC protein is located at the
basolateral membrane in colorectal epithelial cells with expression more pronounced
as cells migrate up through the crypt column (Smith et al., 1993; Miyashiro et al.,
1995). Expression of wild-type APC in colorectal epithelial cells with APC mutations
results in apoptosis, suggesting that APC may control cell death process (Morin et al.,
1996). The APC gene encodes a 310kDa cytoplasmic protein consisting of 2843
aminoacids, with many structural and binding domains, however without strong
similarities to proteins of known function. APC binds with high affinity to P- and y-,
but not a-catenin, members of a family of proteins associated with intercellular
adhesion (Rubinfeld et al., 1993; Su et al., 1993). The catenins are part of
desmosomal and adherens junction complexes and bind to the cytoplasmic domain of
E-cadherin - a calcium dependent cell-cell adhesion molecule (see Cowin, 1994 for
review). Although APC is not found in a cadherin complex its association with
components of this structure suggests that its role in the generation of neoplasia may
occur through the modulation of cell-cell interactions. APC has also been shown to
interact with EB-1 a highly conserved 30kDa protein of unknown function (Su et al.,
1995). It has been suggested that mutant APC protein may interfere with the function
of wild-type protein through the formation of partially insoluble aggregates and
therefore function not only as a tumour suppressor gene but act in the dominant
negative fashion described for p53 (Howe and Guillem, 1997). Mutations of APC
cause aberrant accumulation of P-catenin which then binds T cell factor-4 (Tcf-4)
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causing increased transcriptional activation of unknown genes. c-MYC oncogene has
been identified as one of the target genes in this signalling pathway (He et at., 1998).
The role of APC in the development of colorectal adenomas and carcinomas is
supported by a knockout mouse model. The multiple /nterstinal neoplasia mouse
(,Min) is characterised by a dominantly inherited phenotype caused by a nonsense
mutation at codon 850 in one copy of the murine APC gene (Su et at., 1992). Min
mice develop multiple bowel polyps in a similar manner to FAP patients. In contrast
to the human disease, these are found not only in the colon but also throughout the
small interstine. The severity with which the mice are affected is modulated by an
unlinked locus known as modifier of min 1 (Moml). This gene is homologous to the
human gene encoding type II non-pancreatic phospholipase A2 (PLA2s). It has been
suggested that the action of PLA2s is complex (see also 1.2.3.4) and affects lipid
homeostasis and digestion of dietary fats as well as maintenance of normal bacterial
flora and elimination of aberrant crypt cells (MacPhee et at., 1995).
The study ofAPC gene in sporadic colorectal cancer revealed the presence of somatic
mutation in the great majority of tumours (Miyoshi et at., 1992; Powell et at., 1992).
Previous studies frequently demonstrated deletions in the 5q21 region in sporadic
colorectal carcinomas (Solomon et at., 1987; Vogelstein et at., 1988). Mutations in
the APC gene occur with the same frequency in carcinomas and in nonmalignant
adenomas as small as 5 mm suggesting that loss ofAPC function is one of the earliest
steps in sporadic colonic neoplasia (Powell et at., 1992). There is conflicting data
published on the frequency ofmutations in the APC gene in sporadic RER+ and RER-
colorectal cancers. It has been found to appear equally frequently in RER+ and RER-
tumours in some studies (Huang et at., 1996), while other investigators have shown
the APC mutations to be more frequent in RER- (Olschwang et al., 1997) or RER+
(Konishi et at., 1996) sporadic colorectal cancers. Due to these discrepancies it is
difficult to speculate on the relative importance of inactivation of this particular
tumour suppressor gene in two different pathways of colorectal carcinogenesis.
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1.2.3.2. The p53 gene.
Mutations in the p53 gene are the most common genetic aberrations currently
detected in various types of human malignant tumours (Nigro et al., 1989; Hollstein et
al., 1991; Levine et al, 1991 and 1994). The Li-Fraumeni syndrome is an autosomal
dominantly inherited syndrome caused by a germ-line mutation in the p53 gene.
Patients with this syndrome develop numerous carcinomas and sarcomas as well as
leukemias, but rarely colorectal carcinomas. The p53 gene is located on the short arm
of chromosome 17 (Isobe et al., 1986) and encodes a nuclear phosphoprotein which
has ability to bind to DNA in a sequence-specific manner and acts as a DNA-
dependent transcription factor. It is involved in a wide range of cellular functions,
most important of which is the maintenance of genomic stability. For this reason p53
has been named "guardian of the genome".
Evidence from mice null for the p53 gene, which develop normally but have a high
incidence of tumour development in adulthood (Donehower et al., 1992), suggests
the function ofp53 in the protection of cells after genomic damage. Indeed, certain
types of DNA damage induce p53 and lead to cell cycle arrest allowing for repair of
DNA damage preventing the passage of potentially harmful genetic mutations to
daughter cells. Alternatively, p53 can induce apoptosis in these cells with the same
end result (Fritsche et al., 1993). The mechanisms of p53-induced cell cycle arrest and
apoptosis are complex and involve numerous components. The p53 mediated Gi
arrest requires transcriptional induction of p21nAFhUFl gene (el-Deiry et al., 1994),
while /?53-dependent apoptosis appears to be related to modulation of the function of
the members of the Bcl-2 gene family, transcriptional activation of Bax (apoptosis
promoter) in particular (Miyashita and Reed, 1995). It is generally accepted that p53
plays a critical role in maintaining genomic integrity (Kastan et al., 1991; Lane, 1992;
Livingstone el al., 1992; Yin et al., 1992; Nelson and Kastan, 1994). Association of
p53 defects with chromosomal instability is well documented (Bischoff et a/., 1990;
Livingstone et al., 1992; Yin et al., 1992; Carder et al., 1993; Deangelis et al., 1993;
Meling et al., 1993; Carder et al., 1995; Bouffler et al., 1995; Donehower et al.,
1995; Gualberto et al., 1998; Venkatachalam et al., 1998). However, RER+
colorectal cancer cell lines with p53 mutations have been shown to remain
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chromosomally stable (Eshleman et al., 1998a) indicating that p53 mutation does not
invariably induce chromosomal instability. There are also implications of p53
involvement in the regulation of hMSH2 and it therefore has a possible role in
mismatch repair (Schrerer et al., 1996).
Loss ofp53 function occurs frequently in sporadic colorectal cancer and is found in
up to 75% of cases (Baker et al., 1990; Cunningham et al., 1992; Vandenbroek et al.,
1993; Khine et al., 1994). It has also been shown to be a rather late event in
colorectal carcinogenesis, occurring usually at the transition from the late adenoma to
carcinoma (Vogelstein et al., 1988; Baker et al., 1990; Fearon and Vogelstein, 1990).
p53 mutations detected in colorectal carcinomas are mostly missense mutations. They
often result in the nuclear accumulation of abnormal protein with increased half-life,
allowing detection by immunohistochemical methods. It has also been shown that
90% of all mutations in the p53 gene are located in exons 5-8 (Levine et al., 1991).
Although, according to Knudson's two-hit hypothesis (Knudson, 1971), defects in
both copies of a tumour suppressor gene are required for its inactivation, some
mutations in the p53 gene appear to exert a dominant negative effect (Eliyahu et al.,
1988; Milner and Medcalf, 1991). An oncogenic form of p53, with a missense
mutation which confers a dominant gain-of-function phenotype disrupting spindle
checkpoint control leading to genomic instability has also been described (Gualberto
et al., 1998).
Although published reports of the overall frequency of p53 mutations in sporadic
colorectal cancer are similar, conflicting data has appeared with regard to the
frequency of p53 mutations in RER- and RER+ colorectal carcinomas (Aaltonen et
al., 1993; Ionov et al., 1993; Kim et al., 1994; Ilyas et al., 1996; Cottu et al., 1996;
Remvikos et al., 1997). Recent reports indicate that p53 mutations are significantly
less common in RER+ than in RER- colorectal cancers (Cottu et al., 1996; Eshleman
et al., 1998a) suggesting that its inactivation is not necessary for tumour progression
in colorectal cancers with microsatellite instability.
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1.2.3.3. DCC: the Deleted in Colon Cancer gene.
DCC was one of the earliest genes found to be associated with colorectal cancer.
Deletions of chromosome 18q, to which DCC was subsequently mapped in the region
18q21, are very common in colorectal carcinomas (Vogelstein et a/., 1988).
DCC is a large gene that extends over 1.35 million bases and has at least 29 exons
(Fearon et al., 1990). It encodes a cell adhesion protein predicted to have 1447
amino-acids which resembles most a neural cell adhesion molecule. DCC is normally
widely expressed on the colon mucosa (Hedric et al., 1994) and has been
demonstrated to mediate epithelial-epithelial and epithelial-mesenchymal interactions
(Chuong et al., 1994). It was hypothesised that loss of DCC might result in loss of
cell-to-cell contact, thereby enhancing metastasis. Indeed DCC expression is reduced
or absent in 70-75% of colon cancers (Vogelstein et al., 1988; Fearon et al., 1990;
Itoh et al., 1993; Cho et al., 1994). Loss of heterozygosity in 18q21 region is seen in
11% of adenomas and in 47% of adenomas with microinvasion, suggesting that it is a
late alteration that might be involved in the progression of colorectal cancer.
Complete or partial loss of 18q is also significantly more frequent in advanced stages
of the disease (Jen et al., 1994) and 18q deletions are indicative of poor prognosis
(Kern et al., 1989). Recently described mutant mice lacking both alleles of DCC
however show no abnormalities of intestinal biology (Fazeli et al., 1997), questioning
the role ofDCC in colorectal carcinogenesis.
Studies of the frequency of inactivation of the DCC gene in RER+ and RER-
colorectal cancers have shown the loss or reduction of DCC mRNA expression and
allelic loss at the DCC locus to be significantly less frequent in RER+ cancers
compared to RER- tumours, suggesting its limited role in the tumourigenesis of
colorectal cancers with microsatellite instability (Yamamoto et al., 1998a).
1.2.3.4. TGF-J3 R II: Transforming Growth Factor [3 type II receptor (RII).
TGF-P is a potent inhibitor of epithelial cell growth (Roberts et al., 1985) and can
induce apoptosis of normal colonic epithelial cells (Wang et al., 1995). Loss of
responsiveness to TGF-p is common in human cancers and is thought to be an
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important step in tumourigenesis. Most colon cancer cells are resistant to the anti¬
proliferative effects of TGF-p (Hoosein et al., 1989).
The intracellular biological effects of TGF-P are initiated following ligand binding to
oligomeric complexes of high affinity TGF-P type I and type II receptors. If one of
the receptors is absent or inactivated, the cells lose their responsiveness to TGF-p.
The mammalian type II receptor for TGF-P is a transmembrane serine/threonine
kinase (Mathew and Vale, 1991; Lin et al., 1992). Signalling by this receptor is
mediated by Smad protein family which upon phosphorylation by activated receptors
form complexes move to the nucleus associate with DNA-binding proteins and
activate gene transcription (Massague et al., 1997).
Inactivation of the type II TGF-P receptor has been reported in colon cancer cells
with microsatellite instability (Markowitz et al., 1995; Parsons et al., 1995; Akiyama
et al., 1996; Togo et al., 1996a). Mutations of TGF-fl receptor II are frequently
found in adenomas and are present in the vast majority of carcinomas from HNPCC
patients where they appear to be an early event in cancer progression (Lu et al., 1996;
Akiyama et al., 1997). RII mutations in colon cancers with microsatellite instability
usually result in frameshifits clustered in a naturally occurring 10-bp microsatellite-like
polyadenine tract at codons 125-128 of its 565-codon open reading frame (BAT-RII).
In a few MIN colon cancers inactivation of one of the RII alleles occurs via non-BA T-
RII mutations that alter the RII kinase domain (Markowitz et al., 1995; Parsons et al.,
1995) demonstrating an underlying selective advantage for RII inactivation. This is
irrespective of whether it occurs via BA T-Rll or non-BA T-RII mutational events. In
most MIN colorectal cancers the polyadenine tract mutations affect both alleles ofRII
suggesting tumour suppressor activity of wild-type RII (Parsons et al., 1995).
Recently inactivation of TGF-P receptor II through non-BAT-RII point mutations has
been found to occur in 15% of RER- colorectal carcinomas. In addition another 55%
of RER- cancers demonstrate a transforming growth factor P signalling blockade
distal to RII (Grady et al., 1999) indicating that TGF-P pathway is a major target for
inactivation in both RER+ and RER- colorectal cancers.
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1.2.3.5. Otherputative tumour suppressor genes in colorectal cancer.
Mutated in Colorectal Cancer gene (MCC) was first identified as a candidate gene
responsible for FAP due to its location in the 5q21 region (Kinzler et a/., 1991). The
protein encoded by MCC shows sequence homology to a murine G protein receptor,
important in signal transduction. However, no germline mutations were detected in
MCC in FAP patients eliminating the possibility that defects in MCC cause FAP
syndrome (Nishisho et al., 1991). Although loss of heterozygosity (LOH) in the MCC
locus is frequently detected in colorectal adenocarcinomas, independent loss ofMCC
without APC is a rare event and in cases where allele loss occurs mutation of the
retained allele is uncommon (Curtis et al., 1994). This suggests that MCC does not
function as an independent tumour suppressor in the majority of sporadic colorectal
cancers.
BAX is a 21 kDa protein, a member of the BCL2 family of proteins which controls an
important checkpoint prior to activation of the caspase family of proteases in
apoptosis. Unlike BAX-BCL2 heterodimers which appear to promote cell survival,
BAX-BAX homodimers are potent death inducers (Webb et al., 1997) and a
significant effector in the initiation of apoptosis. Inactivating mutations in BAX have
been observed in a proportion of colorectal cancers (Rampino et al., 1997; Yagi et
al., 1998; Yamamoto et al., 1998; Ouyang et al., 1998). These mutations are
restricted to tumours with mismatch repair deficiency and usually occur in G8 tract of
exon 3 (Rampino et al., 1997). It has been argued that selective loss of a death
pathway in these tumours, due to BAX inactivation, represents a critical event in early
carcinogenesis. However, the G8 tract is a classical target site for nucleotide mismatch
and it has been shown that BAX mutation, in a proportion of RER+ colorectal
cancers, is not necessary for formation of the founder clone and can occur later in the
tumour progression (Abdel-Rahman et al., 1999).
The tumour suppressor gene pl6 located on the short arm of chromosome 9 (9p21)
encodes for a cyclin-dependent kinase 4 (CDK4) inhibitor that binds to and inactivates
cyclin D/CDK4 complex responsible for phosphorylation of the retinoblastoma gene
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product. Hypophosphorylated retinoblastoma protein blocks the transcription of
important cell-cycle regulatory proteins and is critical in inhibition of cellular
proliferation. In human neoplasms pl6 is silenced in three ways; by homozygous
deletion, methylation of the promoter, and point mutation. The first two mechanisms
comprise the majority of inactivation events in most tumours. Additionally, the loss of
pl6 may be an early event in cancer progression, because deletion of at least one copy
is high in some premalignant lesions (see Liggett and Sidransky, 1998 for review).
Inactivation ofpl6 through hypermethylation of its promoter region has been found in
most sporadic colorectal cancers with microsatellite instability and in a small
proportion of RER- tumours (Toyota et al., 1999). However, the exact frequency of
pl6 inactivation through all three mechanisms has not been established in colorectal
cancer.
18q21 region has been shown to contain another gene that was found to be frequently
deleted in pancreatic cancer and therefore named Deleted in Pancreatic Cancer locus
4 (.DPC4). Subsequently, 16% of colon cancers were demonstrated to have mutations
in the DPC4 gene (Takagi et al., 1996). The significance ofDPC4 lies in its homology
to Drosophila melanogaster gene MAD (Mothers against c/pp). Mutations in MAD
and dpp lead to defects in midgut morphogenesis and dorsal-ventral pattering during
embryogenesis. The dpp protein is a member of a family related to TGF-(3, a potent
inhibitor of epithelial cells growth. MAD appears to function downstream of dpp in
the signalling pathway. At least two other components related to MAD called MADR2
(Eppert et al., 1996) and SMAD4 (Takagi et al., 1996; Thiagalingam et al., 1996)
have been identified and both have been mapped to 18q21. MADR2 and SMAD4 are
known to be central players in the signal transduction pathway activated in response
to the large family of TGFP-like ligands.
Partial deletion in the short arm of chromosome 1 occurs in up to half of all colorectal
cancers (Leister et al., 1990; Muleris et al., 1990; Couturier-Turpin et al., 1992;
Bardi et al., 1993 and 1995; Bomme et al., 1996; di Vinci et al., 1996) and has been
shown to be an early event in colorectal carcinogenesis (di Vinci et al., 1998). It is
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also an indicator of poor prognosis (Ogunbiyi et al., 1997). One of the three
commonly deleted regions in chromosome 1 overlaps with the region to which PLA2s
has been mapped. PLA2s encodes type II non-pancreatic phospholipase A2 (MacPhee
et al., 1995) one of the enzymes responsible for the production of arachidonic acid (a
prostaglandin precursor). It is not clear however how loss of its function contributes
to tumour development (see also 1.2.3.1). Ip36 region contains another candidate for
a tumour suppressor gene - p72. This gene encodes a protein highly homologous to
p53 (Kaghad et al., 1997) but subsequent search for somatic mutations inp73 gene in
colorectal carcinomas revealed that such mutations are extremely rare (Han et al.,
1999). Human aflatoxin B-l aldehyde reductase gene located at Ip35-lp36 has also
been suggested to play a role in colorectal carcinogenesis due to its presumptive
involvement in detoxification of genotoxic and cytotoxic substances (Praml et al.,
1998). Other putative tumour suppressor genes located on the short arm of
chromosome 1 include ID3 (inhibitor of DNA binding 3; 1 p36.13 - p36.12), NB/NBS
(neuroblastoma suppressor; 1 p36.13 - p36.11), TNFR2 (tumour necrosis factor
receptor 2; lp36.3 - p36.2), DAN (differential-screening-selected gene aberrant in
neuroblastoma; 1 p36.13 - p36.11), CDC2L1 (cell division cycle 2-like 1; lp36) and
BRCD2 (breast cancer suppressor-2; lp36) (Knuutila et al., 1999) but their role in
colorectal carcinogenesis is unclear.
Allelic loss on chromosome 8p is found in about half of all sporadic colorectal
carcinomas (Cunningham et al., 1993) however no tumour suppressor genes have
been convincingly identified in this region. Possible candidates include FEZ1 gene
encoding Fezl protein containing leucine-zipper region with similarity to the DNA-
binding domain of the cAMP-responsive activating-transcription factor 5. FEZ1 gene
transcripts are undetectable in more than 60% of epithelial tumours and mutations in
FEZ1 have been found in oesophageal cancers and prostate cancer cell lines,
suggesting that its inactivation may play a role in development of various human
tumours (Ishii et al., 1999). Other possible candidates include a gene frequently
deleted in human liver cancer DLC1 (iTynein /ight-chain gene 7;
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8p21.3-p22), PRLTS (PDGF-7'eceptor P-/ike tumour suppressor), EXT1 and EXTL3
[exostoses (multiple)-like 3] (Knuutila et al., 1999).
1.2.4. Oncogenes in colorectal carcinogenesis.
1.2.4.1. The ras oncogene and receptor-mediated signal transduction pathways.
Ras is a member of a large family of genes highly conserved between species encoding
for guanosine triphosphate (GTP) binding proteins involved in many processes
including transmission of extracellular signals. The p21ras protein is the product of
three homologous genes, H-ras, N-ras and K-ras. It is located on the inner surface of
the plasma membrane where it takes part in the transduction of growth and
differentiation signals. Although the ras genes are highly homologous only the K-ras
gene, located in the short arm of chromosome 12 (12p 12), plays a significant role in
the development of colorectal cancer with approximately 50% of the tumours carrying
mutations in one of the gene alleles (Vogelstein et al., 1988). K-ras mutations are
almost always localised to one of the three codons, with codon 12 being most
frequently affected. Few mutations are found in codons 13 and 61. Mutations in the
K-ras gene cause the protein to be constitutively active in the GTP-bound state,
leading to a continually growth-stimulated state. Alteration in the K-ras gene were
found with similar frequency in large adenomas (>lcm) and carcinomas in cancer
bearing bowels, 42% and 47% respectively, but in only 10% of small adenomas
obtained mostly from FAP patients (Vogelstein et al., 1988), placing this genetic
event relatively early in colorectal carcinogenesis, between an early and a late
adenoma. However, there is evidence suggesting that K-ras mutations might occur
even earlier since they were detected in 57% to 73% of aberrant crypt foci (Pretlow et
al., 1993; Losi et al., 1996).
Activation of the K-ras oncogene appears to be equally important in the development
of RER+ and RER- colorectal cancers (Olschwang et al., 1997). Although other
reports indicate that mutations in the K-ras gene are significantly more frequent in
RER- cancers (Konishi et al., 1996).
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1.2.4.2. c-myc.
c-myc encodes a 62 kDa phosphoprotein localised to both the cytoplasm and nucleus
which as a heterodimer with a nuclear protein Max binds to DNA and can activate
transcription. Activation of c-myc with increased levels of both mRNA and protein
has been associated with cellular proliferation in numerous tissues. Rearrangements
and amplifications of the c-myc gene are responsible for elevated expression of the c-
myc protein. In normal colonic mucosa c-myc protein is present in the proliferative
compartment in the lower one third of the crypts. Elevated levels of c-myc protein
have been described in colorectal carcinomas (Melhem et al., 1992; Royds el al.,
1992). Recently previously enigmatic overexpression of c-myc in colorectal
carcinomas have been elucidated by the discovery of its interactions with APC and P-
catenin through Tcf-4 signalling pathway. Expression of c-myc gene was shown to be
repressed by wild-type APC and activated by P-catenin which aberrant accumulation
is caused by mutations of APC. These effects were mediated through Tcf-4 binding
sites in the c-myc promoter (He et al., 1998).
1.2.4.3. bcl-2.
bcl-2 was originally cloned from a 14; 18 translocation breakpoint associated with
several human B cell lymphomas (Tsujimoto et al., 1985; Cleary and Smith, 1986).
The bcl-2 protein is a member of a large family of homo- and heterodimerising
proteins, some of which are survival-supporting, like bcl-2 itself and bcl-xL, whilst
others are death promoting (e.g. bax, bad and bcl-xS) (see Webb et al., 1997 for
review). Its oncogenic potential has been attributed to its ability to inhibit apoptosis.
Expression of bcl-2 is normally confined to the base of colonic crypts, but with the
onset of dysplasia and progression to early adenoma its expression increases and is
seen throughout the crypts (Watson et al., 1996). It has been postulated that deranged
expression of the bcl-2 protein may cause resistance to apoptosis in colonic epithelial




CD44 is a family of type I transmembrane glykoproteins that are widely expressed on
a variety of cells including cells of epithelial, mesenchymal, and hematopoietic origin.
All members of CD44 family are encoded by a single gene located on the short arm of
chromosome 11 (11 p 13) that consists of 19 exons (Stamenkovic et al., 1989;
Screaton et al., 1992). CD44 has been implicated in lymphocyte homing and
activation, hematopoiesis, and tumour progression and metastasis. It is believed to
function as a cell adhesion receptor linking the cell and the cytoskeleton to
extracellular matrix molecules. In the normal colorectal mucosa, CD44 protein is
expressed at low levels and is confined to the base of the crypts. In colorectal tumours
expression of CD44 protein is generally strongly enhanced in comparison to normal
mucosa, although there is marked inter- and intratumoral heterogeneity. The major
upregulation of CD44 occurs at the transition from normal mucosa to adenoma, but
CD44 overexpression is already present in aberrant crypt foci with dysplasia. This
indicates that deregulation of CD44 represents an early event in colorectal
carcinogenesis. CD44 upregulation is thought to be direct or indirect result of
constitutive activation of the Wnt pathway. Enhanced CD44 expression is seen in
tumours from FAP patients with a germline APC mutation as well as in Ape mutant
mice (see Wielenga et al., 2000 for review).
1.2.5. DNA methylation.
The term DNA methylation refers to the methylation of cytosine residues (5-
methylocytosisne) at CpG sites which is characteristically clustered to so-called CpG
islands in gene promoter regions. Hypo- and hypermethylation of these regions are
related to activation and inhibition of transcription and this type of regulation is
essential to cell differentiation and embryological development (see Monk, 1995 for
review). DNA methylation is closely related to the mechanism by which one copy of a
gene is preferentially silenced according to parental origin, generally referred to as
genomic imprinting (Feil and Kelsey, 1997). Patterns of DNA methylation are
maintained during cell division by 5-cytosine DNA methyltransferase (DNMT).
DNMT preferentially methylates hemimethylated CpG sites copying established
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methylation patterns to the newly synthesised DNA strands. This ensures that
information related to gene expression is maintained through cell division.
Both global hypomethylation compared with normal tissue as well as regional
hypermethylation have been observed in human malignancies. Alterations in DNA
methylation have been proposed as a central pheneomenon underlying the neoplastic
process (Laird and Jaenisch, 1994; Counts and Goodman, 1995; Baylin et a!, 1998;
Breivik and Gaudernack, 1999).
Widespread genomic hypomethylation occurs early in colorectal carcinogenesis with
similar levels of hypomethylation found in benign and malignant colorectal neoplasms
(Goelz et al., 1985b; Feinberg, 1988). Hypomethylation of proto-oncogenes has been
observed in liver tumours and leukemias. A variety of proto-oncogenes such as c-fos
gene, the c-myc gene and the Ha-ras and Ki-ras genes have shown reduced levels of
DNA methylation (see Laird and Jaenisch, 1994 for review). DNA hypomethylation
leads to elevated mutation rates in murine embryonic stem cells nullizygous for the
major DNA methyltransferase (Dnmtl). Gene deletions were found to be predominant
mutations in these cells and their major cause was either mitotic recombination or
chromosomal loss accompanied by duplication of the remaining chromosome. Both
aneuploidy and DNA hypomethylation are observed early in the transformation
process. It has therefore been postulated that genomic hypomethylation provides the
incipient cancer cells with a mutator phenotype promoting loss of heterozygosity in
regions containing tumour suppressor genes (Chen et al., 1998).
There have been many reports of regional increases in DNA methylation levels.
Regional hot spots of hypermethylation have been found on chromosome 3p, lip and
17p in a variety of human tumours. There is evidence for inactivation of tumour-
suppressor gene function through hypermethylation of the Rb gene in sporadic
retinoblastoma. It is possible, therefore, that hypermethylation of the promoter region
of tumour suppressor genes leading to gene inactivation results in a selective growth
advantage of neoplastic cells (see Laird and Jaenisch, 1994 for review). Tumour
suppressor gene methylation in cancer is usually associated with lack of gene
transcription and absence of coding region mutation. Thus it has been proposed that
methylation of CpG islands serves as an alternative mechanism of gene inactivation in
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carcinogenesis (Toyota et al., 1999). It has also been shown that methylation of
cytosine to 5mC leads to a higher rate of C—>T mutations compared with that of
unmethylated sites (Rideout et al., 1990). Recently, it became apparent that
hypermethylation of the promoter region of hMLHl is responsible for its inactivation
and subsequent development of RER+ phenotype in the vast majority of sporadic
colorectal cancer with microsatellite instability (Cunningham et al., 1998; Herman et
al., 1998; Deng et al., 1999; Maekawa et al., 1999; Wheeler et al., 1999). Two
distinct types of hypermethylation in cancer have been described; A - for ageing-
specific and C - for cancer specific. Both may have distinct causes and different roles
in cancer development. The mechanism of type A methylation is unknown, but it is
likely that it results from physiological rather than genetic alteration. Type A
methylation is very frequent and present in large numbers of cells, it is present in all
individuals, not just patients with cancer; and it is gene and tissue specific. In contrast
type C methylation is relatively infrequent in primary colorectal cancer and is never
observed in normal colon mucosa. Detailed analysis of type C methylation in
colorectal cancers revealed a striking pattern suggesting the presence of
hypermethylator phenotype in a subset of sporadic colorectal cancers (Toyota et al.,
1999). Through its ability to silence multiple genes simultaneously CpG island
methylator phenotype would be functionally equivalent to genetic instability, resulting
in rapid accumulation of molecular alterations with a potential to accelerate the
neoplastic process.
1.2.6. Genomic instability in colorectal carcinogenesis.
1.2.6.1. Introduction.
Carcinogenesis is a multistep process which is increasingly viewed in terms of
evolutionary mechanisms and natural selection at the somatic level. Although, the
genes of multicellular organisms exist in an environment that promotes cellular
cooperation, the genes in the somatic cells are not exceptions to the general rule of
natural selection. Somatic mutations are selected solely based on their ability to
improve the reproductive capacity of a somatic clone and natural selection will favour
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cells that escape the organism's control mechanisms even if it contradicts the goal of
reproduction of the organism.
Evolution through natural selection depends on two essential elements, selection
pressure and availability of genetic variation. A selection pressure that favours escape
from the organism's growth control mechanisms is an inevitable consequence of
multicellularity. A somatic mutation will have a larger potential to reproduce if the cell
can escape from the suppressive signals brought on by the other genes and cells of the
organism. However, since preservation of genetic homogeneity is crucial for survival
of a multicellular organism, a number of homeostatic processes ensuring integrity of
the genome have evolved. These mechanisms include antioxidation and detoxofication
preventing DNA damage, DNA repair mechanisms, elimination of cells that have
sustained unrepairable DNA damage and mechanisms ensuring fidelity of DNA
replication. A DNA damaging environment will therefore, exert growth-inhibiting
effect on normal cells, and consequently selection pressure that favours escape from
these control mechanisms (see Breivik and Gaudernack, 1999 for review).
No evolution can occur without the availability of genetic variation. It has been
postulated that spontaneous mutation rate in somatic cells is not sufficient to account
for multiple mutations observed in human tumours. An underlying genomic instability
(mutator phenotype) is required for the generation of the multiple mutations that
underlie cancer (Loeb, 1991). It has been argued that an early step in tumour
progression is one that induces a mutator phenotype providing the required genetic
variation for natural selection at the somatic level.
This hypothesis has subsequently been proved and two major levels of genomic
instability have been identified in human malignances. The first involves subtle
sequence changes that alter one or a few DNA base pairs. These mutations usually
result from defects in one of the two major DNA repair systems - nucleotide-excision
repair and mismatch repair. The second involves changes at chromosomal level
including chromosomal gains and losses, chromosome translocations and gene
amplifications, the molecular bases of which are not yet clear (see Lengauer et al.,
1998 for review). Two kinds of genomic instability have been so far identified in
colorectal cancer: microsatellite and chromosomal instability.
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Here, the mechanisms implicated in destabilisation of the genome in colorectal cancers
are reviewed.
1.2.6.2. The role ofdefects in mismatch repair system and microsatellite instability
in colorectal carcinogenesis.
1.2.6.2.1. Introduction.
Long before the discovery of its involvement in human carcinogenesis, mismatch
repair was extensively studied in bacteria. Later it was described in yeast and finally in
higher eukaryotes. The information gained from studies of the MMR system in
bacteria suddenly become relevant to human neoplasia in 1993 when the RER
phenotype of microsatellite instability was discovered in human cancers and was
rapidly shown to be due to defects in mismatch repair.
Evidence supporting the role of MMR defects in carcinogenesis includes: (i)
theoretical considerations of the requirement for aquisition of a mutator phenotype as
an early event in the multistep carcinogenesis, (ii) discovery that MMR defects cause
a mutator phenotype destabilising the genome and altering expression of genes
integral for carcinogenesis, (iii) presence of defects in MMR genes in the germline of
HNPCC kindred members, (iv) finding that such defects behave as classic tumour
suppressor genes in both familial and sporadic colorectal cancers, (v) the fact that
MMR knockout mice have an increased incidence of tumours, and (vi) that genetic
complementation of MMR defective cells stabilises the MMR deficiency-associated
microsatellite instability (see Eshleman and Markowitz, 1996 for review).
1.2.6.2.2. MMR system in bacteria, Saccharomyces cerevisiae and its human
homologues.
One role of MMR is to recognise and repair mistakes made by DNA polymerases
during replication. While the MMR system in bacteria requires 10 independent
components there are three critical ones, named after their corresponding bacterial
mutator strains: MutS, MutL and MutH. MutS recognises and binds to the mispair or
loop, then recruits MutL and MutH to form a complex which scans the duplex for the
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nearest hemimethylated site which MutH then nicks on the unmethylated strand. An
exonuclease then excises the nascent strand from the nick back past the mismatch.
This patch is then resynthesised and ligated.
There are extensive similarities between bacterial and human MMR system. Most
importantly, both provide the genome with a 100-1000-fold level of protection against
mutations arising during DNA replication. A major difference is that the human
system has multiple homologues for each bacterial component (Table 1). Human
homologues of MutS include hMSH2 (Auman MutS homologue 2), GTBP (G T
mismatch binding protein; also referred to as hMSH6) and hMSH2. The gene product
of hMSH2 binds the mismatch as heteroduplex with the products of hMSH6 or
hMSH3. However, hMSH2 is capable of binding mismatched nucleotides
independently and its absence results in an extreme mutator phenotype with numerous
mutations in repeat units and increased rate of point mutations (Bhattacharyya et al,
1994; Shibata et al., 1994; Boyer et al., 1995). Neither hMSH6 nor hMSH3
deficiency is sufficient for establishing strong mutator phenotype indicating a high
degree of redundancy in their function (Kolodner, 1995; Risinger et al., 1996; Umar
eta/., 1998).
Table 1. Human MMR genes.
Bacterial MMR Human gene Chromosomal Germline mutations in
homologue localisation humans
MutS hMSH2 2p 16 yes
hMSH6 (GTBP) 2pl6 yes
hMSm - -
MutL hMLHl 3p21 yes
hPMSl 2q31-33 yes
hPMS2 7p22 yes
Human homologues of MutL include hMLHl (human MutL homologue 1), hPMSl
(human post-meiotic segregation 1) and hPMS2. In Saccharomyces cerevisiae (S.
cerevisiae) MLH1-PMS1 heterodimer interacts with MSH2 bound to a mispaired
base which is consistent with the idea that the MLH1-PMS1 complex plays the same
role in mismatch repair in eukaryotes as MutL plays in bacteria (see Kolodner, 1995
for review). Figure 2 illustrates MMR pathway in human cells.
27
Figure 2. MMR pathway in human cells (Kinzler et al., 1996).
a,b - During DNA replication single base or larger mismatches can occur due to
misincorporation by polymerase or strand slippage,
c - The mismatch is recognised by rnutS homologues. In humans optimal mismatch
recognition is thought to require at least two mutS homologues, hMSH2 and GTBP.
hMSH3 may substitute for GTBP in certain cases.
d,e - MutL homologues are then recruited to the complex (d) and the mismatch is
repaired (e) by a process that in bacteria involves an exonuclease, helicase II DNA
polymerase III, single stranded binding protein, and DNA ligase (Modrich, 1995)
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1.2.6.2.3. The genetic bases of microsatellite instability in familial and sporadic
colorectal cancer.
Discovery of the RER positive phenotype in sporadic and inherited colon cancer
provided the first clue that defects in MMR system might play a role in colorectal
carcinogenesis (Aaltonen et a/., 1993; Thibodeau et a/., 1993; Inov et al., 1993).
Microsatellites are normally stable repetitive genetic sequences where the repeating
unit is one to six bases (Weber et a/., 1989). Because of their repeating nature they
are particularly prone to slippage during replication which results in a small loop in
either the template or nascent DNA strand (Kunkel et al., 1990). Despite these
replicative mistakes which occur in all cells microsatellites are normally stable in
length because of the efficiency of the MMR system. However, the RER+ cancers
have lost strict maintenance of microsatellite length and their microsatellites appear
unstable - they differ in length compared to microsatellites in normal tissue.
Originally it was not clear why instability of microsatellites, which are almost always
non-coding, should contribute to carcinogenesis. This was explained by the discovery
that RER+ colorectal cancers also exhibit an increased mutation rate in endogenous
expressed genes (Bhattacharyya et al., 1995; Eshleman et al., 1995). Sequence
analysis of the mutations in a selectable reporter gene showed the increased rate of
not only the predictable frameshift mutations but also substantial numbers of base
substitutions equal in number to the frameshifts (Bhattacharyya et al., 1995; Eshleman
et al., 1996). In addition, genes such as TGFJ3 RII, which functions as a tumour
suppressor gene and BAX - a significant effector in the initiation of apoptosis, contain
homopolymeric repetitive sequences, a classical target site for nucleotide mismatch. In
fact inactivating mutations in both TGF/3RII and BAX have been found to occur in
colorectal cancers with microsatellite instability (Markowitz et al., 1995; Parsons et
al., 1995; Akiyama et al., 1996a; Togo et al., 1996a; Rampino et al., 1997; Ouyang et
al., 1998; Yagi et al., 1998; Yamamoto et al., 1998b).
Microsatellite instability is present in most tumours from patients with hereditary non-
polyposis colorectal cancer where it is a consequence ofmutations in one of the DNA
mismatch repair genes (hMSH2, hMLHl, hPMSl, hPMS2, hMSH3 or hMSH6)
(Peltomaki et al., 1993; Bronner et al., 1994; Nicolaides et al., 1994; Nystrom-Lahti
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et al., 1994; Papadopoulos et al., 1994; Wijnen et al., 1995; Liu et al1996;
Akiyama et al., 1997b; Miyaki et al., 1997). The majority of HNPCC patients carry a
germline mutation in either hMSH2 or hMLHl (Liu et al., 1996). RER+ phenotype is
also detected in approximately 15-20% of sporadic colorectal cancers (Lothe et al.,
1993; Aaltonen et al., 1994; Wu et al., 1994; Borresen et al., 1995; Liu et al., 1995;
Bubb et al., 1996; Eshleman and Markowitz, 1996; Konishi et al., 1996). Llowever,
inactivating mutations in MMR genes appear to play a limited role in sporadic
colorectal cancers with microsatellite instability. Recent studies suggest that
inactivation ofMMR system in sporadic tumours occurs through hypermethylation of
CpG sites in the promoter region of hMLHl followed by loss of its expression
(Cunningham et al., 1998; Herman et al, 1998; Deng et al., 1999; Maekawa et al.,
1999; Wheeler et al., 1999).
Despite different molecular mechanisms underlying RER+ phenotype in familial and
sporadic form, all colorectal cancers with microsatellite instability, tumours from
HNPCC patients and sporadic cancers share certain clinicopathological
characteristics. They are usually located in the proximal colon (Ionov et al., 1993;
Thibodeau et al., 1993; Lothe et al., 1993; Aaltonen et al., 1993; Kim et al., 1994),
they more frequently show poor differentiation (Ionov et al., 1993; Lothe et al., 1993;
Kim et al., 1994), mucin production (Kim et al., 1994) and they have near-diploid
DNA content (Aaltonen et al., 1993; Lothe et al., 1993; Remvikos et al., 1995;
Schlegel et al. 1995). Sporadic RER+ colorectal cancers also exhibit a substantial
survival advantage, independent of other prognostic factors (Lothe et al., 1993;
Thibodeau et al., 1993; Bubb et al., 1996).
1.2.6.3. Chromosomal instability in colorectal cancer.
The majority of sporadic colorectal cancers display a distinct phenotype characterised
by an increased number of chromosomal abnormalities. Gains, losses and structural
alterations within chromosomes consisting of chromosome deletions, inversions and
gene amplifications are found in many colorectal tumours. Loss of genetic material
from lp, 5q, 8p, 17p and 18q, amplifications of 8q, 13q, 20q and duplication of
chromosome 7 are among the chromosomal abnormalities most frequently identified
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in colorectal carcinomas (Reichmann et al., 1981; Muleris et al., 1985, 1988, 1990,
1994; Yaseen et al., 1990; Konstantinova et al., 1991; Xiao et al., 1992; Bardi et al.,
1993a, 1993b, 1995; Barletta et al., 1993; Herbergs et al., 1994; Gerdes et al., 1995;
Bomme et al., 1996; Herbergs et al., 1996; Ried et al., 1996; Mertens et al., 1997).
Abnormal chromosome copy number (aneuploidy) is nearly ubiquitous in cancer
(Mertens et al., 1997; Mitleman et al., 1997). It could therefore be argued that it
results simply from the abnormal structure and growth properties of cancer cells.
However, there is increasing evidence for its association with underlying
chromosomal instability (Lengauer et al., 1997b; Cahill et al., 1998). As defective
mismatch repair drives neoplasia in MIN tumours and provides genetic variation for
natural selection, CIN has also been suggested as an alternative pathway in colorectal
carcinogenesis driving the tumorigenic process in the majority of colorectal tumours
(Lengauer et al., 1997b). While the mechanisms underlying microsatellite instability
are known to involve the mismatch repair system (Peltomaki et al., 1993; Bronner et
al., 1994; Nicolaides et al., 1994; Nystrom-Lahti et al., 1994; Papadopoulos et al.,
1994; Wijnen et al., 1995; Liu et al., 1996; Akiyama et al., 1997; Miyaki et al.,
1997) and are relatively well understood, the molecular basis of chromosomal
instability, present in the majority of malignancies, is just beginning to be explored.
A number of mechanisms that might underlie chromosomal instability have been
suggested. It is suspected that, in contrast to MIN when only a few genes are
responsible for the phenotype, there is a large number of genes which when altered
can give rise to CIN. They include genes involved in chromosome condensation,
sister-chromatid cohesion, kinetochore structure and function and
centrosome/microtubule formation and dynamics, as well as "checkpoint" genes that
monitor the progression of the cell cycle (Langauer et al., 1998).
Alterations in DNA methylation patterns have also been suggested to play a role in
chromosomal instability. DNA methylation is involved in suppressing mitotic
recombination and/or contributing to faithful chromosomal segregation during mitosis
(Chen et al., 1998). Global DNA hypomethylation has been shown to be associated
with chromosomal aberrations including mitotic dysfunction and it has been frequently
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observed in colorectal cancer cells where it has been associated with abnormal
chromosomal structures (Lengauer et al., 1997a).
Defects in p53 function have been implicated too in genome destabilisation.
Abnormalities of p53 are known to strongly predispose towards chromosomal
instability in many circumstances (Bischoff et al., 1990; Livingstone et al., 1992; Yin
et al., 1992; Carder et al., 1993; Deangelis et al., 1993; Meling et al., 1993; Carder et
al., 1995; Bouffler et al., 1995; Donehower et al., 1995; Gualberto et al., 1998;
Venkatachalam et al., 1998). In vitro studies showed cells in culture often become
grossly aneuploid at the same time that p53 is inactivated (Harvey et al., 1993). It is
unlikely, however, that p53 is generally responsible for CIN, as several cancer lines
with p53 mutations are diploid and chromosomally stable (Lengauer et al., 1997b,
Eshleman et al., 1998a). These findings indicate that, although p53 defects are
unlikely to be a primary cause of chromosomal instability they probably contribute to
this process.
Altered expression of certain spindle checkpoint genes can result in aneuploidy. For
example decreased expression of hMAD2 was observed in the T47D breast cancer
cell line which failed to undergo mitotic arrest after nocodazole (mitotic spindle
inhibitor) treatment. This suggests that loss of hMAD2 function might lead to aberrant
chromosome segregation and aneuploidy (Li and Benezra R, 1996). A small fraction
of colorectal cancer cell lines, proved to exhibit CIN, have been shown to contain
somatic mutations in mitotic checkpoint genes such as hBUBl and hBUBRl (Cahill et
al., 1998).
Several genes involved in the DNA-damage checkpoint have also been implicated to
contribute to the CIN phenotype, including ataxia telangiectasia mutated (ATM)
(Rotman and Shiloh, 1998), the y47M-related gene ATR (Smith et al., 1998) and the
BRCA1 and BRCA2 genes, which interact with the human Rad51 homologue
(Feunteun, 1998).
An abnormal number of centrosomes has been noticed in various human malignancies
and suggested as a potential cause of CIN (Doxsey, 1998). Multipolar spindles have
often been observed in human cancers but the molecular and genetic bases for the
increased number of centrosomes have not yet been defined. Though the involvement
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of certain genes such as ones encoding kinases aurora2/STK15 and PLK1 has been
suggested (Bischoff et al., 1998; Nigg, 1998; Zhou etal., 1998).
Despite these clues the molecular basis of CIN in most human cancers remains
unknown. The fact that genetic defects in so many genes can lead to CIN might
explain why this phenotype is so common. Accordingly with so many genes involved,
each one probably plays a role in a small proportion of cases (Lengauer et al., 1998).
1.2.6.4. Summary: genetic models of colorectal carcinogenesis in sporadic
colorectal cancer.
The following figures summarise the most important genetic events in colorectal
carcinogenesis in MIN and CIN sporadic colorectal carcinomas.
Figure 3. Genetic events inMINpathway in sporadic colorectal cancers.
- hMSH2 or hMLHl mutation
or hypermethylation of hMLHl
promoter region and development ofMIN
- hypermethylation ofpi 6 promoter region
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Figure 4. Genetic events in CINpathway in sporadic colorectal cancers.
-DNA hypomethylation
-hBUBJ or hBUBRl mutation and
development of CIN
1.3. Aims of the study.
The aims of this project were to determine (i) the extent of intratumoral genetic
variation in a series of sporadic colorectal cancers through sampling multiple sites of
the primary tumour (spatial variation) and (ii) the evolution of genetic changes in
colorectal cancer cells in time through their growth as xenografts in SCID mice
(temporal variation). This study also aimed to determine (iii) the association of genetic
changes detected within a tumour with two known types of genomic instability, (iv)
the association of p53 defects with both types of genomic instability and (v) the extent
to which colorectal cancer xenografts are representative of the primary tumour from
which they are derived.
In order to do this samples of fresh tumour tissue were collected from multiple sites
from a series of 22 sporadic colorectal cancers obtained from 21 patients. Colorectal
cancer xenografts were established in SCID mice from primary tumour samples taken
from multiple sites. Successfully established xenografts were harvested and fresh
tissue obtained for analysis. Four loci, D2S123, D13S160, the poly (A) tract BAT-26
and the (A)i0 repeat in exon 3 of TGFJ3RJ1 were examined in all primary tumour and
xenograft samples to determine their RER status. The presence of chromosome copy
number changes was examined in all samples by Comparative Genomic Hybridisation.
Additionally tumour cells' total DNA content was confirmed by Flow Cytometry
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analysis. The immunohistochemical analysis of stabilised p53 protein was carried out
and was complemented by the mutation analysis ofp53 gene in exons 5-8.
Specific genetic changes detected by methods employed at different sites within
primary tumours were compared to determine the level of genetic intratumoral
heterogeneity and whether single sample analysis could affect the results of such
study. These specific genetic changes were compared with changes detected in the
corresponding colorectal cancer xenografts in order to determine whether and to what
extent they are genetically representative of the primary tumour. Multiple sample
analysis also allowed to determine whether both groups of sporadic colorectal cancer
exhibit specific patterns of chromosomal changes possibly selected for during tumour
development and whether these patterns are similar or differ in these tumour groups.
The results of this study provided valuable new information on genetic intratumoral
heterogeneity in sporadic colorectal cancer and its association with different
mechanisms of underlying genomic instability. Although this study did not address
directly the issue of response to therapy, the data gathered is important in establishing






Fresh tissue samples were obtained from 21 colectomy specimens containing 22
colorectal carcinomas removed at operation between April 1997 and November 1997.
One colectomy specimen contained two primary synchronous adenocarcinomas both
of which were used for the study and treated as separate tumours (tumour No9 and
9'). Specimens were immediately collected from the operating theatre and delivered
on ice to the Department of Pathology at the University of Edinburgh. Blocks of fresh
tissue (approximately 10x5x5mm) were taken from 2 to 4 different sites (depending
on the size of the tumour) from each colorectal cancer and one from the normal
mucosa at a point distant from the lesion. Each block of tissue collected from the
tumour was subsequently divided into three separate pieces. One portion was placed
in 1.5ml screw-capped vial, snap frozen in liquid nitrogen and stored at -70°C
awaiting DNA extraction and flow cytometry analysis. The middle portion was fixed
in periodate-lysine-paraformaldehyde-dichromate (PLPD), paraffin-processed and
sections were stained with haematoxilin and eosin (H&E) following standard
methodology for histological assessment. Sections from paraffin blocks were also
used for immunohistochemical detection of stabilised p53 protein.
2.2. Establishment ofcolorectal cancer xenografts in SCID mice.
The third portion of each of the fresh tissue blocks from the tumours was first washed
in PBS and then placed in a vial with antibiotic medium (Glasgow medium
supplemented with penicillin, streptomycin, HEPES and 10% serum) and immediately
taken for implantation in SCID mice. Alternatively, in case when the implantation
could not be performed immediately samples were placed in freezing medium
(Glasgow medium/dimethyl sulphoxide) for slow freeze and stored at -70°C until
animals were available for establishing xenografts.
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Xenografts were established by implantation of two pieces of cancer tissue
approximately 2x2mm through a small dorsal incision in severe combined
immunodeficiency syndrome (SCID) mice. SC1D mice are characterised by deficient
lymphocyte B and T function. Their lymphocytes are unable to correctly rearrange the
immunoglobulin and T-cell receptor genes which normally occurs by site-spacific
[V(D)J] recombination (Bosma et al., 1988). Thus these mice do not reject implanted
foreign tissue. However they retain some non-specific macrophage-mediated immune
response, useful for removal of bacterial contamination from implanted tumour tissue.
Tumours were allowed to grow for a variable length of time usually until externally
visible tumour bulk of approximately 1 cm in diameter was reached. This time varied
extremely between tumours from 23 days to over 5 months but on average lasted 12
weeks. The mice were then killed and the xenograft tissue was harvested. Part of this
tissue was snap frozen in liquid nitrogen for DNA extraction and flow cytometry
analysis. Part of it was fixed, paraffin processed and stained with haematoxilin and
eosin for the histological assessment. Paraffin sections were also used for
immunohistochemical detection of stabilised p53 protein.
The total of 27 colorectal cancer xenografts were successfully established from 10
primary tumours.
2.3. DNA extraction.
2.3.1. Extraction of DNA from frozen tumour tissue, normal colonic mucosa and
xenograft tissue.
The method of Goelz et al., (1985a) was used for the DNA extraction. A small piece
of frozen tissue was finely chopped with a scalpel in a petri dish and placed in 1.5 ml
tube containing 0.5ml TE-9 SDS and 0.5mg/ml proteinase K. This mixture was
incubated for 48 hours at 48°C and was occasionally shaken. After proteinase K
digest was completed, an equal volume of TE-saturated phenol was added to the tube,
mixed and centrifuged at 10000 x g for 2 minutes. The upper, aqueous layer was
carefully removed to a new tube leaving behind any precipitates formed at the
boundary between the two phases. An equal volume of PC-9 was added to it and the
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tube content was mixed and centrifuged again. This extraction procedure was
repeated using an equal volume of 24:1 chloroform:iso-amyl alcohol. The upper layer
was once again removed to a new tube and 0.25ml 7.5M ammonium acetate was
added. DNA was precipitated from the solution with 1ml of cold absolute ethanol and
left -70°C for 1 hour. In order to obtain high molecular weight genomic DNA it was
removed from the tube with a sterile pipette tip. DNA was briefly washed in 70%
ethanol and resuspended in 150gl sterile TE buffer. It was allowed to dissolve at 4°C














2.3.2. Estimation ofDNA concentration.
DNA concentration was measured using CE 2020 spectrophotometer with readings of
OD taken at 260nm. An optical density ratio (OD 260/280) was measured for each
sample to estimate DNA purification. Concentration of DNA was adjusted to
100pg/ml for use as template in polymerase chain reactions.
2.4. Analysis ofmicrosatellite instability.
2.4.1. PCR ofmicrosatellite sequences.
Two dinucleotide repeat sequences, D2S123 and D13S160 (Gyapay et al., 1994), the
poly (A) tracts BAT-26 (Hoang et al., 1997) and the (A)m repeat in exon 3 of TGF$
R1I were analysed for evidence of microsatellite instability. Primer sequences are
given in Table 2. All four loci were examined in each of the 74 samples collected
from 22 primary colorectal cancers and in all 27 xenografts. Reactions were carried
out in 0.5 ml tubes in 50pl volumes with a final concentration of lxPCR buffer,
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200p,M each dNTP, 0.5p,M each primer and 300ng genomic DNA template for all loci
except BAT-26 where a final concentration of lOOpM of each dNTP with 450ng
genomic DNA template was found to yield better results. DMSO was added to each
reaction to a final concentration of 10% to improve the reaction specificity. Table 2
contains details of magnesium ion concentrations and annealing temperatures for each
primer set. One drop of paraffin oil was added to each tube to prevent evaporation.
Reactions were hot started by adding 1.25 U Taq DNA polymerase to each tube after
denaturing the samples at 94°C for 5 minutes. 35 cycles of amplification were carried
out on a thermal cycler with each cycle consisting of 30 seconds denaturation at 94°C,
30 seconds annealing at variable temperature (Table 2) and 30 seconds extension at
72°C. Reactions' products were always checked on a 2% agarose gel (See 2.4.2).
PCR buffer (Buffer IV, Advanced Biotechnologies Ltd):
750mM Tris-HCl (pH9 at 25°C)
200mM (NH4)2S04
0.1% w/v Tween









D2S123 2mM 58 210-240 AAACAGGATGCCTGCCTTTA
GGACTTTCCACCTATGGGAC
D13S160 1.5mM 58 229-241 CGGGTGATCTAAGGCTTCTA
GGCAGAGATATGAGGCAAAA




4mM 58 267 CCTCGCTTCCAATGAATCTC
TTGGCACAGATCTCAGGTCC
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2.4.2. Agarose gel electrophoresis.
2g electrophoresis-grade agarose was added to 100ml lxTBE buffer, mixed and
heated to boiling in a microwave oven. The mixture was stirred every 30 seconds, to
dissolve the agarose. The gel was allowed to cool before 20 ng/ml ethidium bromide
was added and it was poured into a 12x16cm gel mould with a 20-well comb. PCR
products were checked by loading 5 pi of the PCR product mixed with
lpl loading dye into the wells of the agarose gel. Electrophoresis was carried out at
125V in lxTBE buffer until the bromophenol blue dye migrated approximately 5cm
through the gel. The PCR products were run against 500ng of marker V (Boehringer-
Mannheim Ltd) to confirm the size. Gels were visualised on a Gel Doc (BIO RAD)
and usually a photograph was taken at the same time.
IOxTBE: Loading dye:
in 11 DDW
pH adjusted to 8.3
2.4.3. Radioactive isotope labelling ofprimers.
The 5' end of one of the pair of primers for each locus was labelled with y33PdATP
using T4 polynucleotide kinase. 4pl of 5xT4 kinase buffer was mixed with 7pi of
DDW in a microfuge tube. 5pi of diluted primer (lOpM), 2pi of y3?PdATP
(equivalent to 20pCi) and 2pl (20U) of T4 polynucleotide kinase was added giving a
final volume of 20pl and the reaction was placed in a water-bath at 37°C for one
hour. This amount was sufficient for labelling up to 40 samples.
Labelled primers were incorporated into PCR products by running 5 cycles of PCR
under conditions specified for each locus (see Table 2). The reaction mixture
consisted of a final concentration of lxPCR buffer, 175pM of each dNTP, 1.5mM
MgCl2, 3 .75mM of end labelled primer to which lOpl of the appropriate PCR product
107.8g Tris (0.89M)




0.25% xylene cyanol FF
40
was added to the final volume of 50pl. 1.25U of Taq DNA polymerase was added to
each reaction and the mixture was covered with one drop of mineral oil.
2.4.4. Preparation ofpolyacrylamide denaturing gel.
Amplified microsatellite sequences for loci D2S123 and D13S160 and poly (A) BAT-
26 sequence were run on polyacrylamide denaturing gel to detect shifts in
electrophoretic mobility between tumour and normal DNA sequences.
34x4 lcm glass plates for vertical gel electrophoresis were cleaned with cream cleaner,
well rinsed and wiped with 70% ethanol. One plate was wiped with 1ml Gel Slick (AT
Biochem), left for 5 minutes and cleaned with 70% ethanol. 0.4mm spacers and 32
square-well comb were used. The gel was prepared by adding 50(.d of TEMED and
500(d freshly prepared (less then two weeks old) 10% ammonium persulphate to 75ml
acrylamide solution immediately before pouring the gel. The gel was left to set for at
least half an hour. The combs were removed, the wells rinsed with 0.5x TBE and the
gel was preran at 70W in 0.5x TBE for one hour prior to loading the samples in order
to raise its temperature to about 55°C.
Acrylamide solution: 0.5 x TBE buffer:
11,25ml 40% Acrylamide (19:1 acrylamide:bis) 5.39g Tris (0.04M)
'Instagel' (Severn Biotech Ltd) 2.75g Boric acid (0.04M)
stored protected from light at 4°C
2.4.5. Electrophoresis on polyacrylamide denaturing gel.
Ten microlitres of y3'P labelled PCR product was denatured at 95°C for 5 minutes in
0.5x volume short tandem repeat (STR) loading solution then immediately placed on
ice. The wells of the polyacrylamide gel were thoroughly rinsed with 0.5xTBE and
then 7.5pl of denetured PCR product was loaded into each well. The electrophoresis






pH adjusted to 8.3
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usually the gel was run until the xylene cyanol marker in the loading dye reached the






2.4.6. Electrophoresis on MDE gel.
The (A)io sequence in exon 3 of TGF-P RII was assessed using Single Stranded
Conformational Polymorphism analysis (SSCP). MDE gel was prepared as described
in 2.8.3. Ten microlitres of 33P-labelled PCR product was denatured for 5 minutes at
50°C in 2pi of the denaturing solution. Six microlitres of stop solution was added to
each tube and the samples were placed on ice and then loaded quickly onto the gel,
after rinsing the wells with lxTBE. Electrophoresis was carried out in lxTBE buffer
at 6W overnight until the xylene cyanol dye reached the bottom of the gel.
Denaturing solution: Stop solution:
0.5M sodium hydroxide 95% formamide
1 OmM EDTA 20mM EDTA
0.05% bromophenol blue
0.05% xylene cyanol
2.4.7. Detection and assessment of electrophoretic mobility of microsatellite
sequences, BA T-26 and TGFJ3 RII.
Gels were fixed in a solution of 10% methanol and 10% acetic acid, transferred to
Whatman paper No 17 and dried on a vacum gel drier. Autoradiography was carried
out for 1-3 days and autoradiographs were assessed visually for the presence of shifts
in electrophoretic mobility of amplified sequences from tumour samples compared to
normal DNA.
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2.5. Analysis of Unbalanced chromosomal abnormalities using Comparative
Genomic Hybridisation.
A series of 74 samples collected from multiple sites from 22 primary colorectal
carcinomas and 26 samples obtained from successfully established xenografts derived
from 9 primary tumours were analysed for the presence of unbalanced chromosomal
abnormalities using Comparative Genomic Hybridisation (CGH). CGH is a method
that detects changes in chromosome copy number (whole or partial) through
competitive hybridisation of DNA derived from normal and tumour tissue onto a
normal human chromosome metaphase spread (Kallioniemi et a/., 1992).
2.5.1. Preparation ofnormaI human metaphase spreads.
2.5.1.1. Blood culture.
Fresh blood, approximately 10 ml, was collected from a healthy male volunteer into a
lithium heparin tube. Using sterile technique culture medium was prepared. It
consisted of RPMI medium (Dutch modification), supplemented with 10% foetal
bovine serum (heat inactivated), phytohemagglutinin (final concentration 9pg/ml) and
L-glutamine (final concentration 2mM). The medium was filtered through a 0.2pm
filter and aliquoted into 8 flat-bottomed 25cm2 plastic tissue culture flasks, 10ml in
each. 0.8 ml of blood was added into each flask, swirled to mix, and cultures were
incubated at 37°C for 72 hours. One hour before harvesting (at exactly 71 hours),
100gl of 1 Opg/ml colcemid was added and the incubation continued for another hour.
After exactly 72 hours the cultures were transferred into 10ml centrifuge tubes and
spun at 800 x g for 5 minutes to pellet cells. Then the supernatant was removed, the
pellet resuspended in prewarmed (37°C) 0.075M KC1 hypotonic solution and
incubated in a 37°C waterbath for 10 minutes. The tubes were removed from the bath,
centrifuged again at the same speed and then the supernatant was removed and the
pellet tapped to loosen the cells. Cells were carefully fixed by adding very slowly
drops of fresh ice-cold fixative solution, consisting of 3:1 methanol:glacial acetic acid
to a final volume of 5ml while being gently vortexed. Then the tubes containing fixed
cells were placed at -20°C for one hour and spun at 800 x g for 5 minutes. In order to
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obtain a white pellet of cells at the bottom of the tube, the procedure of fixing and
spinning was repeated twice. Fixed cells could be stored in 5ml of fixative solution at
-20°C for up to a year.
2.5.1.2. Preparation ofmetaphase chromosome spreads.
Selected microscope slides were prepared by soaking overnight in 10% Decon
detergent and rinsing in water for about an hour. Then the slides were transferred to
100% ethanol to which a few drops of concentrated hydrochloric were added. They
could be stored in this solution until they were used. The tubes with previously
prepared metaphase preparations were centrifuged at 800 x g for 5 minutes in order
to pellet the cells. The supernatant was then removed and the cells were resuspended
in a small amount (a few drops) of freshly prepared fixative solution. The amount of
fixative solution required varied and depended on the size of the pellet. Usually the
fixative solution was added dropwise until resuspended cells formed a milky solution.
Slides were removed from ethanol, polished with a soft cloth and just before use
placed at -20°C for 2 minutes to facilitate spreading of chromosomes. One drop of
fixed chromosome preparation was dropped from approximately 50 cm height directly
on top of each slide. A diamond pencil was used to mark the position of the drop on a
slide. Before the slides were used in the hybridisation procedure they were checked
on a phase contrast microscope at x40 magnification to ensure the sufficient number
of quality metaphases (with chromosomes of the right length and with few
overlapping ones) was present on each slide.
The slides were stored at room temperature in a vacuum desiccator for at least 1
week, but not longer than 2 weeks, before they were used for setting up hybridisation.
2.5.2. Labelling ofcontrol and test DNA by nick translation.
Test DNA was extracted from frozen tissue according to the method of Goelz et al.
(1985a) (see section 2.3).
DNA obtained from lymphocytes of two healthy male volunteers was used as control
DNA for counter-hybridisation. This was kindly provided by Dr Lucy J Curtis who
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also confirmed the normal karyotype of the lymphocytes from which the control DNA
was extracted.
Incorporation of digoxygenin-11-dUTP (normal) or biotin-16-dUTP (test samples) by
nick translation was used to label normal male DNA and test DNA obtained either
from a primary tumour or a xenograft. DNA fragments' length of between 300 and
3000kb, as assessed by running double-stranded DNA on 1% agarose gel against
DNA mass ladder (Life Technilogies Ltd) were found to provide optimal hybridisation
in this study. Using shorter fragments resulted in chromosomes appearing fuzzy and if
fragments were too large hybridisation was rather poor.
The nick translation reaction mixture was prepared. First DNase I (lOu/pl) was
diluted 1/15000 in ice-cold DDW and placed on ice. One 0.5ml microfuge tube for
each sample was also placed on ice to cool. The following components were added to
each tube:





40pM digoxygenin-1 1-dUTP (control) or biotin-16-dUTP (test sample)
lx nick translation buffer
DDW to 38pil
lpl (10U) DNA polymerase I
lpl diluted DNase I
The components were gently mixed, briefly centrifuged and then the mixture was
incubated at 16°C for 1 hour. After the incubation, in order to check the size of DNA
fragments, the tubes were placed on ice and 5 pi of the mixture was removed and run
against lkb ladder molecular weight marker (Life Technologies Ltd) on a 1% agarose
gel until the bromophenol blue had migrated approximately 6cm through the gel. If
there were fragments bigger than 3kb, the tubes were placed again in the water-bath
and the incubation at 16°C continued for another 10-20 minutes after a further lpl
DNase I was added to the reaction tube. When the desirable fragments' length was
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reached, which was between 300 and 3000 bp long, 2pl 0.2mM EDTA/1%SDS were
added to stop the reaction. Fine sephadex G50 Quick Spin columns were used to
clean the labelled DNA and to remove the remaining unincorporated nucleotides
(Boehringer Mannheim Ltd) from the mixture. The column was first inverted to
resuspend the sephadex and then spun at 6000 x g for two minutes to dry. Nick
translated DNA was added to the top of the column and it was spun at 6000 x g for
4 minutes and the drops collected in a tube. Concentration of DNA was
recalculated, making adjustment for the mixture volume obtained after cleaning
through the column. Labelled DNA was stored in -20°C until use.
lOx nick translation buffer:
0.5M Tris pH 7.5
0.1MMgSO4,
1 mM dithiothreitol
500pg/ml bovine serum albumin fraction V.
2.5.3. Hybridisation.
The optimal hybridisation conditions were previously established by Dr Lucy J Curtis.
A modification of the method of Kallioniemi et al. (1992) with incorporated changes
from the methods of Verma and Babu ( Verma and Babu, 1995) and from a method
provided by Dr H.Morrison at the Human Genetics Unit, MRC, Edinburgh was found
to work most consistently.
2.5.3.1. Probepreparation.
The probe mixture consisted of 500ng of normal male genomic DNA labelled with
digoxygenin mixed with 500ng of biotin-labelled test DNA and lOpg human Cot-1
DNA. lOOpl of ice cold ethanol was added to each tube containing the probe mixture
in order to precipitate DNA. The tubes were left at -70°C for 1 hour and then the
ethanol was removed by placing the tubes in a vacuum centrifuge and spinning them
at 1000 x g. Precipitated probes could be stored at -20°C until they were needed.
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Prior to hybridisation the probes were resuspended in 7.5pi CGH buffer. The mixture
was vortexed and left to dissolve at room temperature for at least one hour. In order
to denature the probes, 7.5 pi deionised formamide was added, tubes were vortexed,
briefly centrifuged and placed for 5 minutes in a water-bath at 70°C. To enhance the
blocking effect of non-specific sequences by human Cot-DNA, after denaturation and
prior to the hybridisation step, the probes were allowed to reanneal for between 30
minutes and 2 hours at 37°C.
Slide preparation (see below) was carried out simultaneously to the probe
preparation.
CGH buffer:
20% dextran sulphate (diluted from autoclaved 50% stock)
4xSSC see 2.9.4
2.5.3.2. Slidepreparation.
Competitive hybridisation of test and normal labelled DNA prepared as above (2.5.2)
was carried out on normal male metaphase chromosome spreads previously prepared
and stored for minimum 1 week (see section 2.5.1.2). The preparation was carried
out in 50ml-capacity Coplin jars with forceps being used for moving the slides. 200ml-
capacity glass staining dishes with slides being placed in a slide rack were used for
ethanol washes.
In order to remove RNA slides were first treated with RNase. They were placed in
10pg/ml RNase A solution at 37°C for 1 hour followed by a wash in 2xSSC at room
temperature for 2 minutes. Slides were then washed in proteinase K buffer for 2
minutes and placed in lOOng/ml proteinase K solution for 2.5 minutes, followed again
by 2 minute wash in proteinase K buffer. They were then dehydrated through 70%,
90% and 100% ethanol for 2 minutes in each. Slides were warmed on a hotplate to
70°C prior to being placed into 70% formamide solution at 70°C for 3 minutes. This
procedure was carried out in a fume cabinet and a thermometer was used to check
whether the formamide temperature was exactly 70°C as required, before the slides
were placed there. This procedure was always carried out in a Coplin jar, and no more
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than 4 slides at a time were added at one time. This was necessary to maintain a
constant solution temperature, which was essential for successful slide preparation.
After denaturation, slides were plunged immediately into 70% ice-cold ethanol and
kept on ice for 5 minutes. They were then dehydrated again through the ethanol series
as before.
Slides were marked and warmed up on a hotplate at 37°C prior to adding the probe.
Alongside small (20mm2) coverslips which previously had been thoroughly cleaned
with ethanol were also warmed up. The probe was removed from the water-bath were
it was kept at 37°C and placed onto a cover slip. Appropriate steps were taken to
ensure that the temperature did not drop below 37°C. The slide was placed
chromosome-side down on top of the coverslip containing the probe. Rubber solution
was used to seal the coverslip with the slide to prevent the evaporation of the
hybridisation mixture. The slides were then placed in a humidified chamber and
incubated at 37°C for 2-3 days.
RNase A solution:
lOpg/ml RNase A in
2xSSC
Proteinase K buffer:
0.02M Tris pH 7.5
0.002M calcium chloride
Proteinase K solution:






500ml formamide added to 25g ion-exchange resin beads,
stirred for 45 minutes, then filtered through a paper filter.
Stored at -20°C.
2.5.4. Detection of labelledprobes.
After the slides were incubated for 48-72 hour they were removed from the
humidified chamber. The rubber sealant was carefully removed and an attempt was
made not to tear off the coverslip from the slide. The slides were then washed for 3
minutes in 50% formamide/2xSSC at 45°C, allowing the cover slips to float off. This
procedure was repeated three times and followed by four 3 minutes washes in 2xSSC
at 45°C and then four 3 minutes washes in O.lxSSC at 45°C. Prior to the addition of
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the antibody solution, slides were washed for 2 minutes in 0.1% Tween 20/4xSSC at
room temperature and then they were incubated with lOOpl blocking buffer under a
clean large cover slip at room temperature for 5 minutes. Then the coverslips were
removed and the slides were drained. One houndred pi fluorescein/rhodamine solution
was added to each slide and the slides were covered by a new clean cover slip. They
were incubated for 30 minutes in a damp chamber in the dark at 37°C. Slides were
then drained and washed three times for 2 minutes in 0.1% Tween 20/4xSSC at 37°C,
drained again and air dried. 3 5 pi DAPI/antifade were mounted onto a large coverslip
which was placed on top of the slide. The slides were then sealed with nail varnish,




made to 10ml with DDW and heated to
50°C to dissolved, aliquoted into 1.5ml





Spun at 10000 x g for 15 minutes at 4°C
prior to addition of 1 Opg/ml anti-
digoxygenin rhodamine
DAPI/antifade solution:
0.75pg/ml DAPI in Vectashield antifade
solution
2.5.5. CGH analysis.
The Apple Macintosh-based Quantitative Image Processing System (QUIPS)
software (Vysis, UK, Ltd) was used to assess and analyse the hybridisation. The
system consists of a fluorescent microscope (Zeiss Axioskop 20) with an attached
CCD camera (SenSys) and a triple bandpass filter. The filter is set for three
fluorochromes used in the method: rhodamine, fluorescein and DAPI (see Table 3).
The microscope is also equipped with a computer-controlled filter wheel for image
acquisition.
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Slides were screened for good quality metaphases showing smooth hybridisation of
both test and control DNA. Then grey-level images were captured at xlOOO
magnification. Each one of the three fluorochromes was excited separately by using a
single band-pass excitation filter. The images captured were overlaid and displayed on
the computer screen in pseudo-colour corresponding to the colour of each
fluorochrome. A single grey scale DAPI image representing chromosome pseuo-G-
banding pattern was used for chromosome identification. At least five metaphases
were analysed from each slide. The QUIPS software generated green/red ratios for all
chromosomes after overlapping and damaged chromosomes were excluded and then
an average profile was calculated for each one of the 22 chromosomes included in the
analysis. Green/red ratios generated from a minimum of 5 autosomes had to be
included in the average ratio profile of each chromosome. Because sex chromosomes
might be under different selection pressure in tumours derived from males and females
they were excluded from the analysis in this study. The threshold at which
chromosome copy number changes were scored was established at the green/red ratio
of 1.125 and 0.875. At this cut-off point chromosome copy number changes could
still be easily seen. It represents a loss or gain of one chromosome in 25% of cells in a
diploid karyotype. The standard deviation of green/red ratio profiles generated for
each chromosome was checked and slides were only used if it was small. Telomeres,
pericentric regions and heterochromatic regions were excluded from analysis. A
normal control (hybridisation of differently labelled normal DNA) was carried out
with every batch of slides for quality control of hybridisation conditions. Chromosome
19 occasionally yield aberrant results. These results are included in the study but
should be interpreted cautiously.
It should be pointed out that a substantial proportion of this study was carried out on
primary colorectal cancers. The tissue used for DNA extraction, although not
microdissected, was always histologically examined to confirm the presence of
sufficient amount of tumour tissue. DNA extracted from these samples was therefore
consistently contaminated to some degree with normal DNA. This would usually
decrease the threshold at which chromosomal abnormalities could be detected.
However, it did not present a problem and the 1.125/0.875 green/red ratio cut-off
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point (which was previously applied in this lab for the CGH analysis of colorectal
cancer xenografts by Dr Lucy J Curtis) was used for scoring chromosome copy
number in the primary tumours as well as in the xenografts.






4'-6-diamidino-2-phenylindole (DAP1) 355 450 Blue
Fluorescein 490 520 Green
Rhodamine 545 575 Red
2.6. Flow cytometry.
Flow cytometry was used for assessing cells' total DNA content.
2.6.1. Preparation of tissue.
The method of Vindelov et al. (1983) was followed for tissue preparation before the
assessment of the DNA content was carried out on a Coulter EPICS-XL flow
cytometer. A small fragment of frozen tissue, approximately 4mm^» was finely
chopped using a sterile scalpel. The tissue macerate was suspended in 200pl of citrate
buffer and 450pl of solution A was added to lOOpl of this solution to obtain partial
cell lysis. This mixture was mixed gently for 10 minutes at room temperature. Then
325pl of solution B was added to neutralise trypsin and remove RNA, followed by 10
minutes incubation at room temperature. After the incubation 250pl of solution C,
containing propidium iodide (a DNA binding fluorochrome) was added. This
procedure was carried out on ice and samples were left there for 10 minutes. The cell
suspension was then filtered through a syringe with glass wool to dispose of large
clumps of cells. The analysis was performed within 4 hours, during which time
samples were kept on ice.
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Solution A: Solution B
15mg trypsin 250mg trypsin inhibitor
500ml stock solution 50mg ribonuclease A










dissolved in 800ml DDW
50ml DMSO added and volume made up to 2ml Nonidet P40





2.6.2 Flow cytometry analysis.
This was carried out on a Coulter EPICS-XL flow cytometer. The excitation
wavelength was 488nm. Immuno-Check alignment fluorospheres (Coulter Electronics
Ltd) were used each time to check the alignment of the laser before the analysis of a
sample batch begun and half-peak coefficients of variation were less than 2%. Cells
were analysed according to forward and side scatter and double compensation was
performed. At least 5,000 nuclei were analysed in each sample, and at the same time
identical analyses of normal tissue from the same patient were carried out. The first
peak was treated as a diploid one, and the DNA index of an aneuploid peak was
calculated as a ratio of the aneuploid and the diploid peak position values.
2. 7. Immunohistochemical detection ofstabilised p53 protein.
Immunohistochemical (IHC) methods are widely used to detect stabilised p53 protein.
This is possible due to the short half-life (20-30 minutes) of the wild-type p53 protein,
which is therefore undetectable by such methods (Oren, 1985). In this study DO-7
antibody (Dako), which recognises an amino terminal epitope of p53 protein and
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reacts with both wild-type and mutant protein was chosen for the
immunocytochemical detection of stabilised p53 protein.
Slides were prepared in the Department of Pathology, University of Edinburgh. 3gm
sections from tissue fixed in periodate-lysine-paraformaldehyde-dichromate (PLPD)
and embedded in paraffin wax were cut and placed on poly-L-lysine (Sigma) coted
slides.
Slides were first warmed up on a hot plate at approximately 50°C to allow the wax to
melt and then they were deparaffmised by placing in xylene for 10 minutes. The
sections were rehydrated through the washes in absolute ethanol for 1 minute, 740P
for 1 minute and 640P for 1 minute and then they were rinsed in water. Slides were
treated with 3% hydrogen peroxide for 15 minutes in order to block the endogenous
peroxidase activity and then washed for 5 minutes in DDW and 5 minutes in tris-
buffered saline (TBS). Slides were then wiped to remove excess fluid and the area
around the section was marked with a wax pen to retain solutions. Sections were then
incubated for 20 minutes with normal rabbit serum (NRS) diluted 1:5 in TBS then
drained. The slides were incubated overnight at 4°C with a 1:100 dilution of DO-7
antibody in 1:5 NRS/TBS solution.
Following the overnight incubation, the slides were washed twice for 5 minutes in
TBS before the secondary antibody was applied. The 1:400 dilution of biotinylated
rabbit anti-mouse immunoglobulins (Dako Ltd) in the above NRS/TBS solution was
prepared and 100j.il of this solution was added to each slide and incubated for 30
minutes at room temperature. An avidin/biotinylated horseradish peroxidase (HRP)
complex (ABC kit, Dako Ltd) was prepared in the meantime by adding 1 drop of
avidin and 1 drop of biotinylated horseradish peroxidase to 5ml TBS and allowing 30
minutes for the reagents to conjugate. The slides were washed twice in TBS for 5
minutes and 100gl ABC complex was added followed by 30 minutes incubation at
room temperature. Then again slides were washed twice for 5 minutes in TBS and
then incubated for 3 minutes in diaminobenzidine (DAB) solution at room
temperature to allow formation of brown colouration through oxidation of DAB by
HRP. This was followed by a 5 minutes wash in DDW and then slides were
counterstained with haematoxylin for a few seconds. Haematoxylin was washed off
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with tab water and the slides were dehydrated through alcohol washes: 1 minute in
640P, 1 minute in 740P, 1 minutes in absolute ethanol and then placed for 10
minutes in xylene. They were mounted with DPX mountant and examined on a light
microscope. The presence, intensity and pattern of staining was noted for each slide.
They were classified as positive if more than 10% of nuclei showed strong brown
coloration.
PLPD: TBS:
0.1M lysine 0.05M Tris/HCl
0.1M periodate 0.15MNaCl
2% paraformaldehyde pH 7.6
made to 50ml with Sorensen's phosphate buffer
(0.05M, pH7.4).
5% potassium dichromate in 50ml DDW added
immediately before use
DAB solution: DAB buffer:
5mg DAB 24ml 02.M Tris
4.8ml DAB buffer 38ml0.1NHCl
100pl 1:30 hydrogen peroxide solution 0.0681g imidazole
DDW to 100ml
pH adjusted to 7.6
2.8. Mutation analysis of the p53 gene.
In order to exclude the possible presence ofmutation not detectable by IHC mutation
analysis of the p53 gene was performed on 15 tumours with negative or weak
immunohistochemical staining or staining present in less than 10% of cells. Studies
previously carried out, determining p53 status at different tumour sites (Carder et a/.,
1995) indicated that the mutation in p53 gene, if present, occur at the
adenoma/carcinoma interface during tumour progression and therefore can be readily
detected in any part of the carcinoma. This is why originally only one representative
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sample from each tumour was selected to be screened for the presence of mutation in
p53 gene. The mutation analysis was carried out using single-stranded conformational
polymorphism analysis (SSCP) of exons 5-8, in which 90% of all mutations are
located (Levine et al., 1991). The four samples with known mutations in each of the
exons 5-8 were included as positive controls as well as samples of normal DNA as
negative controls.
2.8.1. PCR ofp53 exons 5-8.
PCR was carried out using the primers listed in Table 4. The reaction mixtures of the
total volume of 50pl consisted of 200ng genomic DNA with final concentration of
0.5pM of each primer, 200pM of each dNTP, 1.5mM MgCl2 and lx PCR buffer
solution. One drop of paraffin oil was overlaid to prevent evaporation. This was
heated to 95°C for 5 minutes and 1.25U of thermostable DNA polymerase was added
to 'hot start' the reaction. 25 cycles of amplification were carried out in a thermal
cycler with each cycle consisting of 30 seconds denaturaion at 94°C, 30 seconds
annealing et variable temperature (Table 4) and 1 minute extention at 72°C. Then 5pl
of diluted end labelled primer (see 2.8.2) was added to each reaction, tubes were
spun, and further 10 cycles were carried out at the conditions described above.
Table 4. Primer sequencesfor amplification ofp53 exons 5-8.














2.8.2. Radioactive isotope labelling.
In this reaction 5' end of one of the pair of primers for each exon was labelled with
y33PdATP using T4 polynucleotide kinase. Primer sequences were diluted with sterile
destilled water before use to a final concentration of 10ng/pl.
The reaction was carried out in a microfuge tube where 4pl of 5xT4kinase buffer was
mixed with 7pl of DDW. 5pl of diluted primer, 2pl of yv,PdATP (equivalent to
20pCi) and 2pl (20U) of T4 polynucleotide kinase was added giving a final volume of
20pl and the reaction was placed in a water-bath at 37°C for one hour. This amount
was sufficient for labelling up to 40 PCR products and was diluted with DDW to the
final volume sufficient to add 5 pi of the mixture to each of the PCR reactions.
5xT4 polynucleotide kinase buffer:




2.8.3. Preparation ofMDE gel.
0.5xMDE gel solution was prepared by mixing 36.5ml DDW, 3.6ml lOxTBE buffer,
6ml glycerol and 15ml MDE (AT Biochem). 256gl of freshly prepared 10%
ammonium persulphate and 31 gl TEMED were added, the solution was mixed and
poured immediately between 34x4lcm vertical electrophoresis plates with 0.4mm
spacers and 49-well combs. The gel was allowed to polymerise at room temperature
for one hour.
2.8.4. SSCP analysis of33P labelled PCR product.
lgl of denaturing solution was added to five microlitres of "P labelled PCR product.
The mixture was denatured for 5 minutes at 50°C. Then 3 pi of stop solution were
added to each tube and the samples were placed on ice and loaded quickly onto the
gel, after rinsing the wells with lxTBE. Electrophoresis was carried out in lxTBE
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buffer at maximum 30W in order to keep the gel temperature at approximately 20°C.
Running time varied according to fragment size, good fragment separation was
achieved when samples were ran such that the xylene cyanol marker dye had migrated
between 25 and 35cm through the gel.
After the electrophoresis was completed, the gel was transferred onto Whatman No
17 paper and dried on a vacuum gel drier. Autoradiography was carried out for 1-3
days and autoradiographs were assessed visually for shifts in electrophoretic mobility
of amplified sequences compared to positive controls (samples with known mutations
in exon 5-8) and negative controls (samples of normal DNA).
0.5xMDE gel solution: Denaturing solution: lOxTBE:
15ml MDE gel See 2.4.6 See 2.4.2
6ml glycerol
3.6ml lOx TBE Stop solution:
36.6ml DDW See 2.4.6
2.9. DNA fingerprinting.
DNA fingerprinting was carried out in order to confirm that DNA from xenograft
tissue corresponded to that of the primary tumour from which it had been established
and to the normal tissue from that patient. This procedure was performed in a few
selected cases where the results of the microsatellite analysis of the xenograft DNA
were not consistent with the primary tumour. This applied to the xenograft 3xb which
did not exhibit microsatellite instability, unlike the primary tumour it was established
from and to one of the xenografts derived from tumour No 19 (19xa) which showed
shifts at all four loci examined contrary to the primary tumour which microsatellites
were stable. A few matched primary tumour/xenografl pairs were also analysed for
comparison.
The probe 29C1 was chosen for DNA fingerprinting. It recognises a highly
polymorphic region of human telomeric DNA located in the pairing regions of the
short arms of the sex chromosomes (Cooke et a/., 1985).
57
2.9.1. Restriction endonuclease digestion ofgenomic DNA with EcoRI.
10|.ig of genomic DNA extracted from frozen tissue as described in section 2.3.1 was
digested overnight at 37°C in a 50j-d volume with 30U EcoRI and lx enzyme buffer.
The efficiency of the reaction was checked by running 5|lx1 of the reaction mixture
with 5 pi bromophenol blue loading dye on 1% agarose gel with 5(0.1 lOmg/ml ethidium
bromide to confirm that digest was complete.
2.9.2. Electrophoresis and DNA transfer.
A 0.8% agarose horizontal gel 20x20cm was prepared. 2.4g electrophoresis-grade
agarose was mixed with 300ml lxTBE buffer and boiled until agarose dissolved. 5j.il
lOmg/ml ethidium bromide was added and the gel was left to cool to 55°C before
pouring. 5j.il bromophenol blue loading dye was added to each sample and the samples
were loaded into the wells, ljig of a DNA molecular weight marker lkb ladder (Life
Technologies Ltd) was loaded alongside the samples and electrophoresis was carried
out overnight at 80mA in lxTBE until the dye had migrated approximately 20cm.
After the electrophoresis was completed the gel was photographed on a GEL DOC
alongside a ruler for scale.
The gel was then prepared for blotting. It was shaken gently for 45 minutes in 500ml
denaturing solution. It was very carefully transferred to the blotting apparatus which
consisted of a 20x35cm of Whatman no. 17 paper wick placed over a perspex plate.
This was suspended over a tank containing denaturing solution. The wick was soaked
in denaturing solution and carefully rolled flat before placing the gel on top. A sheet
ofHybond N+ nylon membrane was cut to the size of the gel and one corner was cut
off for orientation. It was soaked in DDW, then in denaturing solution, placed on top
of the gel and rolled flat to remove bubbles. On top of this 2 sheets of Whatman
no. 17 chromatography paper cut to size of the gel were placed, followed by a pile of
paper towels, a perspex plate and a 1kg weight. The edges of the gel were covered by
clingfilm to prevent evaporation and aberrant buffer flow and the apparatus was left
overnight for the DNA to transfer to the membrane.
58
lOx EcoRI buffer:






2.9.3. Preparation of the probe.
2.9.3.1. Restriction enclonuclease digestion ofplasmidp29Cl.
Pstl restriction enzyme was used to cut out the insert from plasmid p29Cl. The
reaction mixture consisted of 20U enzyme, 4pg plasmid DNA and lx Pstl buffer
made to the volume of lOOgl with DDW. Digestion was carried out for 3 hours at
2.9.3.2. DEAE membrane purification of the plasmid insert for the preparation of
the probe.
The p29Cl plasmid insert was purified for use as a probe using DEAE (Schleicher
and Schuell) membrane. Briefly, digested plasmid DNA was electrophoresed in 1%
agarose gel at 100V in lxTBE against Ikb ladder molecular weight marker for 1
hour. The 1.7kb insert was visualised briefly under UV light (to minimise DNA
damage). A slit was cut in the gel, just in front of the required band, and a piece of
DEAE membrane placed in the slit. The band was electrophoresed onto the
membrane and then eluted from it by incubating at 65°C, for one hour, in a high salt
buffer. The resulting DNA solution was extracted once with phenol:chloroform and
then precipitated with ethanol. The DNA pellet was washed in 70% ethanol, air dried
and then dissolved in sterile TE. Concentration was measured using CE 2020




lOxPstl buffer: lOxTBE: High salt buffer:
50mM Tris
ImMEDTA
500mM Tris HC1 (pH8.0) See 2.4.2
lOOmM MgCl2
500mM NaCl lMNaCl
pH adjusted to 9.0
2.9.3.3. Labelling of the probe using random primers.
The random priming method was used for labelling probes with a32PdCTP. The
Prime-It RmT kit (Stratagene) was chosen for this purpose and it was used according
to the protocol recommended by the manufacturers.
50ng of probe was added to a reaction tube containing random primers, nucleotides,
buffer and co-factors for use with a,2PdCTP and denatured by boiling for 5 minutes.
50jaCi of a?2PdCTP (ICN) and 12 units of DNA polymerase was added to this tube
and the contents incubated at 37°C for 30 minutes. After half an hour the reaction
was terminated by the addition of 2pi stop mix (0.5M EDTA, pH8.0). Unincorporated
or2PdCTP was removed with a Sephadex G-50 nick column (Pharmacia), used
according to the manufacturers instructions. The column was rinsed with TE and
equilibrated by allowing 3ml of TE to pass through the column. The labelled DNA
probe was added along with 400f.il TE and allowed to pass into the column bed. The
probe was then eluted from the column by the addition of a further 400pl of TE and
collected in an eppendorf. An approximate measure of isotope incorporation into the
probe was obtained by comparing the Geiger counter reading of the tube relative to
the column.
2.9.4 Hybridisation.
After completing Southern transfer overnight the nylon membrane was washed in
neutralising buffer for 45 min. It was than placed onto a square nylon mesh, rolled,
and placed into a Hybaid bottle with 20 ml hybridisation buffer to prehybridise in
order to reduce non-specific background. The bottle was placed on a rotating wheel
in a 65°C oven for 4 hours. After this time, probe prepared as above was denatured
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by boiling for 3 minutes. The hybridisation buffer was removed from the bottle, the
denatured probe added and the buffer returned to the bottle. The bottle was placed
again on a rotating wheel in a 65°C oven for overnight hybridisation.
The next day the hybridisation buffer was poured out and the membrane was washed
by adding 100ml 2xSSC prewarmed to 65°C and replacing the bottle in the oven at
65°C for 30 minutes. This procedure was repeated with 2xSSC/l% SDS and then
0.5xSSC/l% SDS. The membrane was then removed from the bottle, placed into
O.lxSSC at room temperature and soaked for 30 minutes. It was sealed in Clingfilm
and placed in an X-ray cassette (Hypercassette, Amersham) containing two
Hyperscreen (Amersham) intensifying screens and a sheet of Kodak X-OMAT film,
and exposed at -70°C for 1-10 days. Then the film was developed using an automatic
developing machine.
Neutralising buffer: 20xSSC:
0.5M Tris pH 7.4 3M NaCl
1,5M NaCl 0.3M Trisodium citrate
pH7
Hybridisation buffer:
5g dextran sulphate dissolved in 25ml DDW at 65°C for 30




Immediately before use, lOmg salmon sperm DNA denatured
by boiling for 5 minutes before adding to above buffer at
65°C.
pH to 7, DDW to 11
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2.10. DNA fingerprinting using microsatellite analysis.
This procedure was carried out in one case of the primary tumour No 3 and the
xenograft 3xb, after the results of the DNA fingerprinting using 29C1 probe were
inconclusive. A set of seven microsatellite markers was used. The analysis was
performed by Mr Peter Han from the Police Forensic Science Laboratory and
therefore will not be discussed here in details.
2.11. Investigating the origin of tumour cells in the xenograft 3xb by
immunohistochemistry.
This was carried out on paraffin tissue sections by the research laboratory of the
Department of Pathology, University of Edinburgh, following standard methodology
for immunohistochemistry using antibodies against common leucocytic antigen CD45,
B-cells antigen CD20, pan-T-cell marker CD3 and cytokeratin CAM 5.2.
Additionally, immunohistochemical detection of the Epstein-Barr virus was performed
on paraffin tissue section from the 3xb xenograft by the research laboratory of the
Western Infirmary Department of Pathology in Glasgow. A routine
immunohistochemistry protocol was followed.
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CHAPTER 3.
Spatial and temporal analysis of microsatellite instability in sporadic colorectal
cancer.
3.1. Introduction.
One of the two major mechanisms of genomic instability identified to date in
colorectal cancer leads to the development of a distinct phenotype characterised by an
increased rate of frameshift and point mutations. This is manifested in a high rate of
alterations in length of repetitive nucleotide sequences, known as microsatellite
instability (Aaltonen et a/., 1993; Ionov et al., 1993; Thibodeau et al., 1993;
Eshleman et al., 1995).
Microsatellites are normally stable repetitive genetic elements, where the repeating
unit is one to six bases (Weber et al., 1989). Because of their repetitive nature they
are particularly prone to replication errors (Kunkel et al., 1990), which in normal cells
are swiftly corrected by the efficient mismatch repair system. Defects in MMR genes
result in a failure to correct these errors, creating the replication error phenotype.
The RER+ phenotype is a characteristic of most tumours from patients with
hereditary non-polyposis colorectal cancer, where it is a consequence of mutations in
one of the DNA mismatch repair genes (hMSH2, hMLHl, hPMSl, hPMS2, hMSH3
or HMSH6) (Peltomaki et al., 1993; Bronner et al., 1994; Nicolaides et al., 1994;
Nystrom-Lahti et al., 1994; Papadopoulos et al., 1994; Wijnen et al., 1995; Liu et al.,
1996; Akiyama et a/., 1997; Miyaki et al., 1997). This phenotype is also detected in
approximately 15-20% of sporadic colorectal cancers (Lothe et al., 1993; Aaltonen et
al., 1994; Wu et al., 1994; Borresen et al., 1995; Liu et al., 1995; Bubb et al., 1996;
Eshleman and Markowitz, 1996; Konishi et al., 1996). Inactivating mutations in
MMR genes, however, appear to play a limited role in sporadic colorectal cancers
with microsatellite instability. Recent studies suggest that inactivation ofMMR system
in sporadic tumours occurs through hypermethylation of CpG sites in the promoter
region of hMLHl followed by loss of its expression (Cunningham et al., 1998;
Herman et al, 1998; Deng et al., 1999; Maekawa et al., 1999; Wheeler et al., 1999).
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There are still many unresolved issues regarding the diagnosis of a tumour as RER+.
They include the degree to which the microsatellite sequence has shifted compared to
the normal allele (Thibodeau et al., 1993), the number of shifted microsatellite loci
sufficient to diagnose the tumour as RER+ (Aaltonen et al., 1993) and the optimal set
of informative loci (Liu et al., 1995).
The aim of this study was to determine the RER phenotype of 22 primary sporadic
colorectal carcinomas which were randomly chosen for this project. The analysis of
samples taken from multiple sites from each tumour and the corresponding xenografts
was designed to gain more information about the genetic intratumoral heterogeneity
and the temporal evolution ofmicrosatellite instability in sporadic colorectal cancer.
3.2. Materials and methods.
For the purpose of this study two dinucleotide repeat sequences D2S123 and
D13S160 (Gyapay et al., 1994), the poly (A) tract BAT-26 (Hoang et al., 1997) and
the (A)io repeat in exon 3 of TGFJ3RJI were chosen to determine the RER phenotype
of the primary tumours and the xenografts. Details of the methods can be found in
section 2.4. The samples were classified as RER+ if they displayed band shifts at two
or more loci and the primary tumours were considered RER+ if any of the multiple
samples analysed met these criteria (see Figure 5).
Clinicopathological features of these tumours (ie. tumour location, Dukes' stage,
histological features) were assessed based on the histopathology reports.
Unfortunately the patients' survival data were not available since the tumours were
collected at the time of this study.
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Figure 5. Analysis ofmicrosatellite instability using autoradiography with 33P-
labelled PGR amplified sequences after electrophoresis on denaturing
acrylamide gel. Tumours were classified as RER+ if they displayed
microsatellite instability (generation ofshorter or longer fragnients in
the tumour DNA compared to normal DNA) at two or more loci at
any of the multiple sites examined.
RER- RER+
a) N Ta Tb Tc b) N Ta Tb Tc Td
Locus: D2S123




Ta, Tb, Tc, Td, multiple samples collected from one primary tumour
a) An example ofRER- tumour.
b) An example ofRER+ tumour. In this case shifts in allele size at locus DJ3S160
are present at all sites examined.
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3.3. Results.
3.3.1. Analysis ofmicrosatellite instability in primary tumours.
Five out of 22 primary colorectal cancers (22%) included in this study were classified
as RER+. None of these patients met the Amsterdam Criteria (Vasen et at., 1991) for
diagnosing hereditary non-polyposis colorectal cancer (the presence of three or more
family members with colorectal cancer in at least two successive generations, with at
least one affected member having been diagnosed at less than 50 years of age). These
tumours therefore represent RER+ cases of sporadic colorectal cancer.
The clinicopathological features ofRER+ tumours are summarised in Table 5.
Table 5. Clinicopcithologicalfeatures ofRER+ colorectal cancers.
Sample Patient's Dukes' Tumour site & Differen¬ Mucinous
ID: age stage side tiation
3 64 A asc.col./right moderate
12 60 C asc.col. /right poor -/+ (signet ring cells)
17 76 C caecum/right poor -/+
18 77 B asc.col. /right poor -
20 70 C asc.col./right poor +
asc.col, ascending colon
no evidence ofmucin production
-/+, mucinous pattern present, but comprises less than 60% of the tumour and therefore the tumour can not be classified
as a mucinous adenocarcinoma
+, mucinous pattern comprises more than 60% ofthe tumour
The age of patients with RER+ colorectal cancer ranged from 60 to 77 in this study.
Three of the five tumours were classified as Dukes' stage C, one Dukes' stage B and
one Dukes' stage A. All of the RER+ tumours were right sided cancers (located in the
proximal part of the large bowel up to and including splenic flexure), four being
located in the ascending colon and one in the caecum. Four of these adenocarcinomas
showed poor differentiation and three of these showed evidence of mucin production
(see Table 5). Only one was classified as moderately differentiated adenocarcinoma.
The association of RER+ phenotype with p53 status, tumour DNA content and
chromosomal abnormalities is discussed later (see Chapter 4 and 5).
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3.3.2. Analysis ofmicrosatellite instability at diferrent tumour sites.
Analysis of all four microsatellite loci at different tumour sites revealed the presence
of substantial genetic heterogeneity in all of the tumours. In three of the five tumours
the number of microsatellite loci affected and the allele size of affected loci differed
between different sites within the tumour. In the two remaining cancers, only allele
length differed between sites but the same loci were affected within these tumours
(see Figure 6 and Table 6).
In case No 18, two of the four samples collected from the tumour (18a and 18d) did
not meet the criteria employed to establish the RER+ phenotype and they showed a
shift in allele size at only one locus (see Table 6). However, the tumour was classified
as RER+ since two other samples showed shifts at multiple loci (18b and 18c).
Shifts in allele size were not detected at any of the four microsatellite loci examined in
any of the multiple samples analysed from RER- primary tumours.
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Table 6. Presence ofshifts in allele size atfour microsatellite loci examined at
different tumour sites in RER+ cancers.
Sample D2S123 D13S160 BAT-26 TGFP RII RER status
3a shift - shift shift +
3b shift - shift shift +
3c shift - shift shift +
3d shift - shift shift +
12a shift shift shift shift +
12b shift shift shift shift +
12c shift shift shift shift +
12d shift shift shift shift +
17a - shift shift shift +
17b - shift shift shift +
17c shift shift shift shift +
17d shift shift shift shift +
18a - - shift - -
18b - shift shift - +
18c shift - shift - +
18d - - shift - -
20a - shift shift shift +
20b - - shift shift +
20c - shift shift shift +
20d - - shift shift +
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Figure 6. Analysis ofmicrosatellite instability using autoradiography with 33P-
labelled PCR amplified sequences after electrophoresis on denaturing
acrylamide gel. This figure shows heterogeneity ofmicrosatel/ites
between different tumour sites.
a) N Ta Tb Tc Td







N Ta Tb Tc Td
♦ -i
♦





Ta, Tb, Tc, Td, multiple samples collected from one primary tumour
a) Tumour showing microsatellite instability detected at all tumour sites examined;
however, the allele length differs at the site Ta not only compared to normal N, but
also to allele sizes at the other sites.
b) Tumour showing microsatellite instability with different allele length at each of
the examined sites.
c) Tumour showing shifts in allele size only at one of the four sites examined.
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3.3.3. Temporal evolution ofmicrosatellite sequences in sporadic colorectal cancer
with underlying microsatellite instability, as reflected by the analysis ofxenografts
established in SCID mice.
Colorectal cancer xenografts were successfully established from samples collected
from multiple sites from three RER+ tumours (see section 2.2 for details). Analysis of
the selected microsatellite loci in DNA from the normal tissue, primary tumour tissue
and corresponding xenograft tissue revealed additional changes in both numbers of
altered microsatellite loci and size of altered alleles in xenografts compared with
primary tumours and normal tissue (see Figure 7). The RER+ phenotype was always
preserved in colorectal cancer xenografts established from tumours with MfN
regardless of sample site. In one case (3xb, see Appendix lb) a xenograft established
from a RER+ tumour appeared to have lost its RER+ phenotype but further
investigation allowed the identification of this xenograft as a B-cell lymphoma and not
an adenocarcinoma. Therefore, this interesting case has been excluded from this study
and is discussed in detail in Chapter 6. None of the xenografts established from RER-
tumours acquired a RER+ phenotype during passage in SCID mice, which on average
lasted 12 weeks. One of the three xenografts established from RER- tumour No 22
(22xb, see Appendix 1) acquired a shift in one of the four loci that was not present in
the sample from the primary tumour but this did not satisfy the RER+ criteria. In
addition xenograft 19xa unexpectedly showed allele size shifts at all four loci, unlike
the sample from the primary tumour (19a), where no shifts were detected. However,
DNA fingerprinting of this xenograft failed to match this sample to the normal tissue
of the patient from whose tumour the xenograft was established. It was therefore
excluded from this study but the case is described in detail in Chapter 6.
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Figure 7. Analysis ofmicrosatellite instability using autoradiography with 33P-
labelled PCR amplified sequences after electrophoresis on denaturing
acrylamide gel. Three examples of changes in the number of loci and
size ofalleles affected in xenografts compared to primary tumour and
normal tissue.






N Ta Xa Tb Xb Tc Xc Td Xd
llli
I




Ta, Tb, Tc, Td, multiple samples collected from one primary tumour
Xa, Xb, Xc, Xd, xenografts established from samples Ta,Tb,Tc and Td collected from the primary tumour.
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The results of the microsatellite analysis in primary tumours sampled at multiple sites
and in corresponding xenografts are summarised in Table 7.
Table 7. Presence and distribution ofshifts in allele size at the
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o indicates no shift in allele size from normal
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★ indicates complete loss of normal allele in the xenograft
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3.4. Discussion.
This study of 22 sporadic colorectal cancers identified 5 tumours (22%) exhibiting
microsatellite instability. These results are in concordance with the previously
published data, stating the prevalence of the RER+ phenotype in sporadic colorectal
cancer to be 15-20% (Lothe et a/., 1993; Aaltonen et al., 1994; Wu et al., 1994;
Borresen et al., 1995; Liu et al., 1995; Bubb et al., 1996; Eshleman and Markowitz,
1996; Konishi et al., 1996). Clinicopathological features of RER+ colorectal cancers
have been described in detail (Lothe et al., 1993; Aaltonen et a/., 1994; Kim et al.,
1994; Bubb et al., 1996; Senba et al, 1998) and our data are in concordance with the
published results (Table 5). This includes predominant location in the proximal colon
and characteristic histopathological features (poor differentiation and evidence of
mucin production).
The results of the analysis of microsatellite instability at different tumour sites indicate
that despite the presence of substantial intratumoral heterogeneity, in the majority of
cases the RER+ phenotype could be readily identified by analysing a single tumour
sample. Only in one of the five cases analysed was this not always possible. In this
instance two out of four samples collected from the tumour (18a and 18d) showed
allele size shifts at one locus only, which on their own would not have satisfied the
criteria employed in this study for defining the RER+ phenotype. However, there is
still a disagreement concerning the minimal number of microsatellite loci that should
be studied and what proportion of loci displaying instability should result in the
classification of a tumour as RER+. A number of authors have classified tumours as
RER+ when as few as one of two loci appeared unstable (Chong et a!., 1994). Our
data show that even when more stringent criteria are employed, single sample analysis
is usually sufficient for detecting RER+ phenotype.
The analysis of four microsatellite loci at different sites within RER+ tumours and in
the corresponding xenografts confirmed the presence of substantial genetic
intratumoural heterogeneity regarding the number and size of alleles affected and
revealed the temporal evolution of these changes in the colorectal cancer xenografts.
These observations remain in concordance with the hypothesis that MIN is a
consequence of an underlying mechanism of genetic instability which continuously
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targets repetitive DNA motifs and leads to increased numbers of frameshift mutations.
Our data suggest that the defect in the mismatch repair system responsible for these
mutations either occurs early in colorectal carcinogenesis, or confers substantial
growth advantage on the tumour cells, thus permitting massive clonal expansion. High
homogeneity of the resulting RER+ phenotype, which can be readily detected at
different sites within a tumour supports this hypothesis. It also confirms that once this
defect is acquired, the RER+ phenotype that subsequently develops is preserved in
colorectal cancer xenografts. Further, the data emphasise the multiplicity of clonal
divergence due to repeated episodes of mismatch at microsatellite sites in these
tumours.
Previous studies demonstrated the maintenance of the RER+ phenotype in vitro and
in vivo (Shibata et al., 1994; Ottini el al, 1997; Curtis, 1998) and our results are in
concordance with this data. They additionally prove the colorectal cancer xenografts
to be highly representative of the primary tumour, as far as RER status is concerned,
regardless of genetic intratumoral heterogeneity. Although it is possibile that
additional genes are targeted in xenografts compared to the primary tumour,
colorectal cancer xenografts still represent an extremely valuable tool in studies on
colorectal cancer genetics and treatment response.
3.5. Summary.
In summary, this study has confirmed that a single sample analysis is sufficient for
determining RER+ phenotype in sporadic colorectal cancer. It has also shown that the
RER+ phenotype is characteristic of a proportion of sporadic colorectal cancers
where it is preserved in RER+ tumour cells during passage in SCID mice. It is likely
to have occurred early during tumour development. This is supported by its
homogenous distribution within RER+ tumours and by the fact that none of the RER-
colorectal cancers acquired this phenotype during passage in SCID mice. The
multiplicity of clonal divergence in RER+ colorectal tumours detected in this study
further supports the high mutation incidence in these tumours. This study has
determined that colorectal cancer xenografts are representative of the tumour of
origin with regard to RER status.
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CHAPTER 4.
Spatial and temporal analysis of chromosomal instability in sporadic colorectal
cancer.
4.1. Introduction.
A distinct phenotype identified in colorectal cancer is characterised by an increased
number of chromosomal abnormalities. This includes both gain or loss of individual
chromosomes and structural alterations within chromosomes consisting of
translocations, chromosome deletions, inversions and gene amplifications. The former
can easily occur through a non-disjunction event, while the latter are believed to
proceed via chromosomal breaks (Gerdes et al., 1995; Ried et al., 1996; Lengauer et
a/., 1997b; Cahillefa/., 1998; Eshleman et al., 1998a).
Abnormal chromosome copy number (aneuploidy) is nearly ubiquitous in cancer
(Mertens et al., 1997; Mitleman et al., 1997). It could therefore be argued that it
results simply from the abnormal structure and growth properties of cancer cells.
There is however increasing evidence for its association with underlying chromosomal
instability (Lengauer et al., 1997b; Cahill et al., 1998). CIN has been suggested as an
alternative pathway in colorectal carcinogenesis where the defect in the mechanism
controlling chromosome segregation and the resultant chromosomal instability drives
the tumorigenic process, just as defective mismatch repair drives neoplasia in MIN
tumours (Lengauer et al., 1997b). The potential molecular mechanisms leading to the
development ofCIN phenotype have been reviewed in Chapter 1 (see 1.2.6.3).
Different mechanisms are thought to be responsible for structural chromosomal
aberrations. Complex translocations are frequently observed in many solid tumours.
Although the molecular basis for the translocations in cancers is not known, it has
been suggested that they arise in cells that enter mitosis before recombination-
promoting double-strand breaks are repaired (Elledge, 1996; Paulovich et al., 1997).
Defects in genes such as ATM, ATR, BRCAJ, BRCA2, p53 and other genes involved
in double-strand breaks repair have been suggested to be involved in this process
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(Lengauer et al1998). Amplifications of oncogenes occur in a subset of late-stage
cancers of many organs, and amplification of genes involved in metabolism or
inactivation of drugs represents a common way for cultured cells to acquire resistance
to chemotherapeutic agents. Although amplifications can significantly affect tumour
biology, they affect only a single or a few genes in each cell and, in general, occur late
in tumorigenesis. The mechanisms through which amplifications are generated are
largely unknown (Lengauer et al., 1998).
A number of studies have revealed a strikingly lower incidence of chromosomal
alterations in the RER+ colon cancers in comparison with RER- tumours. This
supports the hypothesis that the pathway of RER+ colon carcinogenesis is
fundamentally different from that of RER- and strongly links the RER- phenotype
with CIN (Bardi et al., 1995; Schlegel et al., 1995; Lengauer et al., 1997b; Eshleman
etal., 1998a).
The aims of this study were to determine the following:
1. The prevalence of CIN in sporadic colorectal cancer and its relationship to RER
status.
2. Whether, as previous studies suggested, CIN is always detected in RER- colorectal
tumours and therefore can be considered an underlying mechanism of tumorigenesis in
RER- cancers.
3. Patterns of chromosomal abnormalities in RER- and RER+ sporadic colorectal
cancers.
4. Chromosomal change through time in RER- and RER+ cancers.
5. Whether colorectal cancer xenografts are representative of the tumours of origin
with regard to chromosomal abnormalities.
These aims were achieved by establishing the chromosome copy number changes,
using Comparative Genomic Hybridisation at multiple sites in primary tumours (see
2.5 for materials and methods). This allowed the investigation of the clonal evolution
of chromosomal changes in sporadic colorectal cancer and identification of
chromosomal abnormalities specifically selected for during tumour development. In
addition, the extent of chromosomal change through time was assessed by the
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examination by CGH of multiple colorectal cancer xenografts established in SC1D
mice.
4.2. Materials and methods.
Chromosomal copy number changes detected by Comparative Genomic Hybridisation
were examined in the same 22 primary colorectal cancers, sampled at multiple sites, in
which RER status had previously been determined (see Chapter 3).
CGH detects changes in chromosome copy number (whole or partial) through
competitive hybridisation of DNA derived from normal and tumour tissue onto a
normal human chromosome metaphase spread (Kallioniemi et al., 1992). Normal and
test DNA are differentiated by fluorescent coloured labels (red and green respectively)
and a fluorescent ratio is assessed along the length of each chromosome. Regions of
amplification or deletion are detected as a change in the ratio of the two colours
fluorescence. Unlike a conventional amplification/deletion analysis, which is limited to
a single locus, CGH provides information about the whole genome at once and
therefore is a considerably more powerful tool. However, unlike conventional
cytogenetic analysis it cannot detect balanced chromosomal changes such as
translocations or pure polyploidisation. Similarly, it gives no indication of the
character of the structural rearrangements that might be responsible for the deletions
and amplifications that it does identify.
Chromosomal abnormalities detected by CGH were found to consist mostly of
deletions or amplification of either whole chromosomes or entire chromosome arms.
Very occasionally changes that involved interstitial breakpoints and led to the loss of
an arm fragment simultaneous with gain of the remaining part of the chromosome arm
were observed and these changes were scored independently.
From these raw data several different indices were extracted. First, the frequency with
which individual chromosome arms are lost or gained in the RER- and RER+ tumours
was calculated. In order to determine the most frequent chromosomal changes in
colorectal cancers, the prevalence of a particular chromosomal change in RER- and
RER+ tumours was scored. This was expressed as the percentage of all RER- or
RER+ colorectal cancers in which particular chromosomal abnormality was observed,
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regardless of whether it was detected only at one or more of the multiple sites
examined in each tumour.
The CGH analysis of the multiple sites within colorectal cancers allowed identification
of chromosomal changes that either occurred early in the tumour development or
were selected for during tumour progression. These were changes which were present
at the majority of the examined sites within tumours, regardless of the proportion of
colorectal cancers in which they were identified (see Figure 10 and 13, Table 8 and 9).
A chromosomal instability index (CIN index) was calculated for each tumour in order
to assess the level of underlying chromosomal instability in RER+ and RER- tumours.
Two factors that reflect chromosomal instability were assessed; the mean number of
chromosomal gains and losses within a tumour, and heterogeneity of the presence of
particular chromosomal changes within a tumour. The CfN index was expressed as a
sum of these two scores (see section 4.3.5). This index was also calculated in
colorectal cancer xenografts established from RER+ and RER- tumours, when these
could be established successfully from more than one site. This provided additional
information about the progress of chromosomal changes in time in both cancer
groups.
Finally these indices were compared with data on nuclear DNA content, obtained by
Flow Cytometry of propidium iodide stained nuclei prepared by the method of
Vindelov et al. (1983) as described in section 2.6.
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4.3. Results.
4.3.1. Several chromosomes are consistently abnormal in RER- cancers.
A characteristic pattern of chromosomal abnormalities appears to be present in the
majority of RER- colorectal cancers. The commonest chromosomal abnormality
identified by CGH in RER- cancer was gain of the long arm of chromosome 20
observed in 88% of tumours (Figure 10). Next in frequency came 18q- (76%), 13q+
(64%), 8p- (59%) often in association with 8q+ (53%) and lp-, 18p-, 7p+, 4p- (each
present in 53% of RER- tumours). In 2 cases (12%) all of these chromosomal
abnormalities were present in one tumour. More frequently it was a combination of
the above changes. The combination of at least 8 out of 9 of these chromosomal
changes was present in 4 tumours (24%). At least 7 of these changes were present in
8 tumours (47%), 9 tumours (53%) showed the presence of at least 6 characteristic
chromosomal abnormalities and at least 5 of these changes were detected in 10
tumours (59%). Ail of the 17 RER- cancers showed the presence of at least one of the
common chromosomal abnormalities.
Moreover, most of these changes (20q+, 18q-, 13q+, 8p-, lp- and 8q+) when
observed in any tumour were found in 50% or over of the sampled sites suggesting
they may be acquired in time close to the establishment of the founder clone of the
carcinoma. In contrast, whilst every chromosomal arm showed some abnormality in at
least one tumour, most of the less frequent alterations also occurred in only a minimal
subset of the sites sampled within those tumours in which they were observed at all
(Figure 10).
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Figure 8. Example ofCGH ofaRER-primary tumour,
a) Metaphase image (case No 22c).
b) Normal human karyotype with DAPI banding.
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Figure 9. Chromosome copy number changes as detected by CGH in RER-
colorectal cancers sampledat multiple sites.
lp lq 2p 2q 3p 3q 4p 4q 5p 5q 6p 6q 7p 7q 8p 8q 9p 9q lOplOqllpllq 12pl2ql3ql4ql5ql6pl6q 17pl7ql8pl8q 19pl9q20p20q21q22q
-H+H- -H+ W+4fHhH+H+
- - -
1 H f I
E t
11 M 111 U 1111111II111111111111111111111
HI 1111111111 1111111
lp lq 2p 2q 3p 3q 4p 4q 5p 5q 6p 6q 7p 7q 8p 8q 9p 9ql0p 10qllpllql2pl2ql3ql4ql5ql6pl6ql7pl7ql8pl8ql9pl9q20p20q21q22q
□ Loss of chromosome material
Gain of chromosome material
82
Figure 10I Frequency ofoccurrence ofchromosomal abnormalities and their
prevalence at different tumour sites in RER- colorectal cancers.
0 10 20 30 40 50 60 70 80 90 100%
■H Frequency of a particular chromosomal change (gain + or loss - of chromosome material) in
RER- colorectal cancers. This number was calculated as a percentage of all RER- colorectal
tramoiamed in which the particular abnormality was observed at any of the multiple sites
examined.
□ Prevalence of a particular chromosomal change within RER- primary tumours. This number
was calculated as the ratio between the number of sites at which a particular chromosomal
abnormality was detected and the total number of sites examined averaged over all the
tumours where a particular abnormality occured
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Table 8.Chromosomal abnormalities mostfrequently detected in RER-
colorectal cancers.
Chromosomal changes present
in >50% RER- colorectal
cancer cases examined
20q+, 18q-, 13q+, 8p-, lp-,
8q+, 18p-, 7p+, 4p-
Chromosomal changes present
at >50% of different sites
examined within a tumour in
RER- colorectal cancer
15q-, 5q-, 18q-, lq-, 20q+,
8q+, 1 lq-, 13q+, 20p+, 7q+,
16p-, 8p-, 17p-, 3q-, 17q-,lp-
Chromosomal changes present
in >50% of tumours at >50%
of sites within a tumour in
RER- colorectal cancer
20q+, 18q-, 13q+, 8p-, lp-,
8q+
Chromosomal changes present in >50% of tumours at >50% of sites within a tumour are indicated in colour: loss of
chromosome arm - red, gain ofchromosome arm - green.
4.3.2. Chromosomal abnormalities in RER+ colorectal cancers.
An analysis of the most frequent chromosomal changes and changes selected for in
RER+ colorectal cancers was carried out. This group of tumours, as expected, was
substantially less numerous than the group of RER- cancers, rendering this analysis
somewhat difficult (see Figure 13 for details). Nevertheless the analysis of
chromosomal gains and losses detected by CGH identified a different pattern of
chromosomal abnormalities in RER+ tumours.
First of all, chromosomal abnormalities were much less frequent in RER+ cancers
compared to RER- tumours. Detailed analysis of these differences was carried out and
the results are described later in this chapter (see section 4.3.3).
A different subset of chromosomal changes appeared most frequently in RER+
cancers (Figure 13). These were loss of the short arm of chromosome 1 and the whole
of chromosome 19. These results are summarised in Table 9.
Figure 11 shows an example of CGH analysis of one sample collected from a RER+
tumour. Figure 12 presents the results of CGH analysis of primary RER+ colorectal
cancers sampled at multiple sites.
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Figure 11. Example ofCGHofa RER+ primary tumour,







b) Normal human karyotype with DAPI banding.
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c)Metaphase after karyotyping.
d) Average green/red ratioprofile (blue line) calculatedfrom 6
metaphases.Cut-offpoints of 0.875 (red line) and 1.125 (green line)
were chosenfor scoring ofchromosome copy number. Thick lines next
to chromosome ideograms indicate loss (red) or gain (green) of
chromosome material. Thisprofile shows lower number of
chromosomal changes that the number usually detected in RER-
cancers. In this case only duplication ofchromosome 2 and 19 del
were detected.
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Figure 12. Chromosome copy number changes as detected by CGH in RER+
colorectal cancers sampled at multiple sites.
lp lq 2p 2q 3p 3q 4p 4q 5p 5q 6p 6q 7p 7q8p 8q 9p 9q lOplOq 1 lplIql2pl2ql3ql4ql5ql6pl6ql7pl7q 18pl8ql9pl9q20p20q21q22q
lp lq 2p 2q 3p 3q 4p 4q 5p 5q 6p 6q 7p 7q8p 8q 9p 9q lOplOq Ilpllql2pl2ql3ql4ql5ql6pl6ql7pl7q 18pl8ql9pl9q 20p20q21q22q
□ Loss of chromosome material
Gain of chromosome material
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Figure 13. Frequency ofoccurrence ofchromosomal abnormalities and their
prevalence at different tumour sites in RER+ colorectal cancers.
H Frequency of a particular chromosomal change (gain + or loss - of chromosome material) in
RER+ colorectal cancers. This number was calculated as a percentage of all RER+ colorectal
hflffliflaarBsexamined in which particular abnormality was observed at any of the multiple sites,
examined.
CZ1 Prevalence of a particular chromosomal change within RER- primary tumours. This number
was calculated as the ratio of the number of sites at which a particular chromosomal
abnormality was detected and the total number of sites examined averaged over all the
tumours where the abnormality occured.
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Table 9. Chromosomal abnormalities mostfrequently detected in RER+
colorectal cancers.
Chromosomal changes present
in >50% RER+ colorectal
cancer cases examined
19p-, 19q-, lp-, 8q+, 16p-, 5q-
Chromosomal changes present
at >50% of different sites
examined within a tumour in
RER+ colorectal cancer
2p+, 2q+, 19q-, lp-, 8q+, 19p-
Chromosomal changes present
in >50% of tumours at >50%
of sites within a tumour in
RER+ colorectal cancer
19p-, 19q-, lp-
Chromosomal changes present in >50% of tumours at >50% of sites within a tumour are indicated in colour: loss of chromosome
arm - red, gain ofchromosome arm - green.
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4.3.3. Chromosomal changes are more frequent in RER- than in RER+ colorectal
cancers.
The number of chromosomal gains and losses detected by CGH was scored in all
RER- and RER+ tumours. The results are presented in Table 10. All statistical
analyses were carried out using mean values calculated for each tumour based on the
results from multiple sites examined. The analysis revealed that RER- and RER+
colorectal cancers differ not only in the pattern of chromosomal abnormalities most
frequently detected but also that the mean frequency of occurrence of chromosomal
changes is significantly lower in the RER+ group (p=0.039, one-tailed Mann-Whitney
Test). Both chromosomal gains and losses are less frequent in RER+ cancers
compared to RER- tumours (median 3 and 5 for losses and 2 and 3 for gains
respectively) but only the number of chromosomal losses is significantly higher in
RER- cancers (p=0.035, one-tailed Mann-Whitney Test). Also the loss of
chromosomal material is a more frequent event in both groups than chromosome gain
although this difference is not statistically significant in either group of tumours
(Mann-Whitney Test, p=0.07 for RER- and p=0.46 for RER+).
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Table 10. Number ofchromosomal changes in RER- andRER+ colorectal cancers.
RER- tumours RER+ tumours
ID No of M No of M No of M ID No of M No of M No of M
chrom. chrom. chrom chrom. chrom. chrom.
losses gains changes losses gains changes
la 4 4 8 3a 0 0 0
lb 6 5 8 1 14 12 3b 0 0 0 0 0 0
1c 7 13 20 3c 1 0 1
Id 4 2 6 3d 1 1 2
2a 10 2 12 12a 4 5 9
2b 17 10 11 6 28 16 12b 6 3 1 3 7 6
2c 7 1 8 12c 0 2 2
2d 6 10 16 [2d 4 5 9
4a 8 5 13 17a 3 2 5
4b 7 6 4 4 11 10 276 3 4 2 2 5 6
4c 5 5 10 27c 4 3 7
4d 5 4 9 I7d 6 2 8
5a 9 5 14 18a 6 3 9
56 0302 0 5 286 351146
5c 1 1 2 28c 8 2 10
5d 4 2 6 isd 2 0 2
6a 5 5 10 20a 2 5 7
(56 8 6 5 4 13 10 266 0 1 1 2 1 3
6c 6 5 11 26c 3 1 4
6rf 6 3 9 20d 1 1 2
7n 0 0 0
76 6 2 1 0 7 2
7c 0 0 0
8(7 1 0 1
86 8 4 2 3 10 7
8c 3 5 8
8rf 4 5 9
6(7 0 1 1
9b 13 6 4 3 17 9
9c 3 3 6
9d 7 3 10
9'o 6 3 2 1 8 4
9'b 1 0 1
10a 2 0 2
10b 7 4 1 0 8 4
26c 4 0 4
22« 12 5 17
lib 7 11 4 6 11 17
22c 14 11 25
lid 11 6 17
13a 4 2 1 1 5 3
13b 1 1 2
14a 8 6 8 8 16 14
14b 4 8 12
15a 3 5 0 1 3 6
15b 7 3 10
16a 2 1 4 5 6 6
16b 0 6 6
Ua 4 I 5
19b 11 9 4 3 15 12
19c 12 5 17
22(7 4 3 7
226 1 5 2 3 3 8




4.3.4. Comparison of chromosomal abnormalities present in primary RER- and
RER+ colorectal cancers and in corresponding xenografts.
This comparison aimed to establish whether colorectal cancer xenografts are
representative of the primary tumour with regard to the assessment of chromosomal
abnormalities. Considering the existence of genetic intratumoral heterogeneity within
primary tumours, confirmed previously by the study of samples collected from
different tumour sites, this study aimed to determine whether the pattern of
chromosomal changes detected in the xenografts is influenced by the site of origin of
tumour cells used for establishing xenografts.
Some discrepancies between the CGH results for primary tumours and corresponding
xenografts were expected, since such differences were detected within primary
tumours. It was important, however, to establish whether despite these discrepancies,
a similar pattern of chromosomal changes to that detected in RER- and RER+ primary
colorectal cancers was present in xenografts derived from these tumours and whether
they were therefore representative of their tumours of origin.
An attempt was made to establish xenografts from all collected tumour samples. Out
of 76 samples implanted in SCID mice 27 were successfully established. This
included 15 xenografts derived form 6 RER- cancers and 12 xenografts derived from
4 RER+ tumours. Two of these xenografts had to be subsequently excluded from the
analysis for the reasons discussed in chapter 6. In two further cases CGH data could
not be obtained, despite numerous attempts.
Figures 14 and 15 present the results of CGH analysis of RER- and RER+ primary
tumours sampled at multiple sites and the corresponding xenografts.
In both groups, more chromosomal changes were found in colorectal cancer
xenografts compared to the primary tumours. This was as expected, since DNA
extracted from primary tumours was contaminated to some degree with normal DNA
reducing CGH sensitivity. Tables 1 la and 1 lb present mean numbers of chromosomal
gains and losses detected by CGH in relevant samples from the primary tumours and
in the corresponding xenografts.
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Table 11a. Mean number of chromosomal gains and losses detected by CGH in
primary RER- tumours and in corresponding xenografts. The last
column indicates the proportion of chromosomal changes detected in
the primary tumours compared to the xenografts.
Primary tumours Xenografts %
Tumour Losses Gains Changes Xenograft Losses Gains Changes
ID ID
1 5 7 12 lx 13 14 27 44%
4 7 4 11 4x 9 10 19 58%
5 3 2 5 5x 12 4 16 31%
19 11 4 15 19x 16 8 24 62%
22 5 3 8 22x 18 7 25 32%
Values in the last column are calculated as an indication ofwhat proportion ofchanges detected in the corresponding xenografts was
detected in the primary tumour. These calculations are based purely on the number ofchanges.
Table lib. Mean number ofchromosomal gains and losses detected by CGH in
primary RER+ tumours and in corresponding xenografts. The last
column indicates the proportion of chromosomal changes detected in
the primary tumours compared to the xenografts.
Primary tumours Xenografts %
Tumour Losses Gains Changes Xenograft Losses Gains Changes
ID ID
12 3 3 6 12x 6 3 9 67%
18 7 2 9 18x 8 4 12 62%
20 2 2 4 2Ox 6 3 9 44%
Values in the last column are calculated as an indication ofwhat proportion of changes detected in the corresponding xenografts was
detected in the primary tumour. These calculations are based purely on the number of changes.
Chromosomal abnormalities present in primary tumours were usually detected in
corresponding xenografts (see Table 12). This rule applied especially to the RJER-
colorectal cancers, where in general 75% of the chromosomal changes present in the
primary tumours were also detected in the corresponding xenografts, compared with
56% in RER+ matched pairs.
The presence of chromosomal changes characteristic for the RER- colorectal cancer
group was highly consistent between primary tumours and corresponding xenografts
(see Table 13). Where changes typically found in RER- cancers (20q+, 18q-13q+,
8p-, lp- and 8q+) were detected in the sample from the primary tumour, 92% were
also present in the corresponding xenograft. This was not found to be the case in the
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RER+ tumours where the consistency of finding chromosomal abnormalities typical of
RER+ tumours (19p-, 19q-, lp-) reached only 57%.
Table 12. The proportion ofchromosomal changesfound in primary tumours
that were also detected in corresponding xenografts.
RER- RER+
Primary tumour/xenografts % Primary tumour/ xenograft %
la/lxa 100 12a/12xa 55
lb/lxb 71 12b/12xb 14
lc/lxc 45 12c/12xc 100
Id/lxd 60 12d/12xd 100
4b/4xb 81 18a/lSxa 20
18c/18xc 0
5a/5xa 50 20a/20xa 43
5b/5xb - 20b/20xb 75






indicates that there were no chromosomal changes present in the primary tumour, rendering the score impossible.
Table 13. The consistency ofchromosomal changes characteristic ofRER-
(20q+, 18q-, 13q+, 8p~, Ip- and 8q+) andRER+ (19p~, 19q~, lp-)
tumours appearing in primary colorectal cancers and corresponding
xenografts.
RER- RER+
Primary tumour/xenografts % Primary tumour/ xenograft %
la/lxa 100 12a/12xa -
lb/lxb 100 12b/12xb -
lc/lxc 75 12c/12xc -
ld/lxd 100 12d/12xd 100
4b/4xh 80 18a/1Sxa 0
18c/18xc 33
5a/5xa 100 20a/20xa 100
5b/5xb - 2Ob/2Oxb 50






indicates that there were no characteristic chromosomal changes present in the primary tumour, rendering the score impossible.
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Figure 14. Chromosomal abnormalities detected by CGH in RER- colorectal
cancers sampled at multiple sites and in the corresponding
xenografts.
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Figure 15. Chromosomal abnormalities detected by CGH in RER+ colorectal
cancers sampledatmultiple sites and in the corresponding
xenografts.
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4.3.5. Assessment of the level of chromosomal instability in RER- and RER+
colorectal cancers based on the CGHdata.
Although the presence of multiple abnormalities in chromosome number or structure
is often taken to represent chromosomal instability, the possibility also exists that
tumour karyotypes represent a new stable equilibrium, adopted after an earlier phase
(or perhaps even single episode) of violent change. To distinguish between these
possibilities two different indices were used. The first was a single count of the
number of gains or losses per genome. In CGH, this number is always referred back
to the standard diploid karyotype, regardless of the total ploidy of the tumour
genome, since equivalent quantities of tumour and normal DNA are cohybridised with
the target standard metaphase chromosomes. Second index sought to express
numerically the extent to which samples from different parts of the tumour displayed
similar or dissimilar features. Once again this index is referenced against the normal
karyotype, so each chromosome arm contributes equally to the analysis. Thus
chromosome arms in which the CGH pattern is identical for each sampled portion of
the tumour score zero, whilst arms for which the sampled portions differ from each
other score unity (for example see Figure 16). Although it is recognised that this index
may be sensitive to the number of sites sampled per tumour, there is no a priori
reason to suppose that the heterogeneity index and the chromosome number index
should measure the same properties. This was the basis of the decision to adopt as
CIN index the sum of the two.
In practice, however, heterogeneity index and number of chromosome changes show
a modest positive correlation (Figure 17). The correlation coefficient was 0.622 and
the significance 0.002 (two-tailed Spearman rank correlation coefficient test). Thus it
is probable that the clonal evolution of these tumours is continuous - tumours with
highest divergence also showing the highest total number of changes. The only
exceptions appear to be tumour No 14 and No 19, both of which have low
heterogeneity indices despite high numbers of altered chromosomes. Since, however,
both were analysed on the basis of two and three separate portions respectively
(rather than 4, as in the majority of tumours analysed), the heterogeneity index may
have been underestimated.
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Figure 16. CGH results of chromosomal gains and losses detected in a primary tumour sampled at 4
different sites and in 4 corresponding xenografts.
CGH results are shown for the tumour from patient no.l as an example of how the 'heterogeneity
score' was calculated for each patient. Chromosome arms are represented vertically in columns,
whilst each different site of the same tumour designated a, b, c and d are in rows, lxa, lxb, lxc, and
lxd are the corresponding xenografted tumours established from sites a, b, c and d.
The heterogeneity score was calculated for the primary tumour and separately for the xenograft by
adding the number of columns representing chromosome arms in which changes were inconsistent
between different sites within the tumour. For example, in the primary tumour, inconsistent
chromosome changes are seen in lp, 3p, 4p, 5p, 5q, 6p, 6q, 7p, 8p, 8q, lOp, lOq, lip, llq, 12p, 12q,
14q, 15q, 17p, 17q, 18p, 19p, 19q, 20q and 22q giving a total heterogeneity score of 25. Consistent
patterns, such as at lq or 7q, do not score.
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□ Loss ofchromosome arm
□ Gain of chromosome arm
Table 14 presents the scores of the mean number of chromosomal changes,
heterogeneity scores and the combined CIN index scores in relation to the tumours'
RER status.
As previously mentioned, the mean number of chromosomal gains and losses was
significantly higher in RER- colorectal cancers compared to RER+ tumours (one-
tailed Mann-Whitney Test, p=0.039). Heterogeneity of chromosomal changes also
appeared higher in RER- cancers, though this did not reach significance (one-tailed
Mann-Whitney Test, p=0.068). The combined score (CIN index), however, was again
significantly higher in RER- than in RER+ tumours (one-tailed Mann-Whitney Test,
p=0.039).
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Table 14. Chromosomal instability index in andRER+ colorectal cancers.
RER- RER+
Tumour Mean number of Heterogeneity CIN index Tumour Mean number of Heterogeneity CIN index
ID: chromosomal
changes
score ID: chromosomal score
changes
1 12 25 37 3 0 3 3
2 16 31 47 12 6 16 22
4 10 16 26 17 6 6 12
5 5 17 22 18 6 17 23
6 10 19 29 20 3 7 10
7 2 7 9
8 7 19 26
9 9 20 29
9' 4 9 13
10 4 12 16
11 17 31 48
13 3 7 10
14 14 8 22
15 6 7 13
16 6 6 12
19 12 12 24
22 8 15 23
p=0.039 p=0.068 p=0.039 Probability that mean values for RER- are greater than for
RER+
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Figure 17. Mean number of chromosomal changes plotted against heterogeneity
score shows correlation ofthese two values.
0 5 10 15 20
Mean number of chromosomal changes
□ RER- tumours
o RER+ tumours
The correlation coefficient 0.622, the significance 0.002 (two-tailed Spearman rank correlation coefficient test)
4.3.6. Comparative studies identify a subgroup of RER- colorectal cancer
exhibiting a low level ofchromosomal instability.
Further data analysis showed that although RER- tumours compared to RER+
cancers show an overall significantly higher level of chromosomal instability there is a
group of RER- colorectal cancers with quite a low level of CIN comparable to that
observed in RER+ cancers (see Figure 18). This group ofRER- tumours fell below a
CIN index of 18 , a subjectively defined borderline between the two groups, which is
a middle value between mean CIN index values for all RER- and all RER+ tumours.
This surprising finding suggests that low CIN subgroup of RER- cancers may
represent separate subclass distinct from high-CIN tumours, since it shows neither
microsatellite instability (as RER+ cancers) nor major repeated changes in
chromosome number (as high-CIN RER- cancers). This non-MIN non-CIN group of
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colorectal cancer quite possibly represents a distinct entity and might harbour none or
yet another mechanism allowing destabilisation of the genome.
The question therefore arises if there are clues to what this mechanism might be. One
immediate possibility is a different pattern of alteration of critical "caretakers" (genes
responsible for stability of the genome), potentially leading to different patterns of
genomic instability.
To further investigate this subset of tumours, any differences in the patterns of
specific clonal chromosomal abnormalities present in low and high CIN RER- cancers
were analysed.
Chromosomal gains and losses most frequently present in high CIN RER- cancers
(20p+, 18q-, 13q+, 8p-, lp-, 8q+) (see Table 8) were consistently less common in the
group of colorectal cancers with low CIN (Table 15). Particularly striking was the
lack of incidence of 13q duplication in RER- tumours with low CIN (detected in 1 out
of 6 tumours) compared with RER- cancers with a high level of chromosomal
instability (10 out of 11 tumours). Although this finding was not entirely surprising,
since this group exhibited an overall lower level of chromosomal instability, it was
more interesting in light of the fact that not all chromosomal changes were less
common in low CIN RER- cancers. Surprisingly deletions of all or part of
chromosome 19, one of the two frequent chromosomal changes in RER+ cancers in
our study (see section 4.3.2), appeared with similar frequency in low and high CIN
RER- tumours (occurring in 3/6 low CIN and 5/11 high CIN RER- tumours).
Table 15. Distribution of the most frequent chromosomal changes detected in
RER- colorectal cancers with regard to CIN level.
All RER- RER- tumours RER- tumours
tumours with CIN>18 with CIN<18
Total number of tumours in each
group: 17 11 6
Most frequent chromosomal
abnormalities in RER- tumours:
20q+ 88% (15) 100% (11) 67% (4)
18q- 76% (13) 91% (10) 50% (3)
13q+ 65% (11) 91% (10) 17% (1)
8p- 59% (10) 73% (8) 33% (2)
8q+ 53% (9) 64% (7) 33% (2)
lp- 53% (9) 64% (7) 33% (2)
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4.3.7. Clinicopathological features of RER- tumours with low levels of
chromosomal instability.
Overall, this entire series consisted of 8 right-sided and 14 left-sided tumours (see
Appendix la).
An attempt was made to establish whether the group of RER- colorectal cancers
exhibiting low levels of chromosomal instability might constitute a distinctive entity
based on clinicopathological features. All of the 6 RER- sporadic colorectal cancers
with low levels of CIN were left-sided compared with 8 of 11 high-CIN RER-
tumours. Four of the tumours were moderately differentiated adenocarcinomas but
well and poorly differentiated tumours were also observed. There was no difference
between the proportion of low CIN and high CIN cancers with regard to Dukes'
stage or patient age. Thus there appeared to be no substantial clinicopathological
differences between high and low CIN RER- tumours. Significantly, however, the low
CIN RER- tumours differed radically in location from the RER+ tumours, which also
included low CIN cancers, but which were all right sided.
4.3.8. Progress of genomic instability in CIN colorectal cancers reflected by
genomic differences between primary tumours and corresponding xenografts.
Passage of tumour cells derived from primary RER- and RER+ colorectal cancers as
xenografts in SCID mice allowed the assessment of the temporal evolution of
chromosomal abnormalities in the examined tumours and thus assessment of the level
ofunderlying chromosomal instability.
To assess the progress of chromosomal changes in these tumours, a scoring system
similar to that for primary tumours was applied. For this purpose only those
xenografts successfully established from at least two separate sites from the primary
tumour were used, since this was a prerequisite for calculating the heterogeneity
score. The assumption was made that if chromosomal instability is an underlying
mechanism driving tumorigenesis in a proportion of tumours, the CIN index should be
even higher in the corresponding xenografts. On the other hand, if the chromosomal
changes represented accidental events, the CIN index should not differ dramatically
between primary tumours and corresponding xenografts.
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The fact that the same cut-off point of 1.125 an 0.875 in CGH analysis was used for
scoring chromosomal gain and loss in primary tumours and in xenografts could result
in possible underscoring of chromosomal changes in the primary tumours, which were
contaminated to some degree with normal stromal DNA. However, since the same
error applied to both RER- and RER+ groups of colorectal cancer, direct comparison
of the results could be made.
Table 16 presents the results.
Table 16. Chromosomal instability index in RER- andRER+ colorectal cancer
xenografts.


























lx 27 27 54 15 12x 10 16 26 4.5
5x 17 27 44 12 lSx 13 17 30 12.5
19x 25 7 32 12 20x 9 7 16 11
22x 26 24 50 9.5
The data showed substantial differences in the degree to which CIN index increased
between primary tumours and xenografts of RER- and RER+ cancers (74% and 34%
respectively), reflecting in general an increased rate of acquisition of chromosomal
abnormalities in RER- tumours compared to RER+ cancers (see Figure 18).
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Figure18.CIN index in RER- andRER+ primary tumours and in the
corresponding xenografts. The figure illustrates substantially greater
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RER-p, RER- primary tumours
RER-x, RER- xenografts
RER+ p, RER+ primary tumours
RER+ x, RER+ xenografts
•4*CIN index 18
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4.3.9. Flow cytometry analysis of the DNA content in RER- and RER+ colorectal
cancers sampled at multiple sites and in the corresponding xenografts.
Following the CGH analysis, the DNA content of all samples included in this study
was re-examined using flow cytometry to test whether the results gained by both
methods were compatible and to provide additional information on the tumour cells'
total DNA content. Samples collected at multiple sites from primary tumours were
examined to determine whether DNA content of tumour cells was consistent within
the tumour or varied between different tumour sites. Samples from corresponding
xenografts were analysed in order to determine whether DNA content of tumour cells
was temporally stable.
The results are presented in Table 17 and 18.
Table 17. Flow cytometry analysis of the DNA content ofRER+ tumours
sampled at multiple sites and of the corresponding xenografts.
Primary tumours Xenografts





12a diploid 12xa diploid
12b diploid 12xb diploid
12c diploid 12xc diploid





18a near tetraploid 1.93 18xa near tetraploid 1.83
18b near tetraploid 1.95 18xb near tetraploid 1.93
18c diploid 18xc diploid
18d near tetraploid 1.87 18xd near tetraploid 1.98
20a diploid 2Oxa diploid
20b diploid -
20c diploid 20xc diploid
20d diploid 20xd diploid
The DNA index was calculated as the ratio of peak positions of the aneuploid and diploid peaks. DNA index values are given for
peaks with cell content exceeding 10% of the total cell count.
Samples were classified as near diploid or near tetraploid ifthe tumour cells' peak fluorescence value was within 10% ofthe diploid
or tetraploid peak fluorescence value, but for statistical purposes were treated as aneuploid.
-, not available
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Table 18. Flow cytometry analysis of the DNA content ofRER- tumours
sampled at multiple sites and of the corresponding xenografts.
Primary tumours Xenografts
Sample ID DNA content DNA index Sample ID DNA content DNA index
la near tetraploid 1.82 lxa near tetraploid 1.85
lb near tetraploid 1.84 lxb near tetraploid 1.89
lc near tetraploid 1.84 lxc near tetraploid 1.80/2.05
Id near tetraploid 1.82 lxd near tetraploid 1.84
2a near diploid 1.1 -
2b near tetraploid 2.2 -
2c n.dipl./n.tetrapl. 1.2/2.2 -
2d near diploid 1.1 -
4a aneuploid 1.54 -
4b aneuploid 1.6 4xb aneuploid 1.94
4c aneuploid 1.59 -
4d aneuploid 1.58 -
5a aneuploid 1.65 5xa aneuploid 1.75
5b aneuploid 1.65 5xb aneuploid 1.64
5c aneuploid 1.58 5xc aneuploid 1.62
5d aneuploid 1.63 -
6a aneuploid 1.66 -
6b aneuploid 1.68 -
6c aneuploid 1.72 -
6d aneuploid 1.68 -
7a near tetraploid 1.81 -
7b aneuploid 1.76 -
7c near tetraploid 1.85 -
8a aneuploid 1.68 -
8b aneuploid 1.73 8xb aneuploid 1.75
8c aneuploid 1.76 -
8d aneuploid 1.65 -
9a near tetraploid 1.87 -
9b near tetraploid 1.92 -
9c near tetraploid 1.96 -






11a aneuploid 1.43 -
lib near tetraploid 2.05 -
11c aneuploid 1.45 -
lid aneuplod 1.36 -
13a diploid -
13b diploid -
14a near diploid 1.1 -
14b diploid -




19a aneuploid 1.54 -
19b aneuploid 1.54 19xb aneuploid 1.62/3.2
19c aneuploid 1.52 19xc aneuploid 1.62
22a aneuploid 1.32/2.43 22xa aneuploid 1.34/2.6
22b aneuploid 1.32/2.3 22xb near tetraploid 1.8
22c aneuploid 1.4/2.3 22xc aneuploid 1.42
The DNA index was calculated as the ratio of peak positions of the aneuploid and diploid peaks. DNA index values are given for
peaks with cell content exceeding 10% ofthe total cell count.
Samples were classified as near diploid or near tetraploid if the tumour cells' peak fluorescence value was within 10% of the diploid
or tetraploid peak fluorescence value, but for statistical purposes were treated as aneuploid.
-, not available
106
Similar to the results of the CGH analysis which revealed that fewer chromosomal
changes are present in RER+ tumours compared to RER- cancers, flow cytometry
analysis of the total DNA content showed most of the RER+ colorectal tumours (4
out of 5) to have diploid DNA content, whilst in RER- cancers the majority of
tumours (13 out of 17) were aneuploid. This difference was statistically significant
(two-tailed Fisher exact test, p=0.039). Moreover, all but one of the 6 RER- cancers
with a diploid clone were classed as non-MIN non-CIN tumours whilst only one of
the 6 non-MIN non-CIN RER- cancers was aneuploid.
Interestingly many of the RER- tumours exhibited intratumoral heterogeneity of the
DNA content with DNA indexes varying in samples taken from different tumour sites
(see Figure 19). This phenomenon was present in only one RER+ cancer and the four
remaining tumours retained their diploid DNA content within the tumour and in the
corresponding xenografts (see Figure 20).
Change in the total DNA content with time could be observed in RER- colorectal
cancers, where many of the corresponding xenografts showed a somewhat different
DNA content to the tumour sample from which they were established (see figure 21).
However colorectal cancer xenografts established from tumours with diploid DNA
content always remained diploid and those established from aneuploid tumours
remained aneuploid.
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Figure 19. Flow cytometry profiles of the DNA content of two RER-













a) and b) show flow cytometry profiles for two sites within RER- tumour No4 (4c and 4d) with similar aneuploid peak
positions
c) and d) show flow cytometry profiles for two sites within RER- tumour Noll (lib and lid) with substantially
different aneuploid peak positions
Figure 20. Flow cytometryprofiles of the DNA content ofa RER+ colorectal





a) and b) show flow cytometry profiles for two sites within diploid RER+ tumour No 12 (12a and 12c)
c) and d) show flow cytometry profiles of xenografts established from samples 12a and 12c which retained their diploid DNA
content
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Figure 21. Flow cytometryprofiles of the DNA content ofa RER- colorectal
cancer sampled at multiple sites and of the corresponding xenografts.
a) and b) show flow cytometry profiles for two sites within aneuploid RER- tumour No 22 (22 a and 22b)
c) and d) show flow cytometry profiles of xenografts established from samples 22a and 22b which remained aneuploid, despite
changing their DNA content compared to their samples of origin
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4.4. Discussion.
4.4.1. Frequency of chromosomal abnormalities in RER- and RER+ sporadic
colorectal cancers.
Differences in the frequency of chromosomal abnormalities in RER- and RER+
colorectal cancers have been previously reported. RER+ tumours have been shown to
retain their diploid DNA content (Aaltonen et al., 1993; Lothe el a/., 1993). Studies
of chromosomal abnormalities in RER- and RER+ colorectal cancers cell lines
indicated chromosomal gains and losses to be substantially less common in RER+
tumours (Schlegel et a/., 1995; Eshleman et al., 1998a). The results of this study are
in concordance with these findings.
Differences in the frequency of occurrence of chromosomal changes in RER- and
RER+ groups of colorectal cancer support the hypothesis that two distinct
mechanisms drive carcinogenesis in these two colorectal cancer groups.
Although the incidence of chromosomal instability is significantly higher in the RER-
colorectal cancers compared to RER+ tumours, the results of our study suggest that
CIN is probably not the sole mechanism responsible for cancer development in the
RER- group of sporadic colorectal cancer.
Unlike the results of Eshleman et al. (1998a), which indicated that RER- and RER+
colorectal cancer cell lines could be clearly distinguished on the basis of chromosomal
instability index (which they defined as the sum of all non-disjunction events and all
chromosomal breaks) we observed substantial variation in levels of chromosomal
abnormalities between the two groups. Methods and scoring systems used in these
two studies were not identical but both reflected the level of chromosomal instability
in the tumours examined. These results were confirmed by the flow cytometry analysis
of the total DNA content. Most of the MIN and non-MIN non-CIN cancers appeared
to retain the diploid DNA content.
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4.4.2. Identification of a novel non-MIN, non-CIN phenotype in sporadic
colorectal cancer.
This study has identified a significant proportion of sporadic colorectal cancers, up to
one quarter, which do not display instability of either chromosomes or microsatellites.
These tumours do not to show any striking differences in clinical and pathological
features to high CIN RER- tumours but may harbour fewer abnormalities of p53 (see
Chapter 5). The data also suggest that these cancers might display a different pattern
of clonal chromosomal abnormalities to high CIN RER- tumours. More frequent loss
of chromosome 19, despite infrequent chromosomal abnormalities together with rare
defects of p53 might indicate that a different subset of tumour suppressor genes is
targeted in these tumours. Interestingly mutations in STKJ1, a recently identified
tumour suppressor gene (Peutz-Jeghers gene) mapped to 19p 13.3 (Hemminki et al.,
1997) were found only in left sided colorectal cancers (Dong et al., 1998). All non-
MIN non-CIN colorectal cancers identified in this study were left sided tumours.
Failure to distinguish this group of tumours prior to this study may be due to the
heavy reliance of many investigators on tumours established as cell cultures and
under-representation of non-MIN non-CIN cancers among colorectal cancer cell lines
(Eshleman et al., 1998a). Although we have not attempted to establish cell lines from
the tumours in this study we did, unusually, fail to establish xenografts from all six of
the non-MIN non-CIN tumours, despite implanting multiple samples from each. The
other colorectal cancers in this series were implanted with a success rate of 36% for
RER- and 60% for RER+.
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4.4.3. Patterns of chromosomal abnormalities in RER- and RER+ colorectal
cancers.
4.4.3.1. Specific pattern of chromosomal abnormalities in RER- sporadic
colorectal cancers.
The specific pattern of chromosomal gains and losses (20q+, 18q-, 13q+, 8p-, lp-,
8q+) identified in the 17 RER- sporadic colorectal cancers included in this study
generally conforms with the results of many previous cytogenetic and CGH studies
(Reichmann et a/., 1981; Muleris et al., 1985, 1988, 1990, 1994; Yaseen eta/., 1990;
Konstantinova et al., 1991; Xiao et al., 1992; Bardi et al., 1993a, 1993b, 1995;
Barletta et al., 1993; Herbergs et al., 1994; Gerdes et al., 1995; Bomme et al., 1996;
Herbergs et al., 1996; Ried et al., 1996; Mertens et al., 1997). The only exception is
duplication of chromosome 7, previously reported as a frequent and early event in
colorectal carcinogenesis (Griffin et al., 1993; Muleris et al., 1994; Bomme et al.,
1996; Herbergs et al., 1996). In this study 7p+ and 7q+ was found in 53% and 35%
of RER- colorectal cancers respectively but gain of the whole chromosome 7 was
present in less than 50% of RER- tumours and was not detected at all in RER+
cancers. The results also do not confirm gain of chromosome 7 to be an early event in
colorectal cancer development, since its distribution within tumours was rather
heterogeneous.
CGH analysis of chromosome abnormalities at different tumour sites in RER- and
RER+ sporadic colorectal cancers allowed the identification of chromosomal changes
that are most likely specifically selected for in these groups of tumours. Frequent loss
of the long arm of chromosome 18 in RER- cancers could be explained by the fact
that tumour suppresser genes such as DCC (Itoh et al., 1993; Cho et al., 1994),
SMAD4 (Takagi et al., 1996; Thiagalingam et al., 1996) and MADR2 (Eppert et al.,
1996) are located there. DCC encodes a cell adhesion molecule, normally widely
expressed on the colon mucosa (Hedric et al., 1994). Its expression is reduced or
absent in 70-75% of colon cancers (Vogelstein et al., 1988; Fearon et al., 1990; Itoh
et al., 1993; Cho et al., 1994). Its role in colorectal carcinogenesis has however
recently been questioned, since mutant mice lacking both alleles of DCC show no
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abnormalities of intestinal biology (Fazeli et al., 1997). Whether a neighbouring gene
may in fact be the actual tumour suppresser gene on 18q remains to be determined.
SMAD4 and MADR2 are known to be central players in the signal transduction
pathway activated in response to the large family of TGF(3-like ligands. Frequent 8p
loss detected in this study supports the hypothesis that other, as yet unidentified,
oncosuppresser genes important in colorectal carcinogenesis are located on the short
arm of chromosome 8 (Cunningham et al., 1993; Fujiwara et al., 1993; Kelemen et
al., 1994a, 1994b; Yaremko et al., 1994; Farrington et al., 1996). Possible candidates
include FEZ1 gene encoding Fezl protein containing leucine-zipper region with
similarity to the DNA-binding domain of the cAMP-responsive activating-
transcription factor 5. FEZ1 gene transcripts are undetectable in more than 60% of
epithelial tumours and mutations in FEZ1 have been found in oesophageal cancers and
prostate cancer cell lines, suggesting that its inactivation may play a role in
development of various human tumours (Ishii et al., 1999). Other possible candidates
include a gene frequently deleted in human liver cancer DLC1 (t/ynein /ight-chain gene
7; 8p21.3 - p22), PRLTS (PDGF-receptor (3-/ike /umour suppresser), EXT1 and
EXTL3 [exostoses (multiple)-like 3] (Knuutila et al., 1999). Deletions within the short
arm of chromosome 1 in colorectal carcinomas have been previously reported (Leister
et al., 1990; Praml et al., 1995; di Vinci et al., 1996; Matsuzaki et al., 1998). One of
the three commonly deleted regions in chromosome 1 overlaps with the region to
which PLA2s has been mapped. PLA2s encodes type II non-pancreatic phospholipase
A2 (MacPhee et al., 1995), one of the enzymes responsible for the production of
arachidonic acid (a prostaglandin precursor). It is not clear however how loss of its
function contributes to tumour development. In min mice, which are heterozygous for
APC mutation and develop multiple bowel polyps in a similar manner to FAP patients
(Moser et al., 1990), a null mutation in one allele oilMom 1 (the mouse homologue of
PLA2s) is associated with lower number of polyps. Region 1 p36 contains another
candidate for a tumour suppresser gene - p73 which encodes a protein highly
homologous to p53 (Kaghad et al., 1997). Flowever subsequent search for somatic
mutations in p73 gene in colorectal carcinomas revealed that such mutations are
extremely rare (Han et al., 1999). Human aflatoxin B-l aldehyde reductase gene
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located at Ip35-lp36 has also been suggested to play a role in colorectal
carcinogenesis due to its presumptive involvement in detoxification of genotoxic and
cytotoxic substances (Praml et al., 1998). Other putative tumour suppressor genes
located on the short arm of chromosome 1 include ID3 (inhibitor of DNA binding 3;
lp36.13 - p36.12), NB/NBS (neuroblastoma suppressor; lp36.13 - p36.11), TNFR2
(tumour necrosis factor receptor 2; lp36.3 - p36.2), DAN (differential-screening-
selected gene aberrant in neuroblastoma; 1 p36.13 - p36.11), CDC2L1 (cell division
cycle 2-like 1; 1 p36) and BRCD2 (breast cancer suppressor-2; lp36) (Knuutila et a!.,
1999) but their role in colorectal carcinogenesis is unclear. The search for specific
tumour suppresser genes located on the short arm of chromosome 1 continues. Gain
of chromosome material on 20q has been reported in various malignancies including
colorectal cancer (Kallioniemi et al., 1994; Iwabuchi et al., 1995; Schlegel et al.,
1995; Reznikoff et al., 1996; Larramendy et al., 1997; Mahlamaki et al., 1997) and
the location of STK15 on 20ql3 makes it a likely target of this amplification. STKI5
(also known as BTAK and auroral) encoding a centrosome-associated kinase is
amplified and overexpressed in many human tumour cell types (Sen et al., 1997;
Bischoff et al., 1998). It is involved in the induction of centrosome duplication-
distribution abnormalities and aneuploidy in mammalian cells (Zhou et al., 1998).
It is difficult to speculate on the significance of 8q and 13q duplications, since the
regions of amplification include such large portions of the genome in which so far no
genes of known importance in colorectal cancer are located.
The fact that there was an excellent consistency (92%) in the presence of
chromosomal changes characteristic of RER- cancers (18q-, 8p-, lp-, 20q+, 13q+,
8q+) between primary tumours and the corresponding xenografts and that other
chromosomal changes were less frequently preserved indicates that these particular
chromosomal amplifications or deletions gain tumour cells growth advantage and are
therefore specifically selected for during tumour development.
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4.4.3.2. Chromosomal abnormalities in RER+ sporadic colorectal cancers.
A different subset of chromosomal changes was found to be present most frequently
in RER+ tumours. Although loss of the short arm of chromosome 1 appeared with
similar frequency in both tumour groups, the frequent occurrence of 19del in RER+
tumours is a surprising finding and has not been previously reported. It is of particular
interest now, since the Peutz-Jeghers gene has recently been mapped to the short arm
of chromosome 19 (19pl3.3) by linkage analysis (Hemminki et al., 1997) and was
subsequently found to encode serine threonine kinase STKJJ (Jenne et al., 1998;
Hemminki et al., 1998). Data gathered to date indicate that LOH in this locus appears
in 20%-50% of sporadic colorectal cancers (Resta et al., 1998; Dong et al., 1998). It
is difficult to interpret the importance of the loss of chromosome 19 and the short arm
of chromosome 1 in RER+ colorectal cancers. Our results showing frequent 19del in
these tumours should be interpreted cautiously due to occasional aberrant results
yielded by CGH for this particular chromosome (Kallioniemi et al., 1994). However,
the aberrant result usually represented gain rather then loss of chromosome 19. The
small number of RER+ colorectal cancers included in this study further complicates
the interpretation of the results. However, low consistency (57%) of the presence of
these chromosomal changes between primary tumours and their xenografts suggests it
is unlikely they confer a substantial positive growth advantage on cells. In view of this
data, it can not be convincingly claimed that these abnormalities are specifically
selected for in RER+ colorectal cancers.
4.4.4. Colorectal cancer xenografts are in general representative of the tumours of
origin with regard to chromosomal abnormalities.
That more chromosomal abnormalities were detected in the xenografts compared to
primary tumours can be partially explained by the fact that the test DNA isolated from
primary tumours was consistently contaminated to some degree with normal DNA
which decreases the CGH sensitivity. However, since the same error applied to both
tumour groups the difference in the proportion of chromosomal abnormalities
detected in the primary tumours when compared with their xenografts, which was
greater in RER+ than in RER- cancers (58% and 45% respectively) could only be
115
explained by additional chromosomal changes appearing during the passage in the
xenografts derived from RER- tumours. This difference indicates, although indirectly,
the presence of an underlying mechanism of chromosomal instability in a proportion
of RER- colorectal cancers.
The analysis of chromosomal abnormalities detected in the colorectal cancer
xenografts established from samples taken from multiple sites showed that most of the
chromosomal changes present in the primary tumour can be detected in the
corresponding xenografts. Consistency in detecting the same chromosomal
abnormalities in a primary tumour and in the corresponding xenograft reached 75% in
RER- and 56% in RER+ tumours. This number was substantially higher in RER-
cancers (92%) when only typical chromosomal changes were considered (18q-, 8p-,
lp-, 20q+, 13q+, 8q+). It does not appear be the case with RER+ xenografts, where
consistency of the presence of specific changes (19del, lp-) in primary tumours and in
the xenografts was only 57%. Although a lower consistency was observed between
RER+ cancers and their xenografts, chromosomal abnormalities are known to be
infrequent in these tumours and are likely to be less important in their development. In
this sense RER+ colorectal cancer xenografts are representative of their tumours of
origin in as far as they show a small number of random chromosomal changes.
4.4.5. A proportion ofRER- colorectal cancers are characterised by a high level of
chromosomal instability.
Substantial differences found in the degree to which the CIN index increased between
primary tumours and xenografts of RER- and RER+ cancers (74% and 34%
respectively) reflects the high degree of underlying chromosomal instability in some
RER- tumours. This instability is also well illustrated in a proportion of RER- cancers
by differences in the total DNA content detected by flow cytometry analysis at
different sites within the tumour and in the corresponding xenografts. However, it
should be pointed out that tumours that were shown to be diploid by flow cytometry,
did exhibit some chromosomal abnormalities when examined by CGH. One possible
explanation is that these few chromosomal changes fell below the level of sensitivity
of the flow cytometry as a method of detecting chromosomal copy number. It is also
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important to note that aneuploidy is a state not a rate and though sometimes equated
with chromosomal instability, aneuploidy could result from many factors other than a
persistently elevated rate of chromosomal change. This could explain aneuploid DNA
content detected by flow cytometry in some of the tumours showing few
chromosomal changes by CGH, including one of the RER+ tumours. Alternatively,
although one of the two mechanisms of genomic instability has been suggested to be
sufficient for driving the neoplastic process both can coexist. The presence of MIN
does not preclude the presence of CIN and vice versa (Lengauer et al., 1997b). A
recent study suggests, however, a good correlation between aneuploidy and
chromosomal instability (Miyazaki et al., 1999).
The results of the study strongly suggest that similar to MIN in RER+ cancers, CIN is
a dynamic process which progresses with time. It further supports the hypothesis that
CIN is a mechanism underlying tumorigenesis in a proportion of RER- colorectal
cancers.
4.4.6. Molecular mechanisms underlying chromosomal instability.
While the mechanisms underlying microsatellite instability are known to involve the
mismatch repair system (Peltomaki et al., 1993; Bronner et al., 1994; Nicolaides et
al., 1994; Nystrom-Lahti et al., 1994; Papadopoulos et al., 1994; Wijnen et al., 1995;
Liu et al., 1996; Akiyama et al., 1997; Miyaki et al., 1997) and are relatively well
understood, the molecular basis of the chromosomal instability present in the majority
ofmalignancies is just beginning to be explored.
Defects in p53 function have been implicated as contributory factor in destabilisation
of the genome. In vitro studies have shown that cells in culture often become grossly
aneuploid at the same time that p53 is inactivated (Harvey et al., 1993). Abnormalities
of p53 have also been shown to precede aneuploid clonal divergence in colorectal
cancer and are known to strongly predispose to chromosomal instability in many
circumstances (Bischoff et al., 1990; Livingstone et al., 1992; Yin et al., 1992; Carder
et al., 1993; Deangelis et al., 1993; Meling el al., 1993; Bouffler et al., 1995; Carder
et al., 1995; Donehower et al., 1995; Gualberto et al., 1998; Venkatachalam et al.,
1998). It is unlikely, however, that p53 is generally responsible for CIN, as several
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cancer lines with p53 mutations are diploid and chromosomally stable (Lengauer et
al., 1997b, Eshleman et al., 1998a). Additionally, some studies indicate that
aneuploidy appears early during tumorigenesis (Steinbeck et al., 1994; Bardi et al.,
1997b, Bomme et al., 1998), while p53 mutations do not usually occur until later
(Baker et al., 1990; Auer et al., 1994). These results indicate that, although p53
defects are unlikely to be a primary cause of chromosomal instability they are
probably permissive to this process.
It is suspected that, in contrast to MIN where only a few genes are responsible for the
phenotype there is a large number of genes which when altered can give rise to CIN.
They include genes involved in chromosome condensation, sister-chromatid cohesion,
kinetochore structure and function and centrosome/microtubule formation and
dynamics, as well as "checkpoint" genes that monitor the progression of the cell cycle
(Lengauer et al., 1998).
Altered expression of certain spindle checkpoint genes can result in aneuploidy. For
example decreased expression of hsMAD2 was observed in the T47D breast cancer
cell line, which failed to undergo mitotic arrest after nocodazole (a mitotic spindle
inhibitor) treatment suggesting that loss of hsMAD2 function might lead to aberrant
chromosome segregation and aneuploidy (Li and Benezra , 1996). In addition a small
fraction of colorectal cancer cell lines that exhibit CIN have been shown to contain
somatic mutations in mitotic checkpoint genes such as hBUBl and hBUBRl (Cahill et
al., 1998).
Several genes involved in DNA-damage checkpoints have also been implicated in
contributing to the CIN phenotype, including ataxia telangiectasia mutated (ATM)
(Rotman and Shiloh, 1998), the A7M-related gene ATR (Smith et al., 1998), the
BRCA1 and BRCA2 genes, which interact with the human Rad51 homologue and p53
(Lane, 1998). DNA-damage checkpoints prevent cells with DNA damage from
entering mitosis, which could result in an inappropriate chromosome segregation due
to sister chromatids being still connected by DNA or DNA-protein links (Lengauer et
al., 1998).
Another potential cause of CIN involves centrosomes, an abnormal number of which
have been noticed in various human malignancies (Doxsey, 1998). Multipolar spindles
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have often been observed in human cancers, but the molecular and genetic bases for
the increased number of centrosomes have not yet been defined. Certain genes such as
one encoding kinases aurora2/STK15 have however been implicated (Bischofif et al.,
1998; Zhou et al., 1998).
Despite these clues, the molecular bases of CIN remains unknown in most human
cancers. The fact that genetic defects in so many genes can lead to CIN might explain
why this phenotype is so common. Accordingly, with so many genes involved, each
one probably plays a role in a small proportion of cases (Lengauer et al., 1998).
4.4.7. Molecular mechanisms that could lead to the development of a novel non-
MIN, non-CINphenotype in sporadic colorectal cancer.
It is likely that other than previously discussed mechanisms of genomic instability
contribute to the development of non-CIN non-MIN tumours and there are a number
of conceivable pathways that could result in the development of a colorectal
carcinoma displaying neither of the two major genomic instability phenotypes.
Recently a novel human mutator phenotype was described in the colon cancer cell line
Vaco411, which increases the spontaneous mutation rate 10-100 fold over
background (Eshleman at al., 1998b). Transversion base substitutions were found to
predominate and frameshifts, commonly seen in MMR defective cells, were not
detected in this cell line. If Vaco411 was also lacking chromosomal instability its
phenotype could resemble the phenotype of non-MIN non-CIN cancers detected in
our series. Alternatively, an atypical MMR deficiency cannot be excluded, especially
considering that MMR in bacteria requires at least ten individual components
(Modrich, 1991) and that several components of the more complex human system are
currently unknown (Kolodner, 1996; Modrich and Lahue, 1996). In this context, it is
worth considering that approximately 15% of HNPCC tumours do not exhibit
microsatellite instability (Aaltonen et al., 1993; Ionov et al., 1993; Aaltonen et al.,
1994; Wu et al., 1994) but may well harbour germline mutations in one of these
undiscovered "caretakers" (Kinzler and Vogelstein, 1997). It is unlikely that these
tumours harbour undetected classical microsatellite instability since the loci by which
their RER status was established included one known to be extremely sensitive to
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defects ofmismatch repair (Hoang et al., 1997). Other candidates include DNA repair
systems involved in protecting the genome from genotoxic insult such as nucleotide
excision repair and base excision repair. It would however be difficult to predict the
phenotype resulting from defects in these genes as it would depend on the type of
DNA lesions induced by environmental carcinogens. Finally, the disregulation of DNA
methylation patterns in tumour cells can result in altered gene expression (Laird and
Jaenisch, 1996; Jones and Gonzalgo, 1997; Laird, 1997) and could potentially drive
tumorigenesis. Recently a novel hypermethylator phenotype was described in a subset
of sporadic colorectal cancers (Toyota et al., 1999). Through its ability to silence
multiple genes simultaneously, CpG island methylator phenotype would be
functionally equivalent to genetic instability, resulting in rapid accumulation of
molecular alterations with a potential to accelerate the neoplastic process.
Alternatively, non-MIN, non-CIN cancers might represent cases where carcinogenesis
proceeds exclusively through selection of randomly occurring advantageous mutations
and clonal expansion of tumour cells without acquiring a mutator phenotype. This
model of tumorigenesis was proposed by Tomlinson et al. (1996) who used a
mathematical model, based on colorectal cancer, to analyse the role of the mutation
rate in the growth of sporadic tumours. This argues that selection without increased
mutation rates is sufficient to explain the evolution of tumours. Further detailed
studies of a larger series of colorectal cancers are required to determine the
phenotypes of tumours displaying neither MIN nor CIN and to identify a driving force
behind this neoplastic process.
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4.5. Summary.
The most important finding of this study is the identification of a novel group of
sporadic colorectal cancers which do not display instability of either chromosomes or
microsatellites (called non-MIN, non-CIN cancers). These tumours do not show any
striking differences in clinical and pathological features compared with RER- tumours
exhibiting high levels of chromosomal instability but may harbour fewer abnormalities
of p53 (see Chapter 5). The data also suggest that these cancers display a different
pattern of clonal chromosomal abnormalities than high CIN RER- tumours, indicating
that a different subset of tumour suppresser genes might be targeted in this tumour
group. It is likely that non-MIN, non-CIN colorectal cancers represent a distinct
entity in sporadic colorectal cancer and based on this data, their prevalence might be
as high as 35% of RER- colorectal cancers or 25% of sporadic colorectal cancers in
total. These tumours might harbour one or more novel mechanisms of genomic
instability but alternatively may represent a group of sporadic colorectal cancers
developing without an increased mutation rate through selection of advantageous
mutations and clonal expansion.
The analysis of chromosome copy number changes in the RER- and RER+ groups of
sporadic colorectal cancers confirmed previously reported differences in rates of
chromosomal abnormalities occurring in these two cancer groups. Different patterns
of chromosomal changes were found to occur in RER- and RER+ tumours. The
specific pattern of chromosomal gains and losses identified in RER- sporadic
colorectal cancers (20q+, 18q-, 13q+, 8p-, lp- and 8q+) generally conforms with the
results of previous cytogenetic and CGH studies. However, frequent loss of
chromosome 19 in the RER+ group of tumours found in this study has not been
previously reported. Differences in the rates at which chromosomal abnormalities
occur, together with the different patterns of chromosomal changes appearing in
RER- and RER+ colorectal cancers further support the hypothesis that pathways of
carcinogenesis in these two groups of tumours are fundamentally different.
This study has identified the presence of genetic intratumoral heterogeneity in
sporadic colorectal cancer. The analysis of colorectal cancer xenografts established
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from samples collected from multiple sites from primary tumours showed that a
xenograft established from a single sample is in general representative of its tumour of
origin with regard to chromosomal abnormalities, despite the presence of genetic
heterogeneity within primary tumours.
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CHAPTER 5.
The role ofp53 defects in RER- and RER+ sporadic colorectal cancers.
5.1. Introduction.
Defects in the p53 tumour suppresser gene are the most common genetic changes
found to date in human tumours (Nigro et al., 1989; Hollstein et al., 1991; Levine et
a/., 1991 and 1994). Loss of p53 function occurs frequently in sporadic colorectal
cancer and is found in up to 75% of cases (Baker et al., 1990; Cunningham et al.,
1992; Vandenbroek et al., 1993; Goh et al., 1994). Mutations detected in p53 in
colorectal carcinomas are mostly missense mutations. They often result in the nuclear
accumulation of abnormal protein with increased half-life, allowing detection by
immunohistochemical methods. It has also been shown that 90% of all mutations in
thep53 gene are located in exons 5-8 (Levine et al., 1991).
It is generally accepted that p53 plays a critical role in maintaining genomic integrity
(Kastan et al., 1991; Lane, 1992; Livingstone et al., 1992; Yin et al., 1992; Nelson
and Kastan, 1994). Association of p53 defects with chromosomal instability is well
documented (Bischoff et al., 1990; Livingstone et al., 1992; Yin et al., 1992; Carder
et al., 1993; Deangelis et al., 1993; Meling et al., 1993; Bouffler et al., 1995; Carder
et al., 1995; Donehower et al., 1995; Gualberto et al., 1998; Venkatachalam et al.,
1998). There are also implications of p53 involvement in the regulation of hMSH2 and
it therefore has a possible role in mismatch repair (Scherer et al., 1996).
Although published reports of the overall frequency of p53 mutations in sporadic
colorectal cancer are similar, conflicting data has appeared with regard to the
frequency of p53 mutations in RER- and RER+ colorectal carcinomas (Aaltonen et
al., 1993; Ionov et al., 1993; Kim et al., 1994; Ilyas et al., 1996; Cottu et al., 1996;
Remvikos et al., 1997). Recent reports indicate that p53 mutations are significantly
less common in RER+ than RER- colorectal cancers (Cottu et al., 1996; Eshleman et
al., 1998a). RER+ colorectal cancer cell lines withp53 mutations have been shown to
remain chromosomaly stable (Eshleman et al., 1998a) indicating that p53 mutation
does not invariably induce chromosomal instability.
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In order to determine the role of p53 in RER- and RER+ tumours p53 defects in the
series of 22 sporadic colorectal cancers were investigated. Frequency of the loss of
p53 function in both tumour groups was examined and its association with two types
of genomic instability. The prevalence of p53 defects in previously identified non-MIN
non-CIN group of sporadic colorectal cancer was also determined. Additionally by the
immunohistochemical analysis of multiple sites within each tumour, p53 protein
stabilisation patterns were analysed to estabilish whether one sample analysis is
sufficient for determining p53 status by immunohistochemistry. In order to confirm
that colorectal cancer xenografts are representative of the primary tumours they are
established from with regard to p53 status, immunohistochemical analysis of all
xenografts was carried out. In addition mutation analysis of selected xenografts
corresponding to the primary tumour samples was performed.
Three different methods were used for determining p53 status. First
immunohisochemistry analysis was carried out on all primary tumour and xenograft
samples followed by mutation analysis of exons 5-8 of the representative samples and
the corresponding xenografts. The loss of the short arm of chromosome 17 detected
by CGH was also considered in the interpretation of the results.
5.2. Materials andMethods.
5.2.1. Immunohistochemical detection ofstabilised p53 protein.
An immunohistochemical analysis was carried out using the DO-7 antibody (Dako
Ltd, UK). This recognises an amino terminal epitope of the p53 protein and reacts
with both wild type and mutant protein. A routine immunohistochemistry (IHC)
protocol was followed as previously described (Purdie et al, 1991), using Avidin-
Biotinylated Horseradish Peroxidase Complex (ABComplex/HRP, Dako Ltd, UK)
and 3,3'-diaminobenzidine (DAB) as a substrate on 3pm paraffin tissue sections.
Detailed description of the protocol can be found in section 2.7. The slides were
examined under 400x magnification on a light microscope and tumours were classified
as p53 defective ifmore than 10% of nuclei showed intense positive staining.
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5.2.2. Mutation analysis of the p53 gene.
Mutation analysis of the p53 gene was performed on 15 tumours with low or negative
immunohistochemical staining in order to exclude the possible presence of mutation
not detectable by IHC. This analysis was also carried out on the corresponding
xenografts. Previous studies of p53 status at different tumour sites (Carder et a/.,
1995), indicated that mutation in the p53 gene, if present, occurs relatively early in
tumour progression and therefore can be readily detected in any part of the tumour.
For this reason, only one representative sample from each tumour was screened for
the presence of mutation in the p53 gene in the first instance. Exons 5-8, in which
90% of all mutations are located (Levine et al., 1991), were amplified using the
primers listed in Table 4 (see section 2.8) and details of PCR conditions can be found
in section 2.8.
Single-stranded conformational polymorphism analyses (SSCP) with autoradiographic
detection were undertaken as previously described (Carder et al., 1995).
Autoradiographs were assessed visually for shifts in electrophoretic mobility of
amplified sequences compared to DNA from normal tissue of the same patient (see
Figure 22).
Figure 22. The result ofSSCP analysis of33P-labelled PCR amplified exon 5 of
p53 gene in primary tumour samples 8a and 8b and in the xenograft
8xb. The autoradiogi-aph shows an additional band in tumour samples
and in the xenograft compared to normal control, indicative of the
presence ofa mutation in this exon.
8n 8a 8b 8xb
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5.2.3. Analysis of 17p loss detected by CGH.
Additionally a possible effect of the loss of the short arm of chromosome 17, where




Within the group of 17 RER- colorectal cancers seven showed positive staining
(strong nuclear staining present in more than 10% of cells), a further two tumours
showed some degree of immunohistochemical reaction, which was not sufficient to
classify them as positive (weak staining or staining present in less than 10% of cells).
The remaining eight tumours showed no reaction and were classified as negative.
Among RER+ cancers three showed some staining but none classified as positive. In
the remaining two no staining was observed.
Based on these results 7 out of 17 RER- and none of the RER+ cancers were
classified as p53 defective (see Tables 19 and 20). Substantial heterogeneity of
intensity and patterns of staining within the tumours was observed. It applied to
almost every single sample analysed, where different intensity and patterns of staining
could be observed within one section. This, however, did not affect the overall result
and the final scores for each site within the tumour were consistent. The results
indicate that despite substantial intratumoral heterogeneity regarding intensity and
pattern of immunohistochemical staining, a single sample analysis is sufficient for
determining stabilisation of p53 protein in sporadic colorectal cancer.
The analysis of the staining patterns in the primary tumours and the corresponding
xenografts showed very few discrepancies indicating that the xenografts are, in
general, representative of the colorectal cancers they are derived from (see Tables 21
and 22). Inconsistencies were observed in xenografts established from tumour No 22
which showed little or no staining but was established from a p53 positive RER-
primary tumour. Minor discrepancies were noticed in one RER+ tumour where some
degree of staining was observed in the samples taken from the primary tumour and no
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staining at all was present in the xenografts (see Tables 21 and 22). This, however,
did not affect the score since both primary tumour samples and the xenografts were
classified as negative.
5.3.2. Mutation analysis of the p53 gene.
Mutation analyses were carried out on representative samples from 10 RER- and all
RER+ tumours. Out of 10 RER- tumours three showed the presence of a mutation,
two in exon 5 and one in exon 6. Only one mutation, located in exon 5, was observed
in the five RER+ tumours analysed.
In two cases where samples from multiple sites were analysed, (case No 19) and one
RER+ tumour (case No 12) inconsistencies between different tumour sites were
noticed. In both cases a mutation in the p53 gene was detected in all but one of the
multiple samples examined (see Figures 23 and 24). This can not be explained by a
low concentration of tumour DNA in the analysed sample since in the case of the
RER+ tumour it was sufficient to detect shifts in lengths of microsatellite sequences
and in the case of sample 19a it did not affect the CGH analysis where chromosome
copy number changes could still be detected. Therefore, these cases are most likely to
represent genuine differences in p53 status within examined tumours.
The mutation analyses of xenografts showed that generally the results were consistent
with those of the corresponding primary tumours (see Tables 21 and 22). In the case
of the RER- tumour (case No 5), no mutation was observed in exons 5-8 but LOH at
the p53 locus was noticed in all three xenografts derived from this tumour (see Figure
25). These results are not necesserily inconsistent with the results obtained for the
primary tumour, since presence of LOH in primary tumours is difficult to assess due
to contamination with normal DNA. In one case (No 12) where one out of four
samples collected from the primary tumour (12d) did not show the mutation in exon
5, the corresponding xenograft did (see Figure 24). However all other three samples
collected from this tumour showed presence of a mutation in exon 5 and this
mutation was detected in the corresponding xenografts.
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Figure 23. SSCP analysis ofp53 exon 6.
The sequence was PGR amplified and labelledwith 33PdA TP.
Mutation in exon 6 of the p53 gene was detected in two out three
samples collected from this RER- tumour (case No 19). Xenografts
establishedfrom the two samples with the p53 mutation showed
presence ofp53 mutation in the same exon. The origin of the
xenograft 19xa is disputable and this case is discussed in detail in
Chapter 6.
19n 19a 19xa 19b 19xb 19c 19xc
Figure 24. SSCP analysis ofp53 exon 5.
The sequence was PCR amplified and labelled with 33PdA TP. P53
mutation was detected in all but one sample collectedfrom this
RER+ tumour (case No 12, sample I2d). This mutation was, however
detected in the corresponding xenograft (12xd).
12n 12a 12xa 12b 12xb 12c 12xc 12d 12xd
t
Figure 25. SSCP analysis ofp53 exon 6.
The sequence was PCR amplified and labelled with 33PdA TP.
In case No 5 (a RER- cancer), no mutation was detected in exons 5-8
but due to the presence ofpolymorphism in exon 6, there was
evidence ofLOH in p53 locus in the xenografts. It is difficult to
assess LOH in the primary tumour due to contamination with normal
DNA
5n 5a 5xa 5b 5xb 5c 5xc
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5.3.3. 17p loss as detected by CGH.
The loss of the short arm of chromosome 17 was considered in determining p53
status, and the results are included in the Tables 19 and 20. It is difficult to predict
significance of 17p loss in cases where no p53 protein stabilisation is seen and there is
no evidence of p53 mutation. The significance of LOH in p53 locus without
accompanying mutation in the other allele has not as yet been determined and in at
least a proportion of tumours 17p loss might result from underlying chromosomal
instability. However the dominant negative effect of p53 mutation, inactivating the
protein function has been suggested (Hollstein el al., 1996). An oncogenic form of
p53, with a missense mutation which confers a dominant gain-of-function phenotype
disrupting spindle checkpoint control leading to genomic instability has also been
described (Gualberto el al., 1998).This is why tumours which showed 17p loss but
neither p53 protein stabilisation nor the presence of a mutation in the exons
examined, were treated as p53 proficient for the purpose of the statistical analysis.
Cases where a mutation in p53 gene was detected despite negative IHC were treated
as p53 defective.
Table 19. p53 status, DNA ploidy and the number of chromosomal changes
detected by CGH in RER+ colorectal cancers.
Total number
p53 Overall of CIN
Sample p53 mutation 17p loss p53 status Ploidy DNA chromosomal index
ID IHC analysis by CGH index changes by
ex. 5-8 CGH
3a n - - functional diploid 0
3b n - - functional diploid 0 4
3c n - - functional diploid 1
3d n - - functional diploid 2
12a n* +(ex5) - defective diploid 9
12b n* +(ex5) - defective diploid 7 23
12c n* +(ex5) - defective diploid 2
12d n* - + ? diploid 9
17a n* - - functional diploid 5
17b n* - functional diploid 5 12
17c n* + p.functional diploid 7
17d n* + p.functional diploid 8
18a n* - - functional near tetraploid 1.93 9
18b n* - functional near tetraploid 1.95 4 23
18c n* - functional diploid 10
18d n* - functional near tetraploid 1.87 2
20a n - - functional diploid 7
20b n - functional diploid 1 10
20c n - functional diploid 4
20d n - functional diploid 2
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Table 20. p53 status, DNA ploidy and the number ofchromosomal changes
detected by CGH in RER- colorectal cancers.
Total number
p53 Overall of
Sample p53 mutation 17p loss p53 status Ploidy DNA chromosomal CIN
ID IHC analysis by CGH index changes by index
ex. 5-8 CGH
la n - - functional near tetraploid 1.82 8
lb n + p.functional near tetraploid 1.84 14 37
lc n + p.fiinctional near tetraploid 1.84 20
Id n - functional near tetraploid 1.82 6
2a P - defective near diploid 1.1 12
2b P - defective near tetraploid 2.2 28 47
2c P - defective n.dipl./n.tetrapl. 1.2/2.2 8
2d P - defective near diploid 1.1 16
4a n* +(ex5) - defective aneuploid 1.54 13
4b n* - defective aneuploid 1.6 11 27
4c n* - defective aneuploid 1.59 10
4d n* - defective aneuploid 1.58 9
5a n _* - p.functional aneuploid 1.65 14
5b n _* - p.functional aneuploid 1.65 0 22
5c n _* - p.functional aneuploid 1.58 2
5d n - p.functional aneuploid 1.63 6
6a P - defective aneuploid 1.66 10
6b P - defective aneuploid 1.68 13 30
6c P - defective aneuploid 1.72 11
6d P - defective aneuploid 1.68 9
7a P - defective near tetraploid 1.81 0
7b P - defective aneuploid 1.76 7 9
7c P - defective near tetraploid 1.85 0
8a n +(ex5) - defective aneuploid 1.68 1
8b n +(ex5) + defective aneuploid 1.73 10 26
8c n + defective aneuploid 1.76 8
8d n - defective aneuploid 1.65 9
9a P - defective near tetraploid 1.87 1
9b P - defective near tetraploid 1.92 17 29
9c P - defective near tetraploid 1.96 6
9d P - defective near tetraploid 2.04 10
9a' P - defective diploid 8 13
9a' P - defective diploid 1
10a n - - functional diploid 2
10b n - functional diploid 8 17
10c n - functional diploid 4
11a P + defective aneuploid 1.43 17
lib P + defective near tetraploid 2.05 11 48
11c P + defective aneuploid 1.45 25
lid P - defective aneuplod 1.36 17
13a n - - functional diploid 5 10
13b n* - - p.fiinctional diploid 2
14a n - + p.functional near diploid 1.1 16 22
14b n - - functional diploid 12
15a n - + p.functional aneuploid 1.4 3 13
15b n - + p.functional diploid 10
16a n - + p.functional diploid 6 12
16b n - - functional diploid 6
19a n - - ? aneuploid 1.54 5
19b n +(ex6) + defective aneuploid 1.54 15 24
19c n +(ex6) + defective aneuploid 1.52 17
22a P +(ex5) - defective aneuploid 1.32/2.43 7
22b P +(ex5) - defective aneuploid 1.32/2.3 3 23
22c P +(ex5) + defective aneuploid 1.4/2.3 14
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Table 21. p53 status, DNA ploidy and the number of chromosomal changes
detected by CGH in RER- colorectal cancers and in the
corresponding xenografts.
Total
p53 mutation 17p loss number
Sample p53 IHC analysis ex. 5-8 by CGH p53 status Ploidy DNA index of chrom.
ID changes
P X P X P x P X P X P X P X
la/lxa n n - - - functional functional n.tetrapl. n.tetrapl. 1.82 1.85 8 31
Ib/lxb n n - functional functional n.tetrapl. n.tetrapl. 1.84 1.89 14 32
lc/lxc n n - functional functional n.tetrapl. n.tetrapl. 1.84 1.80 20 30
ld/lxd n n - functional functional n.tetrapl. n.tetrapl. 1.82 1.84 6 16
4b/4xb n* n* +(ex5) +(ex5) + defective defective aneuploid n.tetrapl. 1.6 1.94 11 20
5a/5xa n n _* al.loss + p. functional p.functional aneuploid aneuploid 1.65 1.75 14 22
5b/5xb n n _* al.loss - p.functional p. functional aneuploid aneuploid 1.65 1.64 0 9
5c/5xc n n _* al.loss - p.functional p.functional aneuoloid aneuploid 1.58 1.63 2 20
8b/8xb n n* +(ex5) +(ex5) + defective defective aneuploid aneuploid 1.73 1.75 10 24
19b/19xb n n +(ex6) +(ex6) + defective defective aneuploid aneuploid 1.54 1.62 15 26
19c/19xc n n +(ex6) +(ex6) + defective defective aneuploid aneuploid 1.52 1.63 17 24
22a/22xa P n* +(ex5) +(ex5) - defective defective aneuploid aneuploid 1.32 1.34 7 29
22b/22xb P n +(ex5) +(ex5) + defective defective aneuploid n.tetrapl. 1.32 1.8 3 23
22c/22xc P n* +(ex5) +(ex5) + defective defective aneuploid aneuploid 1.4 1.42 14 25
Table 22. p53 status, DNA ploidy and the number of chromosomal changes
detected by CGH in RER+ colorectal cancers and in the
corresponding xenografts.
Total
p53 mutation 17p loss number
Sample p53 IHC analysis ex. 5-8 by CGH p53 status Ploidy DNA index of chrom.
ID chang;es
P X P X P x P X P X P X P X
12a/12xa n* n +(ex5) +(ex5) + defective defective diploid diploid 9 13
I2b/12xb n* n* +(ex5) +(ex5) + defective defective diploid diploid 7 7
12c/12xc n* n* +(ex5) +(ex5) - defective defective diploid diploid 2 8
12d/12xd n* n* - +(ex5) + + 9 defective diploid diploid 9 12
18a/l8xa n* n - - - functional functional n.tetrapl. n.tetrapl. 1.93 1.83 10 20
18b/18xb n* n - functional functional n.tetrapl. n.tetrapl. 1.95 1.83 4
18c/18xc n* n - functional functional diploid diploid 9 6
18d/18xd n* n - functional functional n.tetrapl. n.tetrapl. 1.87 1.98 2
20a/20xa n n - - - functional functional diploid diploid 7 11
20b/20xb n n - functional functional diploid diploid 4 9
20c/20xc n n - functional functional diploid diploid 2 7
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Key to Tables 19-22:
p, primary tumour
x, xenograft
p53 IHC - p53 immunohistochemistiy results by D07:
n, negative (no staining observed)
n*, negative (weak staining observed or staining present in 10% of the cells or less)
p, positive (strong staining in more than 10% of cells
p53 mutation analysis:
no mutation found in exons 5-8 by SSCP
+, mutation found by SSCP
no mutation found, but LOH was noticed by SSCP
al.loss, allele loss by SSCP
17p loss:
-, not detected by CGH




?, difficult to interpret the results
Ploidy:
n.tetrapl., near tetraploid (samples were classified near tetraploid if the tumour cells' peak
fluorescence value was within 10% tetraploid peak fluorescence value, but for statistical
purposes were treated as aneuploid)
DNA index:




The overall frequency of p53 defects (protein stabilisation detected by IHC or
presence of a mutation detected by SSCP) in our series of sporadic colorectal cancers
was 50%. These results are generally in concordance with previously published data
(Rodrigues et a/., 1990; Vandenbroek et a/., 1993; Goh et a/., 1994). Although p53
defects were more frequently found in RER- cancers compared to RER+ cancers (in
10 out of 17 and in 1 out of 5 respectively) this difference did not appear statistically
significant (Fisher exact test p=0.31). However, analysis of the frequency of p53
defects in tumours with high (CIN>18) and low (CIN<18) chromosomal instability
indices (see section 4.3.5) showed that p53 is more often defective in tumours with
high level of chromosomal abnormalities regardless of their RER status and this
difference is statistically significant (one-tailed Fisher exact test p=0.04). These
results are in general consistent with the findings of Eshleman et al. (1998a), showing
that RER+ colorectal cancer cell lines with p53 mutations remain chromosomally
stable. This indicates that chromosome number and structure in RER+ colon cancers
is independent of whether p53 is mutant or wild-type. However in this series one of
the two RER+ tumours showing a high level of chromosomal instability did harbour a
p53 mutation. Additionally most of the RER- cancers expressing high levels of
chromosomal instability (8 out of 11) were shown to have defective p53 unlike RER-
tumours with low CIN index where only two out of six were found to be p53
defective. This difference however was not statistically significant. Thus both this
study and that of Eshleman et al. (1998a) indicate that p53 mutation does not
invariably induce chromosomal instability, although it is strongly associated with it.
It is not clear exactly how p53 contributes to the maintenance of a stable genome. It
has been suggested to play a role in the Gl-S checkpoint (Kastan et al., 1991 and
1992; Kuerbitz et al., 1992) by delaying cell cycle progression in order to allow DNA
repair and thus inhibiting replication of cells with damaged DNA. It is also implicated
in the G2-M 'spindle-surveillance' checkpoint which prevents the survival of cells
with aneuploid or polyploid DNA content (Gottlieb and Oren, 1996). Although
evidence indicates that p53 defects in themselves are not sufficient to trigger
genomic instability in colorectal cancer, loss of normal p53 function followed by loss
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of cell cycle control permits the rapid accumulation of genetic changes necessary for
tumour development. Its exact role however in chromosomally unstable tumours still
remains to be determined.
The fact thatp53 mutations are quite infrequent in RER+ colorectal cancers indicates
that loss of its function is not prerequisite in the development of this type of genomic
instability. Considering that p53 is directly involved in recognition of
insertion/deletion mismatches (Lee et al., 1995) and binds to the promoter region of
hMSH2 (Scherer et al., 1996) implies its role in mismatch repair. It is not as yet clear
however whether loss of p53 function facilitates accumulation of point mutations in
MMR deficient cells or not. A number of in vitro studies investigating the effect of
p53 on the spontaneous mutation frequency have indicated that p53-null cells do not
bear an increased mutation load (Nishino el a/., 1995; Sands et al., 1995; Clarke et
al., 1997). There is however evidence that p53 status might have significant effects
on the mutation frequency following exposure to DNA damaging agents (Corbet et
al., 1999). Further studies are necessary to clarify the p53 role in both types of
genomic instability.
Analyses of the frequency of p53 defects in the previously identified non-MIN, non-
CIN group of sporadic colorectal cancers showed that p53 is not often targeted in
this group of tumours. Defects in p53 were found in 2 out of 6 (33%) low CIN,
RER- cancers compared to 8 out of 11 (73%) in high CIN, RER- tumours. These
findings, together with the specific chromosomal abnormalities identified in this
group of tumours (see section 4.3.6) indicate that a different subset of tumour
suppresser genes might be targeted in non-MIN, non-CIN cancers.
The immunohistochemical analysis of multiple sites within the tumours proved that
despite the presence of substantial intratumoral heterogeneity regarding the pattern
and intensity of staining, a single sample analysis is sufficient for detecting
stabilisation of p53 protein in sporadic colorectal cancer. Additionally the results
indicate that weak staining or staining present in less than 10% of cells is not always
associated withp53 mutation, although a possibility of a mutation being present in an
exon other than 5,6,7 or 8 can not be excluded. Mutations inp53 were detected in 2
out of 5 colorectal cancers showing some degree of immunohistochemical reaction
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which was not sufficient to be classified as positive. Two out of 10 tumours that
showed no p53 protein stabilisation at all were proved to carry p53 mutation and one
showed an allele loss in p53 locus. These results are in keeping with data published
previously regarding the consistency between p53 IHC staining and mutations in the
p53 gene (Cripps et al., 1994; Dix et al., 1994; Bosari et al., 1995; Costa et al.,
1995).
Due to some discordance between p53 protein stabilisation detected by IHC and the
presence of a mutation in the p53 gene, determination of p53 status in sporadic
colorectal cancers requires the use of additional techniques (ie.SSCP) to detect p53
mutations and the employment of stringent criteria in the interpretation of
immunohistochemistry results.
Discrepancies between different sites within the tumour regarding the presence of
p53 mutation were found in two cases where multiple tumour samples were analysed.
These discrepancies, however, are rare and in keeping with previous findings
indicating that p53 mutations can occur as a late event in colorectal carcinogenesis
(Baker et al., 1990; Auer etal., 1994; Ilyas etal., 1996).
Although loss of the chromosome material on the short arm of chromosome 17 has
been shown to frequently accompany the mutation in the p53 gene (Baker et al.,
1990; Cunningham et al., 1992) in our series of sporadic colorectal cancers it was
found in exactly the same proportion of p53 defective tumours and cancers with
normal p53 function (5 out 11 tumours in each case). Thus, although previous studies
suggested that additional loss of the wild-type allele accompanying p53 mutation
might gain tumour cells further growth advantage, the distribution of 17p loss in the
series of sporadic colorectal cancers examined in this study is not supportive of this
hypothesis. In at least a proportion of tumours 17p loss might result from an
underlying chromosomal instability.
Comparison of the p53 status in the primary tumours and in the corresponding
xenografts showed minor discrepancies mostly regarding staining patterns and in a
few cases 17p loss. However, these discrepancies did not influence the final
classification of primary tumours and xenografts as p53 deficient or proficient. These
results indicate that colorectal cancer xenografts are representative of the primary
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tumours they are established from with regard to their p53 status. They therefore
represent a valuable tool in investigating the response of p53 proficient and deficient
colorectal cancer cells to various therapeutic agents.
5.5. Summary.
The study showed that p53 defects appear more frequently in tumours exhibiting high
level of chromosomal instability, regardless of their RER status and that these defects
are significantly less common in colorectal cancers with low levels of chromosomal
instability. The results also indicate that p53 is not a frequent target in non-MIN,
non-CIN cancers. This study showed that single sample analysis is sufficient for
detecting stabilisation of p53 protein but additional tests are usually required for
adequate determining of p53 status in sporadic colorectal cancers. Satus of p53 in the
primary tumour was shown to remain unchanged in corresponding xenografts.
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CHAPTER 6.
Investigation of the origin ofxenografts 3xb and 19xa.
6.1. Introduction.
Previous studies have demonstrated that the RJER phenotype of the primary tumour is
invariably preserved in colorectal cancer xenografts (Curtis, 1998). The results of this
study are generally in concordance with these data. However, in two cases
discrepancy between the RER status of primary tumours and corresponding
xenografts was observed. These two cases could represent a rare but extremely
important phenomenon of alteration of the RER phenotype of tumour cells during
passage in SCID mice. Although sample mix-up was not suspected, in both cases
where discordance of the RER phenotype was observed, DNA fingerprinting analysis
was carried out to establish whether the xenograft's DNA matched the DNA of the
tumour of origin and normal DNA from the patient from whom the tumour was
obtained. In addition in one case the histogenesis of tumour cells in the xenograft was
investigated.
It was important to determine whether the RER+ phenotype can spontaneously
appear or disappear in the process of establishing colorectal cancer xenografts in
SCID mice. Mismatch repair deficient cells have been shown to confer sensitivity to
chloroethylating agents (Liu et a/., 1996) but resistance to temozolomide, alkylating
agents and cisplatin (Branch et a/., 1993 and 1995; Kat et a/., 1993; de Wind et al.,
1995; Aebi et al., 1996; Drummond et al., 1996a and 1996b; Fink et al., 1996; Liu et
al., 1996; Mello et al., 1996). Presence or absence of RER+ phenotype in colorectal
cancer xenografts indicates deficiency or proficiency ofMMR system in tumour cells.
This may substantially influence their response to various therapeutic agents. It is
therefore prerequisite for proper assessment of genotype-dependent treatment
response, carried out on colorectal cancer xenografts, to establish beyond doubt that
they are in all cases representative of their tumour of origin with regard to the RER
status.
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6.2. Materials and methods.
The probe 29C1 was chosen for DNA fingerprinting. It recognises a highly
polymorphic region of human telomeric DNA located in the pairing regions of the
short arms of the sex chromosomes (Cooke et al., 1985) which is not susceptible to
mismatch repair defects. The analysis was carried out according to the protocol
described in section 2.9 on the xenografts 3xb and 19xa. In each case the DNA
extracted from the xenograft, the presumed sample of origin and normal mucosa from
the patient from whom the tumour was obtained, was analysed for comparison. In
one case, 3xb, DNA fingerprinting using microsatellite sequences was carried out.
The analysis was performed by Mr Peter Han from the Police Forensic Science
Laboratory using a set of seven microsatellite markers. The choice of microsatellites
as markers in this particular case was appropriate since the xenograft 3xb proved to
contain stable microsatellites and could be matched with patient's normal DNA and
their tumour which also contained some normal DNA in contaminating stroma.
After confirming that the xenograft 3xb was established from the tissue obtained from
the same patient from whom normal tissue (3n) and a sample of the primary tumour
(3b) was collected, it became necessary to establish the histogenesis of tumour cells
in the xenograft, since histological patterns of the primary tumour and the
investigated xenografts differed substantially. This was done by
immunohistochemistry using a panel of antibodies. Three pm paraffin sections of the
xenograft 3xb were examined for the presence of cytokeratin (CAM 5.2), common




6.3.1. The origin ofxenograft 3xh.
The xenograft 3xb was established from an RER+ colorectal cancer and despite
implanting multiple samples collected from four different sites, this was the only
xenograft successfully established from this tumour. Unlike sample 3b from the
corresponding primary tumour, which showed shifts in three out of four analysed
loci, no shifts were observed in the corresponding xenograft 3xb and this xenograft
was classified as RER-. The results of DNA fingerprinting analysis, using the 29C1
probe, were inconclusive (see Figure 26a). The xenograft's DNA showed the
presence of two bands present in the primary tumour and in the normal tissue but it
lacked the third band and showed an additional two bands not found either in the
primary tumour or the normal tissue. For this reason the samples were analysed by
the Police Forensic Science Laboratory using a set of seven microsatellite markers.
This analysis showed that the normal (3n), tumour (3b) and xenograft (3xb) DNA
matched each other, which confirmed that tumour No 3 was the tumour of origin for
xenograft 3xb (see Figure 27). This indicated that the RER+ phenotype was not
preserved in this colorectal cancer xenograft. However the study of histological
patterns of the primary tumour and the xenograft revealed that, while the tumour of
origin was a moderately differentiated adenocarcinoma, the corresponding xenograft
represented an anaplastic tumour in which the epithelial origin of tumour cells was
not apparent. Immunohistochemical analysis with a panel of antibodies confirmed that
tumour cells in the xenograft 3xb carried white cell markers (there was a strong
immunohistochemical reaction with antibodies against common leukocytic antigen
CD45 and B-cells marker CD20) but did not show the presence of cytokeratine
filaments. These results facilitated the diagnosis of the xenograft 3xb as a large cell
B-cell lymphoma. Additionally the 3xb cells showed positive reaction with antibodies
against EBV. The significance of this finding is discussed later in this chapter (section
6.4), but due to the nonepithelial nature of the xenograft 3xb, it was not used in the
study of chromosomal abnormalities.
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Figure 27. The results ofDNAfingerprinting using a set ofseven microsatellite loci
carried out in the Police Forensic Science Laboratory byMr Peter Han.
This shows that the microsatelliteprofile ofsamples 3n(normalDNA),
3b (tumour DNA) and 3xb (xenograft's DNA) match, confirming that
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6.3.2. The origin ofxenograft 19xa.
The analysis of microsatellites in xenograft 19xa showed shifts at all four loci
examined, contrary to the primary tumour sample (19a) where microsatellites were
shown to be stable. If sample 19a was proved to be the sample of origin for the
xenograft 19xa it would indicate that the RER+ phenotype can spontaneously occur
during colorectal cancer xenograft establishment or passage. DNA fingerprinting
using the 29C1 probe of normal DNA (19n), DNA from another xenograft
established from this primary tumour (19xb) and DNA from xenograft 19xa showed
however that only samples 19n (normal tissue) and 19xb (another xenograft
established from this primary tumour) matched each other. The sample 19xa showed
an entirely different band pattern (see Figure 26b). The results indicated strongly that
tumour No 19 was not the tumour of origin for xenograft 19xa. For this reason 19xa
was not included in any of the calculations relating to chromosomal abnormalities.
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Figure 26. Autoradiograph ofSouthern blot hybridised with 32P-labelled 29C
probe after DNA digested with EcoRI and electrophoresis.
b)
3n 3b 3xb 19n 19xb 19xa 18n 18c
DNA was digested with EcoRI and electrophoresis was carried out overnight against lkb ladder marker. The marker is not shown
since determination of band sizes is not necessary for the interpretation of the results. Band patterns were compared between
samples (bands are indicated by black arrows) to determine their origin.
a) Normal (3n) and primary tumour (3b) DNA match each other but the xenograft (3xb) shows presence of two extra bands not
detected in the first two samples and lacks one band present in the primary tumour and the normal tissue. The results are
inconclusive.
b) DNA from the xenograft 19xa does not match normal DNA (19n) and DNA from xenograft 19xb which was established from
the same primary tumour as 19xa. Samples 18n (normal tissue) and 18c (RER+ primary tumour tissue) are shown to illustrate that
the sequence chosen for this analysis is not affected by defects ofmismatch repair and can provide conclusive results in such cases.
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6.4. Discussion.
This analysis aimed to establish beyond doubt the origin of two colorectal cancer
xenografts where discrepancy in the RER status with the primary tumour was
observed.
Although in each case the attempt was made to establish colorectal cancer xenografts
in SCID mice in the case of xenografts 3xb cancer cells failed to grow in the mouse
environment. Instead, the xenograft consisted of transformed human B lymphocytes
which exhibited EBV positivity and were proved to derive from the same patient
from whom the primary colorectal cancer was obtained. SCID mice lack functional B
and T lymphocytes, and therefore do not reject foreign tissue. For this reason they
are widely used to grow and study various human malignancies including colorectal
cancers and B-cell lymphomas. The Epstein-Barr virus can be found in most humans
as a lifelong latent infection established in host B cells after a primary viral encounter
(Haque et al., 1996; Pisani et al., 1997; Crowcroft et al., 1998). In
immunosuppressed individuals, such as post-transplant patients, the presence of
EBV-infected B cells may lead to lymphoproliferative disease (Wood et al., 1996;
Lucas et al., 1997; Quintanilla-Martinez et al., 1998; Nalesnik, 1998). Injection of
human peripherial blood lymphocytes from EBV-positive donors into SCID mice
induces human lymphoproliferative disease in the recipient closely resembling that of
human post transplant patients (Mosier et al., 1990; Rowe et al., 1990; Gamier et al.,
1993; Murphy et al., 1995; Fuzzati-Armentero and Duchosal, 1998). The diagnosis
of primary lymphoproliferative disease was not confirmed in the patient from whom
the primary colorectal cancer No3 was obtained. The fact that xenograft 3xb
consisted of transformed human B-lymphocytes can be explained by EBV-infected B-
cells present in the tumour inflammatory infiltrate undergoing malignant
transformation and expansion in the immunodeficient environment after implantation
of tumour tissue in SCID mouse. Expanding transformed lymphocytes possibly
suppressed the growth of colorectal cancer cells. Interestingly, this "new" tumour did
not exhibit microsatellite instability, indicating that multiple malignancies arising from
one individual's cells need not necessarily follow the same pathway of
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tumourigenesis. This example illustrates the necessity for thorough investigation in
any cases where the RER+ phenotype of the primary tumour does not appear to be
preserved in corresponding xenografts.
In the case of the xenograft 19xa the results of the DNA fingerprinting showed that
the xenograft DNA did not match normal DNA (19n) and DNA of another xenograft
(19xb) established from the same primary tumour. All precautions were taken to
ensure the proper labelling of colorectal cancer xenografts established for the purpose
of this study to allow correct identification of the xenografts and their tumours of
origin. Additional investigations were undertaken in cases where the possibility of
human error could not be excluded. Since analysis of polymorphic microsatellite loci
would not be helpful in the case of xenograft 19xa the interpretation relies on the
results of the DNA fingerprinting analysis which indicates that sample 19xa has been
misidentified. There is no reason to believe that the hypervariable telomeric sequence
chosen for the fingerprinting analysis is susceptible to mismatch repair defects. When
other RER+ tumours and normal tissue were tested using the same method (3n and
3b, 18n and 18c, see Figure 26a and b), MMR deficiency did not appear to affect the
results.
6.5. Summary.
In summary, there seems to be very good correlation between the RER status of
primary colorectal cancers and their corresponding xenografts. The RER+ phenotype
was preserved in all colorectal cancer xenografts established from RER+ primary
tumours. No evidence was found that RER+ phenotype can spontaneously appear in
sporadic colorectal cancer during xenograft establishment and passage in SCID mice.
Colorectal cancer xenografts represent an excellent study model for involvement of
mismatch repair system in response of tumour cells to various therapeutic agents.
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CHAPTER 7
Summary and future prospects.
7.1. Summary.
This thesis has analysed genetic intratumoral heterogeneity in sporadic colorectal
cancer and its association with two known types of underlying genomic instability. It
has also established the relevance of colorectal cancer xenografts as models for
investigating the genetics of colorectal cancer. The data gathered will be useful in
assessing treatment response in colorectal cancer xenografts to various therapeutic
agents in relation to specific genetic abnormalities.
In summary, the most important finding of this study is the identification of a novel
group of sporadic colorectal cancers which do not display instability of either
chromosomes or microsatellites (called non-MTN, non-CIN cancers). These tumours
do not show any striking differences in clinical and pathological features compared
with RER- tumours exhibiting high levels of chromosomal instability but may harbour
fewer abnormalities of p53. The data also suggest that these cancers display a
different pattern of clonal chromosomal abnormalities than high-CIN RER- tumours
indicating that a different subset of tumour suppresser genes might be targeted in this
tumour group. It is likely that non-MIN, non-CIN colorectal cancers represent a
distinct entity in sporadic colorectal cancer. Based on this data their prevalence might
be as high as 35% of RER- colorectal cancers, constituting 25% of sporadic
colorectal cancers in total. These tumours might harbour one or more novel
mechanisms of genomic instability or alternatively they represent a group of sporadic
colorectal cancers developing without increased mutation rate thorough selection of
advantageous mutation and clonal expansion.
The analysis of chromosome copy number changes in RER- and RER+ groups of
sporadic colorectal cancers confirmed previously reported differences in rates of
chromosomal abnormalities occurring in these two cancer groups. Different patterns
of chromosomal changes were found to occur most frequently in RER- and RER+
tumours. The specific pattern of chromosomal gains and losses identified RER-
sporadic colorectal cancers (20q+, 18q-, 13q+, 8p-, lp- and 8q+) generally conforms
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with the results of many previous cytogenetic and CGH studies. However, frequent
loss of chromosome 19 in RER+ group of tumours found in this study has not been
previously reported. Differences in rates at which chromosomal abnormalities occur
together with different patterns of chromosomal changes appearing in RER- and
RER+ group of colorectal cancer further support the hypothesis that pathways of
carcinogenesis in these two groups of tumours are fundamentally different.
This study has identified the presence of genetic intratumoral heterogeneity in
sporadic colorectal cancer. The analysis of colorectal cancer xenografts established
from samples collected from multiple sites from primary tumours showed that a
xenograft established from a single sample is in general representative of its tumour
of origin, despite the presence of genetic heterogeneity within primary tumours. This
applies firstly to the preservation of the RER+ and RER- phenotype and secondly to
specific chromosomal abnormalities being retained in RER- colorectal cancer
xenografts. The study also showed that p53 status of the primary tumour is
unchanged in a corresponding xenograft and that the DNA ploidy closely resembles
that of the sample of origin. Preservation of all these important genetic features in
colorectal cancer xenografts makes them a valuable model for investigating the
genetics of the disease.
7.2. Future prospects.
Much remains to be understood about the mechanisms of genomic instability so far
discovered in sporadic colorectal cancer. At present little is known about factors
determining tumour response to radio- or chemotherapy, although there is increasing
evidence connecting treatment response to the specific genetic constitution of the
tumour. At biochemical level the mechanisms of action of commonly used anticancer
treatments are well understood. X-irradiation, topoisomerase inhibitors and alkylating
agents damage DNA. Spindle poisons bind to microtubules and inhibit their function.
Antimetabolites disrupt nucleotide pools and thereby inhibit DNA synthesis.
However, it remains unclear why these biochemical activities, all of which induce p53
dependent cell-cycle arrest, provide tumour specificity, killing cancer cells more
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efficiently than normal cells (Waldman et al., 1997). In experimental systems MMR
deficient cells are highly tolerant to the methylating chemotherapeutic drugs
streptozocin and temozolamide (Koi et al., 1994; de Wind et al., 1995; Liu et al.,
1996a; Umar et al., 1997) and to a lesser extent to cisplatin and doxorubicin
(Drummond et al., 1996b; Aebi et al., 1996; Fink et al., 1996). These drugs are
therefore expected to work less effectively in treatment ofMMR deficient tumours in
humans. Understanding of the complex mechanisms involved in the response of
tumour cells to various therapeutic agents is crucial. Characterising the genotype-
dependent treatment response of colorectal cancers will substantially facilitate the
appropriate choice of treatment according to individual needs and will be extremely
useful in predicting the outcome of such treatment. This issue has been addressed by
other members of this group using the colorectal cancer xenografts characterised in
this study. Additionally, it is important to further characterise the novel group of
sporadic colorectal cancers which do not display instability of either chromosomes or
microsatellites in order to determine whether these tumours harbour other
mechanism(s) of genomic instability.
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ABC avidin/biotinylated horseradish peroxidase complex
ACF aberrant crypt foci
APC Adenomatous Polyposis Coli
ATM ataxia telangiectasia mutated
BRCD2 breast cancer suppressor-2
cAMP cyclic adenine monophosphate
CDC2L1 cell division cycle 2-like 1
CDK4 cyclin-dependent kinase 4
CEA carcino-embryonic antigen
CGH Comparative Genomic Flybridisation
CHRPE congenital hypertrophy of the retinal pigment epithelium
CIN chromosomal instability
DAB 3,3 '-diaminobenzidine tetrahydrochloride




DCC deleted in colon cancer
DDW distilled deionised water
DEPC diethyl pyrocarbonate
dGTP deoxyguanine triphosphate







DPC4 deleted in pancreatic cancer
dUTP deoxyuracyl triphosphate
EDTA Ethylenediaminetetraacetic acid (disodium salt)
EXTL3 exostoses (multiple)-like 3
FAP Familial Adenomatous Polyposis
GTP guanosine triphosphate
GTBP G-T mismatch binding protein
H&E haematoxilin and eosin
liMLHl human MutH homologue
hMSH2 human MutS homologue 2
1iMSH3 human MutS homologue 3
hMSH6 human MutS homologue 6
hPMSl human post-meiotic segregation homologue 1
hPMS2 human post-meiotic segregation homologue 2
HNPCC Hereditary Non-Polyposis Colorectal Cancer
HRP horseradish peroxidase
ID3 inhibitor of DNA binding 3
IHC immunohistochemistiy
LOH loss of heterozygosity
MAD mothers against dpp
MCC mutated in colorectal cancer




Min multiple mterstinal neoplasia
Moml modifier of min 1
mRNA messenger ribonucleic acid
NB/NBS neuroblastoma suppressor
NMSK non-melanoma skin cancer
NRS normal rabbit serum
OD optical density
PLA2s type II non-pancreatic phospholipase A2
PLPD periodate-lysine-paraformaldehyde-dichromate
PBS phosphate buffered saline
PCR Polymerase chain reaction
PhIP 2-amino-l-methyl-6-phenylimidazo[4,5-b]pyridine
PRLTS PDGF-receptor p-/ike tumour .suppressor
QUIPS Quantitative Image Processing System
RER replication error
RER+ replication error positive
RER- replication error negative
RNA ribonucleic acid
SCID severe combined immuno-deficient
SDS sodium dodecyl sulphate
STR short tandem repeat
ssc salt/sodium citrate buffer




TGFP transforming growth factor p
TGFP RII transforming growth factor p receptor subunit II
TNFR2 tumour necrosis factor receptor 2
Appendix 3
Reagents and suppliers
Reagents are listed in alphabetical order against the name of their supplier(s).
96-well PCR plates; Hybaid Ltd
32
a PdCTP; Amersham International pic
ABC kit; Dako Ltd
Agarose; Sigma Aldrich Chemical Company
Alkaline phosphatase substrate kit BCIP/NBT; Vector Laboratories
Ammonium acetate; Fisher Scientific
Ammonium persulphate; Severn Biotech Ltd
Anti-digoxigenin rhodamine; Sigma Aldrich Chemical Company
BCIP/NBT alkaline phosphatase substrate kit; Dako Ltd
Bench alcohol; Genta Medical
Biotin-16 dUTP; Boehringer-Mannheim Ltd
Biotinylated anti-avidin; Vector Laboratories
Biotinylated rabbit anti-mouse immunoglobulins; Dako Ltd
Blocking agent; Amersham International pic
Boric acid; Sigma Aldrich Chemical Company
Bromophenol blue; Fisher Scientific
BSA fraction V; Fisher Scientific
Calcium chloride; Fisher Scientific
Chloroform; Fisher Scientific
Cotl DNA, human and mouse; Life Technologies Ltd
Cover slips (No.O & No. 1, Chance Propper); Fisher Scientific
DEAE membrane; Schleicher and Schuell
'Decon' detergent; Fisher Scientific
DEPC; Sigma Aldrich Chemical Company
Diaminobenzidine (DAB); Sigma Aldrich Chemical Company
Diaininoethanetetra-acetic acid (EDTA), Sigma Aldrich Chemical Company
Diaminophenolindole (DAPI); Boehringer-Mannheim Ltd
Digoxygenin-ll-dUTP; Boehringer-Mannheim Ltd
Dimethyl sulfoxide (DMSO); Sigma Aldrich Chemical Company
DNA mass ladder; Life Technologies Ltd
DNA molecular weight marker V; Boehringer-Mannheim Ltd
DNA molecular weight marker 1 kilobase DNA ladder; Life Technologies Ltd
DNA polymerase I; Life Technologies Ltd
DNase I; Boehringer-Mannheim Ltd
dNTPs; Pharmacia Biotechnologies Ltd
Do7 antibody; Dako Ltd
EcoR\ + buffer; NBL Gene Science Ltd
Ethanol; Hayman Ltd
Ethidium bromide; Sigma Aldrich Chemical Company
Fluorescein-avidin DCS; Vector Laboratories
Formaldehyde solution; Fisher Scientific
Formamide: Fisher Scientific
33
y PdATP; Amersham International pic
'Gel Slick1; AT Biochem
Glacial acetic acid; Fisher Scientific
Glycerol; Sigma Aldrich Chemical Company
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Hybond N+; Amersham International pic
Hydrochloric acid; Fisher Scientific
Hydrogen peroxide; Sigma Aldrich Chemical Company
Ion-exchange resin beads; Bio-Rad Laboratories Ltd
Immuno-Check alignment fluorospheres; Coulter Electronics Ltd
'Instagel' 40% 19:1 acrylamide:bis acrylamide solution; Severn Biotech Ltd
Iso-amyl alcohol; Fisher Scientific
Kodak X-OMAT autoradiography film; Amersham International pic
L-glutamine; Life Technologies Ltd
Magnesium chloride; Sigma Aldrich Chemical Company
Magnesium Sulphate; Sigma Aldrich Chemical Company
MDE gel; AT Biochem
Methanol; Fisher Scientific
Microscope slides 'Select' (Chance Propper); Fisher Scientific
N,N,N',N',-tetramethylethylenediamine (TEMED); Severn Biotech Ltd
Nonidet P40; Fisher Scientific
Normal rabbit serum; Life Technologies Ltd
Phosphate buffered saline (PBS); Life Technologies Ltd
Phytohaemmagglutinin (M-form); Murex Diagnostics Ltd and Sigma Aldrich Chemical Company
Prime-It RmT kit; Stratagene
Potassium chloride; Fisher Scientific
Propidinm iodide; Sigma Aldrich Chemical Company
Proteinase K; ICN Biomedicals Ltd
Pstl + buffer; NBL Gene Science Ltd
Quick Spin columns G50 (fine); Boehringer-Mannheim Ltd
RNase A; Sigma Aldrich Chemical Company
RPMI medium (Dutch modification); Life Technologies Ltd
Sephadex G-50 nick column; Pharmacia Biotechnologies Ltd
Sodium carbonate (decahydrate); Fisher Scientific
Sodium chloride; Fisher Scientific
Sodium citrate; Fisher Scientific
Sodium dodecyl sulphate (SDS); ICN Biomedicals Ltd
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Role of BAX mutations in mismatch repair-deficient colorectal
carcinogenesis
Wael M Abdel-Rahman1, Izabela B Georgiades1, Lucy J Curtis1, Mark J'Arends1 and
Andrew H Wyllie*'1
'Sir Alastair Currie CRC Laboratories, Molecular Medicine Centre, University of Edinburgh, Western General Hospital, Crewe
Road, Edinburgh EH4 2XU ' '
BAX gene mutations occur in approximately 50% of
RER+ colorectal cancers. To determine the role of
these mutations in tumour progression we analysed
multiple different tumour sites from RER + colorectal
cancers for BAX mutations. Sixty colorectal carcinomas
were analysed for microsatellite instability at loci BAT-
26, L-myc, TGF/1RII, D13S160 and D2S123. Twelve
out of 60 tumours (20%) were RER + . Forty-five
different tumour sites from the 12 RER+ carcinomas
were analysed for BAX mutations at the |(G)8| tract in
exon 3. Six out of 12 (50%) RER+ tumours showed
BAX mutations, four of which showed a homogenous
pattern of such mutations detected in all tumour sites. In
the other two cases, BAX mutations were present in
some but not all tumour sites sampled from the same
patient. In contrast, TGFflR/l mutations were found in
9/12 cases (75%) and in each of these were present in all
the sampled sites. Two cases showed neither BAX nor
TGFfRlI mutation. These data suggest that mutations in
TGFjlR/I may occur at a very early stage in tumour
progression, perhaps in the founder clone. BAX muta¬
tions, however, are clearly not necessary for formation of
the founder clone and can occur for the first time later in
tumour progression.
Keywords: BAX; colorectal cancer; RER; mismatch
repair
Introduction
The BCL2 family of proteins control an important
checkpoint prior to activation of the caspase family of
proteases in apoptosis (Brown, 1997; White, 1996). One
prominent, widely expressed member of this family is
BAX, a 21 kDa protein with the capacity to
homodimerize or heterodimerize with other members
of the BCL2 family (Oltvai et al., 1993). Whereas
BAX-BAX homodimers are potent death inducers, the
BAX-BCL2 heterodimers and BCL2-BCL2 homodi¬
mers appear to promote survival (Kroemer, 1997).
Moreover, the tumour suppressor protein p53, a major
element in the response to lethal stimuli arising from
DNA damage or hypoxia, can transactivate BAX
(Miyashita and Reed, 1995) whilst down-regulating
BCL2 (Miyashita et al., 1994). BAX is thus a
significant effector in the initiation of apoptosis.
■"Correspondence: AH Wyllie, Department of Pathology, University
of Cambridge, Tennis Court Road, Cambridge CB2 1QP
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Recently, clohally expanded, inactivating mutations
in BAX have been observed in a proportion of
colorectal cancers, together with evidence for under-
expression of the BAX protein in these tumours
(Rampino et al., 1997; Yamamoto et al., 1998; Yagi
et al., 1998; Ouyang et al., 1998). This provides some
circumstantial evidence for the hypothesis that the
founder cells of cancers may arise through selective loss
of a death pathway and the resultant inappropriate
survival of cells that have sustained DNA damage or
other severe intracellular injury. This hypothesis carries
the significant implication that cancer cells that arise in
this way are liable to be resistant to many cytotoxic
agents to which more normal cells would be sensitive,
because of constitutional loss of a critical death
pathway. Alternative explanations for the BAX
mutations exist, however. These mutations are
restricted to tumours with mismatch repair (MMR)
deficiency, and usually occur in a tract of eight
consecutive deoxyguanosines [(G)8] in the third coding
exon (Rampino et al., 1997). Since this is a classical
target site for nucleotide mismatch (Aaltonen et al.,
1993; Thibodeau et al., 1993), it is possible that
mutations within [(G)8] simply reflect the well-
recognized effect of MMR deficiency on mutation
incidence in tandem repeat microsatellite sequences.
In this paper we seek to distinguish between these
possibilities by studying the homogeneity of BAX
mutation within colorectal cancers. We argued.* that
genetic changes that are critical for carcinogenesis are
likely to be shared by all cells in the expanding tumour
and should therefore be detectable at all sites
throughout the tumour. In contrast, changes that
reflect the genomic instability of malignant cells, but
are not essential for the transition to malignancy might
be expected to occur in some but not all of the
divergent subclones within the given tumour. Accord¬
ingly, in this paper we studied BAX mutations in the




Twelve out of 60 patients (20%) demonstrated
microsatellite instability (Table 1). In some cases (nos.
17, 27, 52, 53 and 55) individual tumour sites from the
same carcinoma demonstrated different sets of muta¬
tions at the five microsatellite loci tested. In some
tumours, biopsies from different sites each exhibited
different mutations at the same microsatellite locus
*
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Table 1 Mismatch repair deficient carcinomas analysed for RER and BAX status







17 81 F cae mucoid A + + + — + + (loss)
B + + + - + + (l°ss)
C — + + — + —
18 67 F sig ac md A + - - - - -
B + — - - - —
C + — — - - —
19 70 M asc ac pd A + + + - + + (loss)
B + + + - + + (l°ss)
C + + + — + + (loss)
22 43 F cae ac/mu A + - - — — + (loss)
B + - - - - + (loss)
25 65 F cae ac/mu A + + + + — + (loss)
B + + + + - + (loss)
C + + + + - -
D + + + - + (loss)
27 88 F asc ac/mu A + + + — + —
B + + + + + -
C + + + + + ■ -
D + + + + + —
E + + + + + -
F + + + + + -
G - +
'
+ — + —
28 75 F cae ac/mu A + + + + - -
B + + + + — —
38 64 M asc ac md A + + + - + + (loss)
B + + + - + + (l°ss)
C + + + — + + (l°ss)
D + + + - + + (loss)
47 60 M asc ac pd A + - + + + —
B + — + + + -
C + - + + + —
D + — + + + —
52 76 M cae ac pd A + + + + - -
B + + + + — —
C + + + + + -
D + + + + + —
53 77 F asc ac pd A + + - — - -
B + + — + - -
C + + — — + -
D + + - — — -
55 70 F asc ac pd A + + + + - +(gain)
B + + + - - +(gain)
C + + + + - +(gain)
D + + + - - +(gain)
Cae
pd =
= caecum, asc = ascending colon, sig = sigmoid colon, mucoid =mucoid
poorly differentiated adenocarcinoma, ac/mu = mixed adenocarcinoma
carcinoma, ac md = moderately differentiated adenocarcinoma, <
glandular/mucoid pattern, + (loss) = deletion of one G from tl
[(G)8] tract, + (gain) = insertion of one G in the [(G)8] tract
(Figure 1). However, in no case was microsatellite
instability present at one tumour site, and completely
absent at all tested loci in others. Hence it was possible
to classify all sampled sites of all tumours as RER + ,
although in two tumours (nos. 18 and 22) the instability
was evident in only one of the five tested loci.
BAX mutation analysis
Mutation in the BAX [(G)8] mononucleotide repeat
tract occurred in six out of 12 (50%) RER+ tumours.
In five, this involved loss of a repeated nucleotide and
in one a gain. Four showed a homogenous pattern,
with identical changes in [(G)8] detected in all sites
sampled from each carcinoma (Figure 2a and Table 1).
In the other two cases, however, [(G)8] BAX mutations
were present in some but absent in other sites from the
same cancers. Thus, case number 17 showed mutation
in tumour sites A and B, but not C and case number
25 showed mutations in A, B and D but not C (Figure
2b and Table 1). In both these cases, the tumour site in
which BAX [(G)8] was unchanged showed unequivocal
evidence of instability at most of the other tested
microsatellite loci.
Discussion
It is clear that deficiency in mismatch repair permits
the generation of large numbers of mutations
throughout the genome, mainly in microsatellite loci
and repetitive polynucleotide tracts (Aaltonen et al.,
1993; Thibodeau et al., 1993). In sporadic colorectal
tumours, the microsatellite instability is generally
found in carcinomas but not adenomas, whereas both
adenomas and carcinomas from HNPCC patients may
show a high proportion of such instability (Samowitz
and Slattery, 1997; Bubb et al., 1996; Jacoby et al.,
1995; Thibodeau et al., 1993). These observations
strongly suggest that microsatellite instability is
acquired at the adenoma-carcinoma interface in the
evolution of sporadic tumours, but can appear at an
*
Role of SAX mutations in colorectal carcinogenesis
WM Abdel-Rahman et al ipP*
2141
NABCDEFG








Figure 1 The band shift pattern of case no. 27 at the BAT-26 (a)
and L-myc (b) microsatellite loci (N = normal mucosa; A-G = 7
different tumour sites from the same carcinoma)
earlier stage in patients who carry germline mutations
in MMR genes. Previous studies have shown clonal
expansion of shifts of different amplitude at the same
microsatellite locus sampled from different sites in the
same tumour (Chung et al., 1997), as observed in the
present work also. This indicates that a proportion of
these microsatellite mutations are acquired as clonal
variants throughout the process of tumour formation
and reflect but do not cause the evolution of such
tumours. In contrast, mutations at some genetic loci
have been found with great consistency in RER +
tumours. An outstanding example is transforming
growth factor beta-type 2 receptor (TGF/IRII), which
is mutated in upwards of 90% of all tested RER +
colorectal cancers (Markowitz et al., 1995; Parsons et
al., 1995). In this series, more than 75% of RER +
cancers showed a mutation in the one site within the
TGF/jRII gene which we tested. Together with
independent evidence that TGF/I exerts a suppressive
effect on colorectal epithelial growth (Wrana et al.,
1994), these observations have been interpreted as
indicative of a causal role for TGF/iRII inactivation in
colorectal carcinogenesis.
Frameshift mutations have been detected in the
[(G)8] tract of exon 3 of the BAX gene in 48% of 63
RER+ sporadic colorectal cancers in a total of two
separate studies (Rampino et al., 1997; Ouyang et al.,
1998), and in a similar proportion of RER +
colorectal cancers from HNPCC patients (Yamamoto
et al., 1998; Yagi et al., 1998). Our own observations
are entirely concordant with these results: we detected
BAX mutations in six out of 12 (50%) RER +
carcinomas. In the presence of BAX and TGF/iRII
mutations, others have shown second allele mutations
in pure cultures of cell lines (Rampino et al., 1997;
Markowitz et al., 1995), but this is much more
difficult to demonstrate in primary tumours due to
contamination by stromal and lymphoid cells. Hence
Figure 2 (a) BAX gene analysis of case no. 55 showing the band
shift pattern on a polyacrylamide gel demonstrating one
nucleotide insertion in the [(G)8] tract from all tumour sites
(A-D), compared to normal mucosa (N). (b) Sequence analysis
of case 17 (B and C) and 25 (B and C). In both cases, site C does
not show the one nucleotide deletion in the [(G)8] tract observed
in site B (indicated by arrow)
some uncertainty remains over the functional status of
BAX in primary human tumours, even when there is
evidence for mutation in one allele. However, we
report here, we believe for the first time, two patterns
for such mutations. In four of the six tumours bearing
BAX mutations, identical alterations in the [(G)8] tract
were found in all sites sampled within each cancer,
supporting the hypothesis that BAX mutation was
present in the founder malignant clone. This pattern is
also consistent with that described for BAX mutations
in gastric cancers (Chung et al., 1997). However, in
two of six cases we demonstrated a second pattern in
which BAX mutation is not shared by all the tumour
sites of the same cancer. We can not completely
exclude the possibility that the apparently unaltered
[(G)8] tract found in subclones of these tumours
represents a reversion, through a second mutation, of
the [(G)8] mutation present elsewhere. This possibility
can in the future be tested in appropriate cell culture
models. A more obvious explanation, however, is that
in these tumours the BAX [(G)8] mutation was not
present in the founder malignant clone but was
acquired later in cancer progression. In these
tumours, it is difficult to sustain the view that
mutational inactivation of BAX could have been a
critical event early in carcinogenesis. These data
therefore raise some doubt as to the significance of
loss of BAX-dependent apoptosis pathways in colo¬
rectal carcinogenesis. Rather than indicating that
failure of apoptosis exerts a critical role in
carcinogenesis, some BAX mutations in colorectal
tumours may merely aid tumour progression, or
indeed may simply reflect the consequences of
mismatch repair deficiency without a functional
connotation.
Role of BAX mutations in colorectal carcinogenesis




Fresh tumour samples were collected from patients with
colorectal carcinoma undergoing surgery in the Royal
Infirmary of Edinburgh NHS Trust. Samples were collected
from the operating theatre within 30 min of resection and
transported to the Pathology Department. Two to seven
small tumour pieces and the matched normal tissues from
each case were frozen in liquid nitrogen, then stored at
— 70°C. DNA was extracted from frozen tissues by the
method of Goelz et al. (1985).
RER status analysis
Sixty tumours were originally screened for microsatellite
instability and only RER+ cases were analysed for BAX
gene mutation. All the samples were tested at five
microsatellite loci including the highly unstable BAT-26
locus, claimed to be sufficient alone for identifying the
RER status (Zhou et al., 1998; Hoang et al., 1997). The
other 4 loci included L-myc, TGF/1RII, D13S160, and
D2S123 using the primers and conditions described
elsewhere (Young et al., 1995; Huang et al., 1996).
A DNA segment of 94-base pairs encompassing the [(G)8]
tract in BAX was amplified by PCR using the primers
described by Rampino et al. (1997). PCR was carried out for
30 cycles, each consisting of denaturation for 30 s at 94°C,
annealing for 30 s at 55°C, extension for 30 s at 72°C.
Reactions consisted of 50 ul volume containing 100 ng
genomic DNA, 10 pmols of each primer, 200 um of each
dNTP (Advanced Biotechnologies Ltd), 1.5 mM MgCl2,
1.25 U of thermostable Taq DNA polymerase and buffer
consisting of 20 mM Tris-HCl (pH 8.4), 50 mM KC1 and
0.05% non-ionic detergent (Life Technologies UK). The PCR
hot start method was used. The products were analysed by
electrophoresis on 2% agarose gels for detection of the
amplified product.
The forward primer was end labelled with y-"P-ATP using
T4 polynucleotide kinase according to the manufacturer's
instructions (Life Technologies UK). This primer was then
used to label the original PCR product by performing one
PCR cycle using the same conditions as described above. The
radio-labelled products were electrophoretically separated in
denaturing 6% polyacrylamide gel and subjected to
autoradiography for detection of band shifts. At the same
time, all the original PCR products were directly sequenced
with Thermosequenase radiolabeled terminator cycle sequen¬
cing kits (Amersham Life Science).
BAX gene analysis
Twelve RER + cases with a total of 45 different tumour
sites and the matched normal tissue constituted in the
material for BAX gene mutational analysis.
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Heterogeneity studies identify a subset of sporadic colorectal cancers
without evidence for chromosomal or microsatellite instability
IB Georgiades1-3, LJ Curtis*1, RM Morris1, CC Bird1-2 and AH Wyllie'-4
'Sir Alastair Currie CRC Laboratories, Molecular Medicine Centre, University of Edinburgh, Western General Hospital, Crewe
Road, Edinburgh, EH4 2XU, UK; 2Department of Pathology, University of Edinburgh Medical School, Teviot Place, Edinburgh,
EH8 9AG, UK
Two apparently independent mechanisms of instability
are recognized in colorectal cancer, microsatellite
instability and chromosomal instability. Evidence from
colorectal cancer cell lines indicates the presence of
either, or both, types of instability in the vast majority.
Here, we sought to determine the prevalence of such
instability in primary sporadic colorectal cancers.
Microsatellite instability was established by demonstra¬
tion of ovel clonal, nongerm-line alleles in at least two of
four tested loci. Chromosomal abnormalities were
identified by comparative genomic hybridization (CGH)
and flow cytometric analysis of nuclear DNA content.
Tumours harbouring chromosomal instability were
distinguished from those with stable but aneuploid
karyotypes by comparing chromosomal defects at multi¬
ple sites throughout each cancer. This analysis allowed
assessment of both the number of chromosomal
abnormalities and their heterogeneity throughout the
tumour. The results confirm that microsatellite instability
is consistently associated with multiple, repeated changes
in microsatellites throughout the growth of the affected
colorectal carcinomas. There were also several carcino¬
mas in which major structural or numerical abnormalities
in chromosomes had clearly continued to arise during
tumour growth. However, a substantial subset of tumours
showed neither microsatellite instability nor multiple,
major chromosomal abnormalities. We suggest that the
development of a proportion of colorectal cancers
proceeds via a different pathway of carcinogenesis not
associated with either of the currently recognized forms
of genomic instability.
Keywords: colorectal cancer; chromosomal instability;
genomic instability; microsatellite instability; RER
Introduction
The development of genetic instability has been
proposed as an important event in multi-step carcino¬
genesis (Loeb, 1991; Hartwell, 1992). In human
colorectal carcinoma (probably the human tumour
most intensively studied at the genetic level) two major
mechanisms of genomic instability have been identified.
The first, known as microsatellite instability (MIN),
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manifests as a high rate of alteration in the length of
short tandemly repeated nucleotide sequences (Aalto-
nen el al., 1993; Ionov et al., 1993; Thibodeau et al.,
1993; Eshleman et al., 1995). Such instability is a
characteristic of tumours from patients with Hereditary
Non-Polyposis Colorectal Cancer (HNPCC) where it is
consequent upon germ-line mutations in DNA mis¬
match repair (MMR) genes (hMSH2, hMLHl,
hPMSl, hPMS2, hMSH3 or hMSH6) (Peltomaki et
al., 1993; Bronner et al., 1994; Nicolaides et al., 1994;
Nystrom-Lahti et al., 1994; Papadopoulos et al., 1994;
Wijnen et al., 1995; Liu et al., 1996; Akiyama et al.,
1997; Miyaki et al., 1997). Defects in these genes result
in multiple inaccuracies in replication of such tandem
arrays, creating frameshifts and, occasionally, point
mutations: the RER+ phenotype. Many genes include
potential target sequences for this type of error, and
mutation in some of these may confer growth
advantage, and so be selected for during tumorigenesis
(Markowitz et al., 1995; Eshleman et al., 1996; Togo et
al., 1996; Rampino et al., 1997). The RER +
phenotype is also detected in 15-20% of sporadic
colorectal cancers (Lothe et al., 1993; Aaltonen et al.,
1994; Wu et al., 1994; Borresen et al., 1995; Bubb et
al., 1996; Eshleman and Markowitz, 1996; Konishi et
al., 1996; Liu et al., 1996). Here, its origins are
conjectural, although acquired bi-allelic mutation in
mismatch repair genes is responsible for some, and
suppression of their activity by other mechanisms
appears to occur in the majority of the remainder
(Thibodeau el al., 1998).
The majority of sporadic colorectal cancers, how¬
ever, do not show the RER+ phenotype. RER —
colorectal cancers, unlike RER+ tumours, frequently
show major abnormalities in chromosome structure
and number, and it has been suggested that these
tumours arise through chromosomal instability (CIN).
Loss of a mitotic checkpoint may account for repeated
errors in chromosome disjunction in many of these
tumours, and loss of function of ItBUBl, a critical
mitotic checkpoint gene, has been observed in a small
proportion of colorectal cancer cell lines exhibiting
chromosomal instability (Cahill et al., 1998). However,
other mechanisms must exist, permitting the growth of
clones of cells that have sustained chromosome break¬
age, fusion, deletion and amplification events. Telo¬
mere erosion, hypomethylation and dysfunction of p53
(all phenomena that are observed frequently and at an
early stage in carcinoma development) may all be
permissive for these events.
In this paper we demonstrate substantial hetero¬
geneity amongst RER— colorectal cancers. To avoid
distortion due to selection for growth potential in vitro,
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we based our study on primary colorectal tumours,
removed at potentially curative operations from
otherwise unselected patients. In classifying these
tumours we devised means of estimating the extent of
chromosome change based upon multiple sampling (to
measure clonal divergence) and, in some instances,
sampling of xenografts to detect sequential changes in
real time. We identify around one third of RER —
cancers in which the extent and frequency of
chromosome change is much less than the majority,
and close to that observed in many RER+ tumours.
Results
Numerical measurement of chromosome instability
To quantify and compare the level of chromosomal
instability in both groups of colorectal cancer we first
carried our comparative genomic hybridization (CGH)
analysis on samples collected from multiple sites from
each tumour. The mean number of chromosomal
changes would be expected to be high in tumours with
underlying chromosomal instability and might vary
between different sites sampled from the same tumour
due to clonal divergence. However, the presence of
chromosomal changes might equally represent a single
catastrophic genomic event, resulting in an aneuploid
but stable genome subsequently carried by all or the
majority of tumour cells. In such cases, chromosomal
changes would be expected to be similar in all or the
majority of the sites examined. To distinguish these
events we scored separately the sum of the mean
number of chromosomal arm gains and losses detected
in each tumour and a heterogeneity score, which was
the number of particular chromosomal changes which
were not consistent between different sites within a
tumour (for example see Figure 1). Added together,
these two scores constituted a 'chromosomal instability
index'. A high heterogeneity score indicates an on¬
going process of chromosomal gain and loss, despite
the fact that some of the changes might have been
selected for early during tumour progression. In
practice, the majority of tumours showed heterogeneity
scores roughly proportional to their mean numbers of
chromosomal gains and losses. In such tumours, either
score would provide a measure of 'chromosome
instability' (Figure 2). In a small number of tumours,
however, despite sampling at a similar number of sites
to the majority, high numbers of gains and losses were
not accompanied by pronounced intratumoral hetero¬
geneity, showing that these two parameters could in
some circumstances be independent.
Chromosomal instability in RER + and RER — tumours
The mean number of chromosomal changes, hetero¬
geneity scores and the combined CIN index scores in
relation to the tumours' RER status are shown in
Table 1. The mean number of chromosomal gains and
losses and the CIN index were both significantly higher
in RER— colorectal cancers compared with RER +
tumours (one-tailed Mann-Whitney Test, P= <0.05
for both comparisons). Scores for RER— tumours
were scattered over a wide range, however, and we
identified a substantial subgroup with low CIN indices
(Figure 3). A tumour's CIN index was deemed to be
low if it fell below an arbitrary value of 18 (which was
the mean CIN index in RER+ cancers, a group
generally believed to have little chromosomal instabil¬
ity).
CGH measures only relative abundances of DNA
and would not identify as abnormal perfect tetraploid
or octapoid genomes. We therefore carried out flow
cytometric analysis of the nuclear DNA content of all
tumour samples (Table 2a,b). As expected, the cells of
most of the RER+ tumours showed near-diploid
DNA content although, as recorded by ourselves and
others elsewhere, abnormalities detectable by CGH
were frequently present. The proportion of tumours
with aneuploid content was significantly higher in the
RER— group of tumours compared to RER+ cancers
(two-tailed Fisher exact test, P= <0.05). Most RER —
colorectal cancers with a low CIN index (four out of
six) and all RER+ tumours with CIN index <18
showed diploid DNA content.
lp lq 2p 2q 3p 3q 4p 4q 5p 5q 6p 6q7p 7q 8p 8q 9p 9q lOplOq 1 lplIql2pl2ql3ql4q 15ql6pl6ql7pI7ql8pl8ql9pl9q20p20q21q22q
lp Iq 2p 2q 3p 3q4p 4q 5p 5q 6p 6q 7p 7q 8p 8q 9p 9q lOplOq 1 lplIql2pl2ql3ql4ql5ql6pl6ql7pl7ql8pl8q 19pl9q20p20q21q22q
-
■■ — T c XX XX XX __ XX









E Loss of chromosome arm
E Gain of chromosome arm
Figure 1 Example calculation of heterogeneity score and CIN index. CGH results in a primary tumour (tumour no. 1) sampled at
four different sites, and in its four corresponding xenografts. Chromosome arms are represented vertically in columns, whilst each
different site of the same tumour designated a, b, c and d are in rows, lxa, lxb, Ixc, and lxd are the corresponding xenografts
established from sites a, b, c and d. The heterogeneity score was calculated for the primary tumour and, separately, for the
xenograft by adding together the number of columns representing chromosome arms in which changes were inconsistent between
different sites within the tumour. In this primary tumour, inconsistent chromosome changes were present in chromosome arms lp,
3p, 4p, 5p, 5q, 6p, 6q, 7p, 8p, 8q, lOp, lOq, lip, 1 lq, 12p, 12q, 14q, 15q, 17p, 17q, 18p, 19p, 19q, 20q and 22q, giving a total
heterogeneity score of 25. Consistent patterns, such as are present in lq or 7q, do not score. CIN index was then calculated by
adding together the mean number of chromosomal gains and losses and the heterogeneity score
*
p53 status and chromosomal instability in RER — and
RER + colorectal cancer
To investigate the role of p53 in chromosomal
instability, we classified tumours as showing evidence
of abnormality in p53 by three criteria; stabilization of
the p53 protein as detected by immunohistochemistry,
mutation analysis of exons 5-8 of the p53 gene
(screened by single stranded conformational poly¬
morphism analysis, SSCP) and loss of the short arm
of chromosome 17. The proportion of RER— and
RER+ tumours with a p53 defect (mutation or
immunohistochemical stabilization) was not signifi¬
cantly different (10/17 and 2/5, respectively) (Table
2a,b). The proportion of p53-defective tumours was
significantly higher (10/13) among tumours with high
CIN (above 18) compared to tumours with a low CIN
index (2/9), regardless of RER status (two-tailed Fisher
exact test, E<0.05). Tumours in which CGH revealed
17p loss, but which showed no positive IHC staining or
presence of a mutation in exons 5-8 of the p53 gene
are indicated in Table 2 as n*, but for the purpose of
statistical analysis were treated as not defective for p53.
Clinicopathological features and chromosomal
abnormalities in RER— tumours with low levels of
chromosomal instability
Of the 22 primary colorectal carcinomas studied, eight
were right-sided and 14 left-sided (Table 2a,b).
Clinicopathological features of RER+ sporadic color¬
ectal cancers have been described in detail (Lothe et al.,
1993; Aaltonen et al., 1994; Kim et al., 1994; Senba et
al., 1998) and our data are in concordance with these
results (Table 2b): of the five studied, all were right-
sided, four were near-diploid in DNA content, four
were poorly differentiated and one showed abundant
mucinous differentiation. The 6 RER— cancers with
low CIN index were uniformly left-sided (compared
with eight of 11 high-CIN RER— tumours [Table 2a[)
and mostly rectal. There was no significant difference
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between the low CIN index and high CIN index
RER— cancers with regard to Dukes' stage or patient
age. Four RER- cancers with low CIN index were
moderately differentiated adenocarcinomas, but a
poorly differentiated tumour was also observed.
Figure 3 CIN index in RER— and RER + primary colorectal
cancers and corresponding xenograft. RER— p, RER— primary
tumours (black points); RER— x. RER— xenografts (grey
points); RER+ p, RER+ primary tumours (black points);
RER+ x, RER+ xenografts (grey points). Numbers shown




























Mean no. of chromosomal changes
Figure 2 Mean number of chromosomal changes plotted against heterogeneity score in primary sporadic colorectal cancers. Two
pairs of tumours had identical score for both values (see Table 1) .
*
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Table 1 Chromosomal instability in RER— and RER+ primary colorectal cancers and their corresponding xeno•grafts
Primary tumors Xenografts (if available from mutilple sites)
Mean number Mean number Average
of chromosomal Heterogeneity of chromosomal Heterogeneity xenograft
Sample changes score CIN index Sample changes score CIN index age (weeks)
RER-
1 12 25 37 lx 27 27 54 15
2 16 31 47 na
4 11 16 27 na
5 5 17 22 5x 17 *27 44 12











9 9 20 29 na
9' 4 9 13 na
10 5 12 17 na
11 17 31 48 na
13 3 7 10 na
14 14 8 22 na
15 6 7 13 na
16 6 6 12 na
19 12 12 24 19x 25 7 32 12
22 8 15 23 22x 26 24 50 9.5
RER +
3 1 3 4 na
12 7 16 23 12x 10 16 26 4.5
17 6 6 12 na
18 6 17 23 18x 13 17 30 12.5




Patient's p53 Duke s established
Sample age DNA content status stage Tumour site/side Differentiation Mucinous (any site)
(a) p53 status, DNA content and clinicopathological data for RER— colorectal cancers
CIN index> 18
1 55 aneuploid - n* C asc.col./right moderate no yes
2 62 aneuploid d B rectum/left moderate no no
4 72 aneuploid d B rectum/left moderate no yes
5 81 aneuploid n* B sigm.col./left moderate no yes
6 63 aneuploid d A sigm.col./left good no no
8 80 aneuploid d B rectum/left moderate , no yes
9 59 aneuploid d C rectum/left poor no no
11 73 aneuploid d B trs.col./right moderate no no
14 46 aneuploid n* C rectum/left moderate no no
19 49 aneuploid d C rectum/left moderate no yes
22 81 aneuploid d C asc.col./right moderate no yes
CIN index < 18
7 89 aneuploid d A des.col.left good no no
9' 59 diploid d C rectum/left poor no no
10 57 diploid n A rectum/left moderate no no
13 77 diploid n C rectum/left moderate no no
15 70 aneuploid n* B rectum/left moderate no no
16 57 diploid n* C rectum/left moderate no no
(b) p53 status, DNA content and clinicopathological data for RER+ colorectal cancers
CIN index > 18
12 60 diploid d C asc.col./right poor no yes
18 77 aneuploid d B asc.col./right poor no yes
CINindex < 18
3 64 diploid n A asc.col/right moderate no no
17 76 diploid n* C caecum/right poor no no
20 70 diploid n C asc.col./right poor yes yes
n, p53 defect not detected by any of the three methods used; n*, IHC and mutation analysis negative, but p53 defect can not be excluded due to
17p loss detected by CGH; d, p53 defective (IHC or mutation analysis positive); des.col., descending colon; trs.col., transverse colon; sigm.col.,
sigmoid colon; asc.col., ascending colon
We next searched for differences in the patterns of
specific clonal chromosomal abnormalities present in
low- and high-CIN index RER— cancers. Analysis of
chromosomal gains and losses in high-CIN index
RER— cancers revealed the most frequent changes to
be 20q + , 18q —, 13q + , 8p—, Ip— and 8q + . All of
these changes were found, although less commonly, in
the group of colorectal cancers with low CIN index
(Table 3). Particularly striking, however, was the low
incidence of 13q duplication in RER— tumours with
low CIN index (detected in 1/6 tumours) compared
with RER— cancers with a high CIN index (10/11
tumours).
Comparison ofprimary tumours and xenografts
Analysis of RER+ primary tumours and their
corresponding xenografts confirmed that microsatellite
instability is a dynamic process. Sampling at multiple
sites revealed that, although many of the sites sampled
showed altered alleles at two or more of the four
microsatellite loci tested, the affected loci and the shifts
observed were often different at different sites within
the same tumour. Xenografts showed further changes
still. Thus, in the xenografts from three tumours, 17 of
44 tested microsatellite loci acquired clonal alleles
different from the primary tumour within a single
passage in vivo (Table 4).
To assess the progress of chromosomal changes, a
scoring system similar to that for primary tumours was
applied. For this purpose, we employed only those
xenografts successfully established from at least two
separate sites from the primary tumour (since this was
a prerequisite for assessing the heterogeneity score). All
of these tumours were either RER+ or RER— with a
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high CIN index. CIN index increased between primary
tumour and corresponding xenograft, particularly in
RER— cancers (Figure 3), suggesting the presence of a
potent mechanism of underlying chromosomal instabil¬
ity in those RER— cancers which were established as
xenografts. Interestingly, we failed completely to
establish xenografts from all six of the RER— tumours
with low CIN index, despite implanting multiple
samples from each.
Discussion
We have used a combination of microsatellite
instability, DNA ploidy and comparative genomic
hybridization patterns to classify human primary
colorectal carcinomas in terms of genomic instability.
A further indication of the character of this instability
has been gained by comparison of multiple samples
gathered from the same tumours, and assessment of
certain tumours after several weeks' regrowth as
subcutaneous xenografts in SCID mice. Three distinct
phenotypes emerge. The first - the RER+ phenotype
- has been documented many times, both in primary
tumours and cell lines. We confirm here the strikingly
Table 3 Most frequent chromosomal changes in
cancers
RER— colorectal
Table 5 Oligonucleotide primer sequences and PCR annealing




temperatures for amplification of p53 exons 5 -8
tumours Annealing
(n= 17) (n = 11) (n = 6) p53 exon Primer sequence (5'-3') temperature
20q + 88% (15)* 100% (11) 67% (4) 5 TTCCTCTTCCTACAGTAGTC 55°C
18q — 76% (13) 91% (10) 50% (3) CCCAGCTGCTCACCATCG
13q + 65% (11) 91% (10) 17% (1) 6 CCTCACTGATTGCTCTTAGG 58°C
8p — 59% (10) 73% (8) 33% (2) AGTTGCAAACCAGACCTCAG
8q + 53% (9) 64% (7) 33% (2) 7 TGTGTTATCTCCTAGGTTGG 58°C
lp- 53% (9) 64% (7) 33% (2) TGGCAAGTGGCTCCTGAC
*Figures are affected tumours as a percentage of all tumours in that
















3a + + na - na + na + na
3b + na — na + na + na
3c + na — na + + na + na
3d + na - na + na + na
12a + + * + + + + + +* + + *
12b + 4- * + + + + * + + * + + *
12c + + * + + + + +* + + *
12d + + * + + + + + + + * + + * + + *
17a - na + na + na + na
17b - na + na + + na + na
17c + na + na + na + na
17d + + na + + na + + + na + na
18a — * + - + + + + + +* + + *
18b - + + + +* + + * + + *
18c + + + — + * + + + + + + + + * + + *
18d — + — + + + + + + + + * + + *
20a - + * + + + + * + +
20b - na — na + na + na
20c — + +* + + * + + * + +
20d - + * - - + + * + +
—, indicates no shift in
indicate further shifts in
allele size from normal; + , indicates a shift
allele size from normal; na, not available; p,
in allele size from normal, + +,
primary tumour; x, xenograft; *,
+ + +, + + + +
indicates complete
loss of normal allele, noted only in xenografts
W
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frequent generation of newly mutant subclones within
these tumours, as identified by clonal errors at
microsatellite sites. Although classically near diploid,
the RER + tumours were shown by CGH to include
several chromosome arm amplifications and deletions.
The number of such events per genome was low,
however, as was the extent to which such chromosome
structural changes varied in time or between adjacent
sites within the same tumour.
The second phenotype is characterized by high
incidence of chromosome arm amplification or dele¬
tion, as detected by CGH. These tumours are
invariably RER—, and the chromosome instability
clearly reflects a continuing state rather than the result
of a catastrophic event early in tumour history:
plurality and divergence of clonal chromosomal
changes are evident both between adjacent sites and
during growth in time. Although the chromosomal
abnormalities in this group favour particular sites
(which we have documented in more detail elsewhere),
no chromosome arm is free from abnormality in the
group as a whole, and the studies with xenografts
clearly show that chromosomes that were normal in the
primary tumour can appear as amplified or deleted in
clonal outgrowths sampled only a few weeks later. This
group probably corresponds broadly to the high CIN
subgroup described by Lengauer et al. (1997), on the
basis of counts of a restricted set of chromosome-
specific centromeres. The CIN score developed here,
however, detects a wider range of structural chromo¬
some abnormalities, since the CGH method takes
account of all chromosomes, and detects amplifications
and deletions within chromosome arms as well as
nondisjunctive lesions involving whole chromosomes.
Unsurprisingly, all the tumours assigned to this group
on the basis of their aberrant CGH profiles were also
DNA aneuploid as assessed by flow cytometry.
The third phenotype combines RER— status with a
propensity for change in chromosome arms as low as
that in most RER+ tumours. For several reasons it is
most improbable that these tumours are merely
misclassified with respect to their RER status. The
interrogated microsatellite sites included some of the
most labile currently known, all the tumours were left-
sided (most were rectal) and none showed mucinous
differentiation. Neither is it probable that these
tumours merely represent temporally early versions of
the high CIN, RER— group. Of the six tumours
assigned to this group, four had penetrated the muscle
layer, three had lymph node metastases and all
exceeded 3 cm in diameter at the time of study.
Although there were some exceptions, many of the
tumours in this group were near-diploid in DNA
content. Thus, we consider it likely that these tumours
arise by a pathway different from both the aneuploid
RER— and the RER+ groups. Although our studies
have not delineated a mutational mechanism, the near-
diploid CGH patterns could accommodate point
mutation, gene conversion, deletions and amplifications
below the limits of resolution of CGH, balanced
translocations or uniparental disomy.
We suspect that the RER— low CIN phenotype may
be under-represented amongst currently available
colorectal cancer cell lines, as RER— near-diploid
lines are rare (Eshleman et al., 1998). A recent study of
primary tumours, however, has also identified a
substantial subset of RER— colorectal carcinomas
with diploid DNA content and therefore probably low
CIN phenotype (Yao et al., 1999). It may be that these
tumours either fail to adapt to growth in vitro or, in
doing so, undergo obligatory further changes in
chromosome structure. In this respect, we were
interested to note that none of our RER— low CIN
tumours adapted to growth as xenografts, in contrast
to RER— high CIN tumours and RER+ tumours
studied around the same time.
Further work with large numbers of cases will be
required to establish whether RER— low CIN tumours
share a particular clinicopathological identity. It
appears probable, however, that each of the three
phenotypes described here arises because of deficiency
in different checkpoint mechanisms. For RER +
tumours, the critical defect (failed recognition of
DNA nucleotide mismatches) is known, but the
corresponding defect or defects for the RER— tumour
groups are still largely unknown. Information on this
topic will be important, as it may be predictive of the
efficacy of various therapeutic measures.
Materials and methods
Tissue samples
Fresh tissue samples were collected from consecutive sporadic
colorectal carcinomas removed at operation between April
and November 1997. Blocks of fresh tissue, approximately
10x5x5 mm, were collected from two to four different sites,
depending on the size of the tumour, from each colorectal
cancer and one from normal mucosa at a point distant from
the lesion. All tumours were from separate individuals except
two (9 and 9') which occurred synchronously. Each block of
tissue was subsequently divided into three separate pieces: the
first for DNA extraction and flow cytometry, the second for
periodate-lysine-paraformaldehyde-dichromate (PLPD) fixa¬
tion, and the third for xenografting (normal tissue was not
xenografted). Sections from PLPD-fixed paraffin blocks were
used for immunohistochemical detection of stabilized p53
protein and haematoxylin and eosin (H + E) staining for
histological assessment. DNA was extracted from frozen
tissue according to the method of Goelz et al. (1985).
Establishment of colorectal cancer xenografts in SCID mice
Xenografts were established from dorsal implants of freshly
obtained tissue fragments, as previously described (McQueen
et al., 1991) but using severe combined immuno-deficient
(SCID) mice as recipients. Tumours were allowed to grow
until an externally visible diameter of about 1 cm was
reached, and were then passaged to new hosts. At the time
of passage, the mice were killed and the tumour tissue divided
into pieces for DNA extraction, flow cytometry and PLPD
fixation. H + E staining and immunohistochemical detection
of stabilized p53 protein was carried out on fixed tissue.
Implantation was attempted from each of the cohort of 74
tumour samples, of which 26 were successfully established as
xenografts. Time to first passage varied between 3 and 20
weeks.
Flow cytometry
Frozen tissue was prepared for flow cytometry according to
the method of Vindelov et al. (1983). Flow cytometry was
performed on an EPICS-XL flow cytometer (Coulter
Electronics Ltd, Luton, UK) at an excitation wavelength of
488 nm. At least 5000 nuclei were analysed in each sample,
■*
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and tumour DNA content estimated by comparison with
identical analyses of normal tissue. Tumour samples were
scored as 'DNA diploid' or 'DNA aneuploid' using
previously described criteria (Carder et al., 1993).
Immunohistochemical detection of stabilized p53 protein
Immunohistochemistry was carried out on 3 pm paraffin
sections using the DO-7 antibody (Dako Ltd, UK.) and an
avidin-biotinylated horseradish peroxidase complex detection
system (ABComplex/HRP, Dako Ltd, UK), with 3,3'-
diaminobenzidine (DAB) as substrate, as previously described
(Purdie et al., 1991). Tumours were classified as p53 defective
if more than 10% nuclei showed intense positive staining.
Mutation analysis of the p53 gene
Mutation analysis of the p53 gene was performed on 15
tumours with faint, sparse or negative immunohistochemical
staining to exclude the possibility of mutation not detectable
by IHC. Previous studies have indicated that mutation in the
p53 gene, if present, occurs relatively early in tumour
progression and therefore can be readily detected in any part
of the tumour (Carder et al., 1995). For this reason, a single
sample was taken as representative of each tumour.
Exons 5-8, in which 90% of all mutations are located
(Levine et al., 1991), were amplified using the primers listed
in Table 5. Reactions were carried out in 50 p\ volumes
consisting of 200 ng genomic DNA, 0.5 pM of each primer,
200 pM of each dNTP, 1.5 mM MgCl2, 1 x PCR buffer
solution (Life Technologies Ltd, UK) and 1.25 U of
thermostable DNA polymerase (Life Technologies Ltd,
UK) with the addition of 50 ng y33PdATP-labelled primer
to each reaction in the final cycles.
SSCP with autoradiographic detection were undertaken as
previously described (Carder et al., 1995). Autoradiography
were assessed visually for shifts in electrophoretic mobility of
amplified sequences compared to DNA from normal tissue of
the same patient.
Analysis ofmicrosatellite instability
Two dinucleotide repeat sequences, D2S123 and D13S160
(Gyapay et al., 1994) and two poly(A) tracts, BAT-26
(Hoang et al., 1997) and the (A)10 repeat in exon 3 of TGF/i
RII (using primers CCTCGCTTCCAATGAATCTC and
TTGGCACAGATCTCAGGTCC), were analysed for evi¬
dence of microsatellite instability. All four loci were examined
in each sampled site of 22 primary tumours and in all
xenografts. Reactions were carried out as described above,
with the addition of 10% DMSO, for all loci except BAT-26,
where a final concentration of 100 pM of each dNTP with
450 ng genomic DNA template was employed, and TGF/J
RII, where magnesium ion concentration was 4 mM. D2S123,
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D13S160 and poly(A) BAT-26 PCR products were heat-
denatured and run on denaturing polyacrylamide gels to
detect shifts in electrophoretic mobility. The (A) 10 sequence
in exon 3 of TGF-fl RII was assessed using SSCP as
described above. Autoradiographs were assessed visually for
the presence of shifts in electrophoretic mobility, comparing
sequences from tumour samples and the corresponding
normal DNA. Tumours were classified as RER+ if they
displayed band shifts at two or more loci.
Analysis of 'unbalanced chromosomal abnormalities using
comparative genomic hybridization
CGH was carried out using a method modified from
Kallioniemi et at. (1992). Briefly, DNA was labelled by
nick translation with biotin (tumour DNA) and digox-
igenin (normal DNA), 500 ng of each prehybridized with
15 pg of human Cot-1 DNA, denatured and hybridized
to a denatured normal male metaphase preparation for
2-3 days. Detection was carried out using avidin-FITC
and anti-digoxigenin-rhodamine and slides were addition¬
ally stained with 4,6-diamidino-2-phenylindole (DAPI) to
allow chromosome identification. Hybridizations were
analysed using the Quantitative Image Processing System
(QUIPS) software (Vysis Ltd, Richmond, Surrey, UK)
coupled to a Zeiss Axioskop 20 fluorescence microscope
(Carl Zeiss Ltd, Welwyn Garden City, UK) equipped
with a SenSys CCD camera (Photometries, Tucson, AZ,
USA) and a triple bandpass filter set for detection of
rhodamine, fluorescein and DAPI. At least five metaphase
spreads were analysed from each slide. Because sex
chromosomes might be under different selection pressure
in tumours derived from males and females they were
excluded from analysis. The ratios of 1.125 and 0.875
were used for scoring chromosomal gains and losses,
ratios at which copy number changes could easily be
visualized by eye. The same ratios were used for both
primary tumours and xenografts, which could result in
scoring of fewer chromosomal changes in the primary
tumours due to contamination with normal stromal DNA.
However, direct comparison of RER— and RER +
cancers could be made since the same error applied to
both groups.
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Current opinion of the genetic events driving colorectal tumourigenesis focuses on genomic
instability. At least two apparently independent mechanisms are recognized, microsatellite
instability and chromosomal instability. The genetic defects underlying each type of instability are
only partially understood and controversy remains as to the role of p53 iti the generation of
chromosomal defects in colorectal cancer. This study sought to clarify the relationships between
chromosomal abnormalities and defects of both p53 and mismatch repair. Extensive chromosomal
analysis was undertaken, using flow cytometry and comparative genomic hybridization, of a series
of sporadic colorectal cancers which had been grown to early passage as subcutaneous xenografts
in SCID mice. Overall levels of chromosomal defects were observed to be low in RER f cancers
compared with RER— and distinctive patterns of chromosomal anomalies were found to be
associated with both the RER + and RER - phenotype. No particular level or pattern of
chromosomal anomalies appeared to l>e associated with p53 status, supporting recent observations
that abnormal p53 function is not sufficient to cause chromosomal anomalies in colorectal
tumours. Copyright f 200(1 John Wiley & Sons, Ltd.
Keywords: colorectal cancer; microsatellite instability; RER + ; chromosome; ploidy; p53; CCII
Introduction
Genomic instability appears to be fundamental to the
development of malignancy. In sporadic colorectal
cancer, two major mechanisms of genomic destabiliza-
tion have been repeatedly demonstrated, involving
either multiple chromosomal abnormalities or instabil¬
ity of microsatellite sequences (the RER4- phenotype)
and other mechanisms may also exist [I]. Chromosomal
instability, in the form of both non-disjunction and
breakage events, has been demonstrated convincingly in
cell lines derived from colorectal cancer [2,3] and it is
likely that the clonal chromosomal abnormalities which
are abundant in colorectal cancer [4-6] arise as a result
of underlying defects of chromosome stability. An
inverse correlation has been demonstrated in colorectal
cancer cells in vitro between the RER + phenotype and
chromosomal instability [2,3] and evidence from pri¬
mary sporadic colorectal cancers reflects this finding;
RER + tumours seldom show evidence for major
abnormalities in chromosome structure or number
[7-10] and if karyotypic abnormalities are present, they
tend towards whole chromosomal duplications rather
than structural anomalies [9], It is believed that either
type of instability is capable of driving tumour progres¬
sion, although the two are not mutually exclusive.
The genetic basis of the RER + phenotype has been
studied extensively in patients with hereditary non-
polyposis colorectal cancer (HNPCC), in whom the
vast majority of cancers display this phenotype [7],
Germ-line defects of genes involved in the mismatch
repair pathway account for almost all cases. A much
lower proportion (around 15%) of sporadic colorectal
cancers display the RER + phenotype [11 14], of
which most lack expression of a mismatch repair
protein, hMLHi [15]. The genetic basis for chromoso¬
mal instability is unclear. Certain celt lines displaying
this phenotype have been shown to be defective in a
kinetochore checkpoint function, potentially facilitat¬
ing chromosomal non-disjunction, and a proportion of
these cell lines harbour mutations in a gene encoding
one component of this checkpoint, hBlIBl [16],
Abnormalities of p53, present in at least 70% of
sporadic colorectal cancers [17,18], could also be
involved in the acquisition of chromosomal defects,
since there is compelling evidence from many sources
linking abnormalities of the p53 protein with both
numerical and structural chromosome abnormalities
[19 22]. Furthermore, disruption of p53 function has
been shown to precede aneuploid clonal divergence in
colorectal cancer [23,24], A number of mechanisms by
which p53 helps to maintain genomic stability have
been postulated, including its involvement in a mitotic
spindle checkpoint and in the p21-mediated G1
checkpoint, preventing the propagation of cells in
which ON A is damaged. However, recen t analyses of
Copyright ;C 2000 John Wiley & Sons. Ltd.
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colorectal cancer cell lines suggest that there is no
direct correlation between abnormalities of p53 and
chromosomal instability [2,3],
In this paper we seek to clarify the roles of defects of
p53 and of the mismatch repair pathway in the
generation of chromosomal abnormalities in primary
tumour colorectal cancer. Recent studies of genomic
instability have gathered much important data from
the analysis of relatively small numbers of cell lines
derived from colorectal cancers Whilst cells grown
in vitro are a valuable resource, they may not be
entirely representative of the spectrum of colorectal
cancers, as they are exposed to selective pressures very
different from those in tumours in vivo. We chose,
therefore, to analyse chromosomal defects in a series of
samples of authentic tumour tissue. We utilized
tumours grown to early passage as xenografts so as
to eliminate human stromal contamination from
tumour material. Tumours grown in this way show
closely similar DNA ploidy to that of the primary
tumour from which they are established and have the
advantage that the neoplastic cells are not admixed
with normal human cells [25,26]. Our results confirm
that chromosomal abnormalities occur less often in
RER + cancers than in RER —. but are not obviously
related to the status of p53. Furthermore, a pattern of
chromosomal copy number changes has emerged in
which certain chromosomal abnormalities are grossly
overrepresented in RER - cancers, whilst others are
overrepresented in RER + , indicating differences
between RER— and RER 4- cancers either in the
mechanisms by which chromosome anomalies occur,




Tissue was harvested fresh from sporadic colorectal
carcinomas removed at elective operation between
1988 and 1994 at Edinburgh Royal Infirmary. Some
tissue was frozen at — 70X3 and the remainder fixed in
periodate -lysine paraformaldehyde dichromate
(PLpp) ancj embedded in paraffin wax. Thirty-six
fresh primary sporadic colorectal carcinomas were
established as subcutaneous xenografts by dorsal
implantation in severe combined immunodeficient
(SCID) mice as previously described [26]. DNA was
extracted from frozen tissue according to the method
of Goelz et al. [27] from xenografts harvested at early-
passage, pass I or 2, except in five cases where passes 3
(three eases), 4, and 5 were used.
Analysis of chromosomal abnormalities
Comparative genomic hybridization (CGH) [28,29]
was used to evaluate abnormalities in copy number of
chromosome arms and flow cytometry was employed
to determine DNA ploidy. CGH was effected by a
Copyright :g) 2000 John Wiley & Sons, Ltd.
modified version of the method described by Kallio-
niemi et al. [28]. Briefly, a normal male metaphase
spread was treated with lOpg/ml RNase A for 1 h.
100 ng/ml proteinase K for 2.5 min, and 70% forma-
tnide at 70 C for 3 min, and dehydrated through 70%,
90%, and 100% ethanol. 500 ng of tumour DNA was
labelled with biotin by nick translation and counter-
hybridized against 500 ng of digoxigenin-labelled
normal DNA and 15 pg of Cot-1 DNA for 2 days. A
rhodamine-conjugated anti-digoxigenin antibody and
Huorescein-conjugated avidin were used to visualize
hybridized normal and tumour DNA. Hybridizations
were analysed using the image analysis software MacP-
robe (Perceptive Scientific Instruments Ltd., Chester,
UK) or QUIPS [Vysis (UK) Ltd., Richmond, Surrey,
UK]. Between five and ten metaphase spreads were
analysed for each tumour and green/red ratio cut-off
points of 1.125 and 0.875 were chosen for scoring of
chromosome copy number changes, the level at which
copy number changes could easily be visualized by eye.
Sex chromosomes were omitted from statistical analysis
because of the bias against X-chromosome loss in males.
Kallioniemi et at. [30] suggest that some chromoso¬
mal regions, namely lp32-pter, 16p, 19, and 22, can
give aberrant results, probably because of their high
guanine/eytosine content. In this study, normal versus
normal controls, which were included in each experi¬
ment, usually demonstrated even hybridization of
DNA to all chromosomes, although chromosome 19
occasionally gave aberrant results. Reversal of the
usual red to green labelling of tumour and normal
DNA demonstrated chromosome 19 to be the only-
region of inconsistency. Hence, although our results
from this chromosome are included, they are inter¬
preted cautiously.
Preparation of frozen tissue for flow cytometry was
carried out according to the method of Vindelov et al.
[31] and performed on an EPICS-XL flow cytometer
(Coulter Electronics Ltd., Luton, UK) at an excitation
wavelength of 488 nm.
Analysis of microsatellite instability
Microsatellite instability was assessed by analysis of at
least four of the following loci: D2S123 [32], D3S1293
[32], D8S282 [32], D13S160 [32]. BAT26 [33], and
TG F/iR 11 (using oligonucleotide primer sequences
CCTCGCTTCCAATGAATCTC and TTGGCACA
GATCTCAGGTCC). Analysis was carried out by
PCR amplification, denaturing polyacrylamide gel
electrophoresis, and silver staining as previously
described [14], Tumours were designated positive for
RER 4- when allele length changes were observed at
two or more loci.
Analysis of p53 status
Immunohistochemical staining of p53 was carried out
using two antibodies, pAblSOl (Oncogene Science,
UK) and DO? (Dako Ltd.. UK). Immunohislochem-
istry (IHC) was performed on 3 pm PLPD/paraffin
m
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sections. Tumours were deemed to be positive if more
than 10% positive nuclei were scored; this excluded
cases in which only occasional nuclei were positive. In
order to clarify the status of p53 in tumours which
scored negative by these criteria or in which numbers
of IHC-positive nuclei were low, SSCP mutation
analysis of exons 5-8 of the gene, the region in which
more than 90% of mutations are found in colorectal
cancer [34], was carried out as previously described
[35]. Thus, p53 status was deemed abnormal on the
basts of either positive IHC or direct identification of a
mutation in exons 5-8, or both.
Oligonucleotide primer sequences for p53 exons 5-8
were (5' to 3'): exon 5 forward TTCCTCTTCCTA
CAGTAGTC, reverse CCCAGCTGCTCACCATCG;
exon 6 forward CCTCACTGATTGCTCTTAGG.
reverse AGTTGCAAACCAGACCTCAG; exon 7 for¬
ward TGTGTTATCTCCTAGGTTGG, reverse TGG




Chromosomal abnormalities determined by CGH
Analysis of tumours by CGH revealed both numerical
chromosomal abnormalities and those involving break¬
age events, though it was notable that many breakage
events occurred in centromeric regions. In keeping with
cytogenetic and other CGH studies [4,5], overall
common chromosomal abnormalities were found to
be gain of chromosome arms 7p, 7q, 8q, 13q, and 20q.
and loss of chromosome arms 8p and 18q. Certain
chromosomal events, namely deletion of chromosome
arms 8p and 18q and duplication of chromosome arms
8q, 13q, and 20q, were notable in that they could
usually still be observed when the CGH cut-off ratio
was increased to the equivalent of loss or gain of one
chromosome in 75% diploid cells, indicating their
presence as the majority clonal population.
Chromosomal abnormalities in RER-f and RER —
colorectal tumours
Nine tumours of the 36 in the series displayed the
RER + phenotype. The characteristics of the cancers in
this series with widespread microsatellite instability con¬
formed to the predicted phenotype. in that they were all
derived from the proximal colon (compared with
RER—, /? — 0.0012, two-tailed Fisher's exact test). The
average age of these patients (69.2 years for RER +,
67.7 years for RER—) and the proportions of cancers
of Dukes' stage A. R, and C/D were similar in RER +
and RER— tumours. Clinico-pathological and genetic
characteristics of the tumours are shown in Table 1.
Although the number of chromosomal changes
detected by CGH, scored as the sum of each chromo¬
some arm which contained a gain or a loss, was higher
in RER — cancers than in RER + , this did not reach
statistical significance (p = 0.111, Mann-Whitney test,
mean values 14.52 and 9.44. respectively). When DNA
ploidy changes, as detected by flow cytometry, were
analysed, a similar picture emerged; RER— cancers
were usually aneuploid (24/27 tumours) whereas most
(7/9) RER-F cancers were near-diploid (p<0.001, two-
tailed Fisher's exact test). However, some unequivocal
RER +• tumours were aneuploid by How cytometry
and most showed some abnormality in chromosomes
as judged by CGH. Similarly, whilst most RER —
tumours were aneuploid, several showed a relatively
low number of chromosome arm gains and losses
within the range observed in RER + tumours. More¬
over. the pattern of chromosomal change observed in
the two tumour groups also differed. Overall, duplica¬
tion of chromosome 7 and arms 8q, 13q, and 20q, and
deletion of chromosome arms 8p and I8q were
frequently observed (Figure I). However, loss of 8p,
which was observed with striking frequency in RER—
tumours (20/27, 74%). was not present in any of the
nine RER-F tumours. RER+ tumours showed loss of
18q in only one of nine tumours (11%) compared with
22/27 (81%) RER- cancers. Only two of the 27
RER — cancers displayed neither 8p nor 18q deletion.
Abnormalities of chromosome 19 occurred in 5/9
RER 4- cancers (compared with only 3/27 RER —),
but the uncertainty regarding interpretation of changes
in this chromosome has already been referred to.
Chromosomal abnormalities in relation to defects
of p53
Twenty-four tumours were positive for abnormalities of
p53. assessed either by the detection of a mutation
within p53 or more than 10% positive nuclei by
inimunohistochemistry. The percentage of immttno-
histochemically positive nuclei per positive tumour
varied from less than 1% to more than 90%. This wide
variation in levels of staining has been reported
repeatedly. There was a consistent strong association
between mutation of the gene and the presence of over
30% more of positive-staining nuclei [36.37], This group
included five tumours which showed negative or very
low levels of nuclear staining by 1HC. but harboured
mutations within exons 5 or 6. Of tumours with defective
pS3, 13/24 were left-sided compared with 4/12 with
apparently normal p53, but this apparent difference was
not statistically significant (p—0.409, Yates' corrected
y2 test). Nor were there significant differences in Dukes'
stages when tumours with normal and abnormal p53
were compared (15/24 with defective p53 were stage C/D
compared with 3/12 with normal p53. p=0.077, Yates'
corrected y2 test). The average age of patients was
similar in both the p53-norma! and -abnormal tumour
groups (67.17 and 68.54 years, respectively).
The numbers of chromosomal changes assessed by
CGH were not significantly different in p53-abnormal
and -normal tumours (/>=0.6G2. Mann Whitney test,
mean values 13.46 and 12.75. respectively). The propor¬
tions of aneuploid and diploid tumours were also
Copyright < 2000 John Wiiey & Sons, Ltd, j Pathol 2000: \ 92: 440-445.
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71 Right Cue C/D* RER + Defective Yes Diploid 2 2 4
2 82 Right Asc B RER + Defective Yes A-neupioid 3 8 11
3 81 Right Cae 8 RER+ Defective No Diploid 3 1 4
4 60 Right Asc C/D* RER + Defective No Diploid 5 6 If
5 68 Right Asc 8 RER + Norma! Yes Diploid 1 0 1
6 49 Right Cae 8 RER + Normal Yes Diploid 8 13 21
7 65 Right Cae 8 R.ER+ Norma! No Diploid 2 0 2
8 77 Right Cae 8 RER + Norma! No Aneupioid 8 13 21
9 70 Right Asc C/D* RER+ Norma! Yes Diploid 5 4 9
10 77 Right Asc 8 RER- Defective No Aneupbid 6 1 7
11 83 Right Cae C/D* RER — Defective No Diploid 4 10 14
12. 84 Right Cae CD* RtR- Defective Yes Aneupioid 4 7 11
13 85 Right Asc C/D* RER- Defective Yes Aneupiold 7 5 12
14 48 Right Asc C/D* RER™ Defective No Aneupioid 5 5 10
15 81 Right. Asc. C/D* RER— Defective No Aneupiod 7 4 11
16 65 Left fee C/D* RER— Defective Yes Aneupioid 14 6 20
17 66 left Rec CD* RER- Defective Yes Aneupioid 6 12 18
18 36 Left. Sig CD* RER— Defective No Aneupioid 6 3 9
19 40 Left Sfg C/D* RER Defective Yes Aneupioid 6 4 10
20 68 Left Des B RER Defective Yes Diploid 5 15 20
21 78 Left Sig 8 RER- Defective No Aneuploid 5 7 12
22 86 Left S'g 8 R£R- Defective No Aneuploid 11 10 21
23 56 Left Sig B RER- Defective No Aneuploid 3 6 9
24 61 Left Sig C/D* RER Defective Yes Aneuploid 5 5 10
25 40 Left Rec C/D* RER-- Defective No Aneupioid 8 2 10
26 95 Left Sig B RER- Defective Yes Aneupioid 6 12 18
27 72 Left Rec B RER™ Defective Yes Aneupioid 11 9 20
28 49 Left Rec CD* RER™ Defective No Aneupioid 10 16 26
29 81 Right Asc C/D* RER- Defective Yes Aneupioid 7 18 25
30 39 Right Cae B RER- Normal Yes Diploid 1 5 6
31 7! Right Asc C/D* RER-- Normal Yes Aneupioid 11 13 24
32 87 Left NK A R£R~ Normal No Aneuploid 0 1 1
33 68 Left Sig B RER™ Normal No Aneuploid 4 1 5
34 76 Left s« A RER- Normal Yes Aneuploid 9 5 14
35 55 Right Asc CD* RER- Normal No Aneuploid 19 16 35
36 81 Left Sig B RER Normal No Aneupioid 7 7 14
♦Tumours were classified as Dukes* C/D because surgical reports permitting classification as Dukes' 0 were not always available.
Abbreviations: Cae-eaecum: Asc ascending colon: Des descending colon; Sig- -sigmoid colon; Rec -rectum: dups-duplications; dels-deletions.
similar when cancers with defective p53 were compared
with normal (p = 0,247, Fisher's exact test). Abnormal¬
ities of p53 appeared more common in RER — tumours
than in RER + , occurring in 20/27 (74%) and 4/9 (44%).
respectively, but this difference was not statistically
significant (p = 0.126, Fisher's exact test).
Because loss of heterozygosity of I7p might indicate
abnormal p53 function, we repeated the above tests,
this time adding to the group defined as 'abnormal for
p53' all cancers in which loss of 17p was identified by
CGH. Using these criteria, only six tumours were
classified as normal for p53. The tumours in this small
group did not differ significantly in terms of ploidy,
location, Dukes' stage or chromosomal alterations at
other sites front those in which p53 was defective.
Chromosomal abnormalities by CGH in relation
to DNA ploidy
The number of chromosome arms exhibiting abnorm¬
alities by CGH was higher in tumours found to be
aneuploid by flow cytometry than in those which were
diploid, though this did not reach statistical signifi¬
cance (p — 0.536, Mann-Whitney test, mean values
14.77 and 9.2, respectively). Diploid and aneuploid
tumours showed similar patterns of chromosomal
abnormalities (Table 2).
Table 2. Frequency of chromosomal abnormalities
detected by CGH in diploid or aneuploid colorectal
tumours scored on the basis of DNA flow cytometry
No. (%) of tumours with abnormality
Chromosomal
abnormality Aneuploid Diploid
4-7 19 (73) 3 (30)
~8p 18 (69) 2 (2.0)
8q + 15 (58) 5 (50)
I3q + 19 (73) 3(30}
I8q- 20 (77) 3(30)
20q + 19 (73) 2 (20)
Copyright ( 2000 John Wiley & Sons, Ltd. J Pathol 2000; 192: 440-445.
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Figure I. Chromosome duplications and deletions by CGH in early passage xenografts derived from sporadic colorectal cancers.
Deletions are represented by grey bars to the left of each chromosome, duplications by black bars to the right, (a) Chromosomal
changes in RER cancers. The most frequent chromosomal abnormalities were deletion of chromosome arms I8q (81%) and 8p
(74%), and duplication of all or part of chromosome 7 (70%) and chromosome arms 13q (70%), 20q (70%), and 8q (63%).
(b) Chromosomal changes in RER + cancers. Duplication of all or part of chromosome 7 occurred in 22% of RER + tumours and
duplication of 8q in 33%, I3q in 33%, and 20q in 22%. Deletion of chromosome arm I8q occurred in I 1% of RER+ cancers and
deletion of 8p was not observed
Discussion
Our data demonstrate appreciable numbers of chro¬
mosomal anomalies in RER+ cancers, as determined
by CGH. These changes clearly differ from those in
RER— cancers, in that they occur at a lower overall
frequency (though this difference is not statistically
significant), are generally present against a background
of diploid DNA content (compared with the grossly
aneuploid content of the majority of RER — tumours),
and tend not to include the same pattern of frequent
chromosomal abnormalities seen in RER— cancers,
most notably loss of arms 8p and 18q. ft is not
apparent whether chromosomal abnormalities in
RER + colorectal cancers are caused by a generalized
defect in chromosomal instability, though at least
one form of chromosomal instability exists in con¬
junction with micTOsatellite instability in cell lines
derived from colorectal cancer [2], If this is the case,
there is little clonal growth of cells which harbour
the abnormalities prevalent in RER-- tumours (invol¬
ving chromosomes 7, 8, 13, 18, and 20). Selection
pressure in favour of these anomalies may be dimin¬
ished if the RER + phenotype predominates in driving
Copyright t: 2000 John Wiley & Sons, Ltd.
tumourigenesis, such that defects of mismatch repair
cause mutations within critical oncogenes and tumour
suppressor genes at an early stage.
Abnormality of a single gene product with multiple
functions in chromosome stability regulation, such as
p53. could allow chromosomal instability to arise. We
found no association between abnormal chromosome
content, assessed either by flow cytometry or by CGH,
and defects of p53 in this series. This is in keeping with
the data of de Angelis et al. [6] and supports data from
other recent studies which suggest that although p53
may play some role in the propagation of chromoso¬
mal defects, other fundamental causative factors exist
[1 3].
In summary, abnormal p53 status does not appear
to differentiate any particular pattern of chromosomal
change. Significant chromosomal changes occur in
RER+ tumours, usually around a near-dipioid total
DNA content, but these do not harbour the very
distinctive patterns of chromosomal changes observed
in RER— tumours. These data suggest that the
mechanisms by which chromosomal abnormalities
arise or are selected for are dependent on RER
status and as such provide further insight into the
0
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mechanisms of genomic instability present in these
tumours.
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